GenCore version 5.1.7 Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 26, 2006, 02:37:44; Search time 47 Seconds

(without alignments)

156.556 Million cell updates/sec

Title: US-10-785-230-5

Perfect score: 463

Sequence:

1 MNAKVVVVLVLVLTALCLSD......VCIDPKLKWIQEYLEKALNK 89

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:*

1: /cgn2_6/ptodata/1/iaa/5_COMB.pep:*

2: /cgn2_6/ptodata/1/iaa/6_COMB.pep:*

3: /cgn2_6/ptodata/1/iaa/H_COMB.pep:*

4: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*

5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep:*

6: /cgn2 6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		8				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	463	100.0	89	1	US-08-323-084A-1	Sequence 1, Appli
2	463	100.0	89	1	US-08-674-008-1	Sequence 1, Appli
3	463	100.0	89	2	US-09-461-912A-46	Sequence 46, Appl
4	463	100.0	89	2	US-09-175-713-1	Sequence 1, Appli
5	463	100.0	89	2	US-09-647-501-4	Sequence 4, Appli
6	463	100.0	93	1	US-08-323-084A-5	Sequence 5, Appli
7	463	100.0	93	1	US-08-674-008-5	Sequence 5, Appli
8	463	100.0	93	2	US-09-919-497-95	Sequence 95, Appl
9	463	100.0	93	2	US-09-949-016-5967	Sequence 5967, Ap
10	463	100.0	93	2	US-09-144-838-7	Sequence 7, Appli
11	463	100.0	93	2	US-09-175-713-2	Sequence 2, Appli

```
12
       463
            100.0
                     119
                          2 US-09-949-016-8247
                                                         Sequence 8247, Ap
13
       463 100.0
                     166 2
                             US-09-646-028-5
                                                         Sequence 5, Appli
14
                     328 2
       463
           100.0
                             US-08-808-720-1
                                                         Sequence 1, Appli
15
       463
           100.0
                     328
                          2
                             US-09-467-638-1
                                                         Sequence 1, Appli
16
       442
            95.5
                      89 1
                            US-08-181-556-2
                                                         Sequence 2, Appli
       442
             95.5
                      93 2 US-09-312-283C-421
17
                                                         Sequence 421, App
18
       440
             95.0
                     326 2
                            US-08-808-720-3
                                                         Sequence 3, Appli
19
       440
             95.0
                     326 2 US-09-467-638-3
                                                         Sequence 3, Appli
20
       377
             81.4
                     177
                          2
                             US-09-646-028-54
                                                         Sequence 54, Appl
                                                         Sequence 55, Appl
21
       377
             81.4
                     339
                          2
                             US-09-646-028-55
22
       369
             79.7
                      90
                          2
                             US-09-175-713-12
                                                         Sequence 12, Appl
23
       369
             79.7
                      94
                          2
                             US-09-175-713-13
                                                         Sequence 13, Appl
       365
             78.8
                      68
24
                          2
                             US-09-175-713-14
                                                         Sequence 14, Appl
25
       365
             78.8
                      69
                          2
                             US-09-175-713-10
                                                         Sequence 10, Appl
26
       365
             78.8
                      72 2
                             US-09-175-713-15
                                                         Sequence 15, Appl
                      72
27
       365
             78.8
                         2
                             US-09-646-193-7
                                                         Sequence 7, Appli
28
       365
             78.8
                      72
                          2
                             US-09-646-192-7
                                                         Sequence 7, Appli
                          2
29
       365
             78.8
                      73
                             US-09-175-713-11
                                                         Sequence 11, Appl
30
       360
             77.8
                      67
                          2
                             US-09-144-838-8
                                                         Sequence 8, Appli
31
       360
             77.8
                      67
                          2
                             US-09-144-838-23
                                                         Sequence 23, Appl
32
       360
             77.8
                      67
                          2
                             US-09-646-193-6
                                                         Sequence 6, Appli
33
       360
             77.8
                      67
                          2
                            US-09-646-192-6
                                                         Sequence 6, Appli
34
     342.5
             74.0
                      66
                          2
                             US-09-144-838-27
                                                         Sequence 27, Appl
35
       321
             69.3
                      68
                          2
                             US-09-144-838-51
                                                         Sequence 51, Appl
36
       309
             66.7
                      68
                          2
                             US-09-144-838-24
                                                         Sequence 24, Appl
37
       306
             66.1
                      67
                          2
                             US-09-144-838-25
                                                         Sequence 25, Appl
38
       304
             65.7
                      67
                          2
                             US-09-144-838-47
                                                         Sequence 47, Appl
39
     291.5
             63.0
                      67
                             US-09-144-838-28
                                                         Sequence 28, Appl
40
       270
             58.3
                      69
                          2
                             US-09-144-838-52
                                                         Sequence 52, Appl
41
     268.5
             58.0
                      66 2
                             US-09-144-838-29
                                                         Sequence 29, Appl
42
       267
             57.7
                      68 2
                             US-09-144-838-53
                                                         Sequence 53, Appl
43
       255
             55.1
                      68
                         2
                             US-09-144-838-26
                                                         Sequence 26, Appl
44
       253
             54.6
                      68 2
                             US-09-144-838-48
                                                         Sequence 48, Appl
45
       250
             54.0
                      67
                          2 US-09-144-838-49
                                                         Sequence 49, Appl
```

ALIGNMENTS

```
RESULT 1
US-08-323-084A-1
; Sequence 1, Application US/08323084A
; Patent No. 5563048
   GENERAL INFORMATION:
;
     APPLICANT: HONJO, TASUKU
;
;
     APPLICANT:
                 SHIROZU, MICHIO
     APPLICANT: TADA, HIDEAKI
;
     TITLE OF INVENTION: No. 5563048el Polypeptides and DNAs encoding them
;
     NUMBER OF SEQUENCES: 20
     CORRESPONDENCE ADDRESS:
       ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
       STREET: 2100 Pennsylvania Avenue, N.W.
;
       CITY: Washington
;
       STATE: D.C.
;
       COUNTRY: U.S.A.
;
       ZIP: 20037-3202
;
     COMPUTER READABLE FORM:
```

```
MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/323,084A
      FILING DATE:
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: JP 280505/1993
      FILING DATE: 14-OCT-1993
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (202)293-7060
      TELEFAX: (202)293-7860
      TELEX: 6491103
  INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 89 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-323-084A-1
                        100.0%; Score 463; DB 1; Length 89;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 9.8e-52;
 Matches
         89; Conservative 0; Mismatches
                                            0; Indels
                                                            0; Gaps
                                                                       0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 2
US-08-674-008-1
; Sequence 1, Application US/08674008
; Patent No. 5756084
 GENERAL INFORMATION:
    APPLICANT: HONJO, Tasuku
    APPLICANT: SHIROZU, Michio
    APPLICANT: TADA, Hideaki
    TITLE OF INVENTION: HUMAN STROMAL DERIVED
    TITLE OF INVENTION: FACTOR 1' AND 1 (As Amended)
    NUMBER OF SEQUENCES: 20
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
      STREET: 2100 Pennsylvania Avenue, N.W.
      CITY: Washington
      STATE: D.C.
      COUNTRY: U.S.A.
      ZIP: 20037-3202
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
```

```
OPERATING SYSTEM: PC-DOS/MS-DOS
;
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
;
      APPLICATION NUMBER: US/08/674,008
;
      FILING DATE: 1-JUL-1996
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: 08/323,084
      FILING DATE: 14-OCT-1994
    PRIOR APPLICATION DATA:
;
      APPLICATION NUMBER: JP 280505/1993
      FILING DATE: 14-OCT-1993
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (202)293-7060
      TELEFAX: (202)293-7860
      TELEX: 6491103
  INFORMATION FOR SEQ ID NO: 1:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 89 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-674-008-1
 Query Match
                        100.0%; Score 463; DB 1; Length 89;
 Best Local Similarity
                        100.0%; Pred. No. 9.8e-52;
 Matches
          89; Conservative
                              0; Mismatches 0; Indels
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             11111111111111111111111111111111111
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 3
US-09-461-912A-46
; Sequence 46, Application US/09461912A
; Patent No. 6709855
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence A.
 APPLICANT: White, R. Tyler
  APPLICANT: Damm, Deborah L.
  APPLICANT: Lewicki, John A.
  TITLE OF INVENTION: Methods for detection and use of
 TITLE OF INVENTION: differentially expressed genes in disease states
  FILE REFERENCE: SCIOS.011A
  CURRENT APPLICATION NUMBER: US/09/461,912A
  CURRENT FILING DATE: 1999-12-15
  PRIOR APPLICATION NUMBER: US 60/113,008
  PRIOR FILING DATE: 1998-12-18
 NUMBER OF SEQ ID NOS: 48
 SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 46
   LENGTH: 89
```

```
TYPE: PRT
   ORGANISM: Homo sapiens
US-09-461-912A-46
                        100.0%; Score 463; DB 2; Length 89;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 9.8e-52;
         89; Conservative
                             0; Mismatches
                                              0: Indels
                                                             0; Gaps
                                                                        0;
Qу
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 4
US-09-175-713-1
; Sequence 1, Application US/09175713
: Patent No. 6852508
 GENERAL INFORMATION:
    APPLICANT: Herrmann, Stephen H.
    APPLICANT: Lu, Zhijian
    APPLICANT: McCoy, John M.
    APPLICANT: Swanberg, Stephen L.
    APPLICANT: Walker, Bruce
    APPLICANT: Yang, Otto
    TITLE OF INVENTION: CHEMOKINES WITH AMINO-TERMINAL MODIFICATIONS
    NUMBER OF SEQUENCES: 15
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genetics Institute, Inc.
      STREET: 87 CambridgePark Drive
      CITY: Cambridge
      STATE: MA
      COUNTRY: U.S.A.
      ZIP: 02140
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
;
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/09/175,713
;
      FILING DATE:
      CLASSIFICATION:
    ATTORNEY/AGENT INFORMATION:
      NAME: Sprunger, Suzanne A.
;
      REGISTRATION NUMBER: 41,323
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (617) 498-8284
      TELEFAX: (617) 876-5851
  INFORMATION FOR SEQ ID NO: 1:
;
    SEQUENCE CHARACTERISTICS:
;
      LENGTH: 89 amino acids
      TYPE: amino acid
;
      STRANDEDNESS:
```

```
TOPOLOGY: linear
    MOLECULE TYPE: protein
US-09-175-713-1
 Query Match
                       100.0%; Score 463; DB 2;
                                                 Length 89;
 Best Local Similarity
                       100.0%;
                               Pred. No. 9.8e-52;
 Matches
          89; Conservative
                              0; Mismatches
                                              0; Indels
                                                                      0;
                                                               Gaps
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             Db
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 5
US-09-647-501-4
; Sequence 4, Application US/09647501
: Patent No. 6863887
: GENERAL INFORMATION:
  APPLICANT: No. 6863887thwest Biotherapeutics, Inc.
  APPLICANT: Murphy, Gerald P.
  APPLICANT: Boynton, Alton L.
  APPLICANT:
             Sehgal, Anil
  TITLE OF INVENTION: THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE
  TITLE OF INVENTION: ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS
  FILE REFERENCE: 20093-000600PC
  CURRENT APPLICATION NUMBER: US/09/647,501
  CURRENT FILING DATE: 2000-09-24
  PRIOR APPLICATION NUMBER: 60/079,916
  PRIOR FILING DATE: 1998-03-30
  PRIOR APPLICATION NUMBER: 60/104,656
  PRIOR FILING DATE: 1998-10-16
  NUMBER OF SEQ ID NOS: 28
  SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 4
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-647-501-4
                        100.0%; Score 463; DB 2;
 Query Match
                                                 Length 89;
 Best Local Similarity
                       100.0%; Pred. No. 9.8e-52;
 Matches
          89; Conservative
                             0; Mismatches
                                              0;
                                                  Indels
                                                           0; Gaps
                                                                       0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
             111111111111111111111111111111111
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
```

```
US-08-323-084A-5
; Sequence 5, Application US/08323084A
; Patent No. 5563048
  GENERAL INFORMATION:
    APPLICANT: HONJO, TASUKU
    APPLICANT: SHIROZU, MICHIO
    APPLICANT: TADA, HIDEAKI
    TITLE OF INVENTION: No. 5563048el Polypeptides and DNAs encoding them
    NUMBER OF SEQUENCES: 20
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
      STREET: 2100 Pennsylvania Avenue, N.W.
      CITY: Washington
      STATE: D.C.
      COUNTRY: U.S.A.
      ZIP: 20037-3202
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/323,084A
      FILING DATE:
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: JP 280505/1993
      FILING DATE: 14-OCT-1993
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (202)293-7060
      TELEFAX: (202)293-7860
      TELEX: 6491103
  INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 93 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-323-084A-5
 Query Match
                        100.0%; Score 463; DB 1; Length 93;
 Best Local Similarity 100.0%; Pred. No. 1e-51;
         89; Conservative
                            0; Mismatches
                                               0: Indels
                                                            0; Gaps
                                                                        0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 7
US-08-674-008-5
; Sequence 5, Application US/08674008
; Patent No. 5756084
```

```
GENERAL INFORMATION:
    APPLICANT: HONJO, Tasuku
    APPLICANT: SHIROZU, Michio
    APPLICANT: TADA, Hideaki
    TITLE OF INVENTION: HUMAN STROMAL DERIVED
    TITLE OF INVENTION: FACTOR 1 AND 1 (As Amended)
    NUMBER OF SEQUENCES: 20
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
      STREET: 2100 Pennsylvania Avenue, N.W.
      CITY: Washington
      STATE: D.C.
      COUNTRY: U.S.A.
      ZIP: 20037-3202
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/674.008
      FILING DATE: 1-JUL-1996
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: 08/323,084
      FILING DATE: 14-OCT-1994
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: JP 280505/1993
      FILING DATE: 14-OCT-1993
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (202)293-7060
      TELEFAX: (202)293-7860
      TELEX: 6491103
  INFORMATION FOR SEQ ID NO: 5:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 93 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-674-008-5
 Query Match
                        100.0%; Score 463; DB 1; Length 93;
 Best Local Similarity
                        100.0%; Pred. No. 1e-51;
 Matches
          89; Conservative
                              0; Mismatches
                                              0; Indels
                                                             0; Gaps
                                                                        0:
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 8
US-09-919-497-95
; Sequence 95, Application US/09919497
```

```
; Patent No. 6773883
; GENERAL INFORMATION:
; APPLICANT: Mutter, George L.
; TITLE OF INVENTION: PROGNOSTIC CLASSIFICATION OF ENDOMETRIAL CANCER
; FILE REFERENCE: B0801/7225
  CURRENT APPLICATION NUMBER: US/09/919,497
  CURRENT FILING DATE: 2001-07-31
  PRIOR APPLICATION NUMBER: US 60/221,735
  PRIOR FILING DATE: 2000-07-31
; NUMBER OF SEQ ID NOS: 100
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 95
   LENGTH: 93
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-919-497-95
 Query Match
                         100.0%; Score 463; DB 2; Length 93;
 Best Local Similarity 100.0%; Pred. No. 1e-51;
         89; Conservative 0; Mismatches
                                               0; Indels
                                                              0; Gaps
                                                                          0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             1111111111111111111111111111111111
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 9
US-09-949-016-5967
; Sequence 5967, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
  TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
  TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES
THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
  PRIOR APPLICATION NUMBER: 60/241,755
 PRIOR FILING DATE: 2000-10-20
  PRIOR APPLICATION NUMBER: 60/237,768
  PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
  NUMBER OF SEQ ID NOS: 207012
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5967
   LENGTH: 93
   TYPE: PRT
   ORGANISM: Human
US-09-949-016-5967
```

100.0%; Score 463; DB 2; Length 93;

Query Match

```
Best Local Similarity 100.0%; Pred. No. 1e-51;
         89; Conservative 0; Mismatches 0; Indels
 Matches
                                                                    0;
                                                          0; Gaps
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
Qу
         61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
            61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 10
US-09-144-838-7
; Sequence 7, Application US/09144838A
; Patent No. 6844161
; GENERAL INFORMATION:
; APPLICANT: Siani, Michael A.
; APPLICANT: Wilken, Jill
; APPLICANT: Simon, Reyna
; APPLICANT: Kent, Stephen B.H.
; TITLE OF INVENTION: Modular Protein Libraries and Methods of Preparation
; FILE REFERENCE: GRFN-020/01US
; CURRENT APPLICATION NUMBER: US/09/144,838A
; CURRENT FILING DATE: 1998-08-31
; EARLIER APPLICATION NUMBER: US 60/057,620
; EARLIER FILING DATE: 1997-09-04
; NUMBER OF SEQ ID NOS: 54
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
   LENGTH: 93
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-144-838-7
 Query Match
                       100.0%; Score 463; DB 2; Length 93;
  Best Local Similarity 100.0%; Pred. No. 1e-51;
 Matches 89; Conservative
                           0; Mismatches
                                             0; Indels
                                                          0; Gaps
                                                                    0;
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
            1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
            Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 11
US-09-175-713-2
; Sequence 2, Application US/09175713
; Patent No. 6852508
; GENERAL INFORMATION:
    APPLICANT: Herrmann, Stephen H.
    APPLICANT: Lu, Zhijian
```

```
APPLICANT: McCoy, John M.
;
    APPLICANT: Swanberg, Stephen L.
    APPLICANT: Walker, Bruce
;
    APPLICANT: Yang, Otto
    TITLE OF INVENTION: CHEMOKINES WITH AMINO-TERMINAL MODIFICATIONS
    NUMBER OF SEQUENCES: 15
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genetics Institute, Inc.
      STREET: 87 CambridgePark Drive
      CITY: Cambridge
      STATE: MA
      COUNTRY: U.S.A.
      ZIP: 02140
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/09/175,713
      FILING DATE:
      CLASSIFICATION:
    ATTORNEY/AGENT INFORMATION:
      NAME: Sprunger, Suzanne A.
      REGISTRATION NUMBER: 41,323
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (617) 498-8284
      TELEFAX: (617) 876-5851
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 93 amino acids
      TYPE: amino acid
      STRANDEDNESS:
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-09-175-713-2
 Query Match
                        100.0%; Score 463; DB 2; Length 93;
 Best Local Similarity 100.0%; Pred. No. 1e-51;
 Matches
         89; Conservative
                            0; Mismatches 0; Indels
                                                            0; Gaps
                                                                        0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
             Db
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Πh
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 12
US-09-949-016-8247
; Sequence 8247, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
```

```
; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES
THEREOF
; FILE REFERENCE: CL001307
 CURRENT APPLICATION NUMBER: US/09/949,016
  CURRENT FILING DATE: 2000-04-14
  PRIOR APPLICATION NUMBER: 60/241,755
  PRIOR FILING DATE: 2000-10-20
  PRIOR APPLICATION NUMBER: 60/237,768
  PRIOR FILING DATE: 2000-10-03
  PRIOR APPLICATION NUMBER: 60/231,498
  PRIOR FILING DATE: 2000-09-08
  NUMBER OF SEQ ID NOS: 207012
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8247
   LENGTH: 119
   TYPE: PRT
   ORGANISM: Human
US-09-949-016-8247
 Query Match
                        100.0%; Score 463; DB 2; Length 119;
 Best Local Similarity 100.0%; Pred. No. 1.4e-51;
           89; Conservative
 Matches
                              0: Mismatches
                                              0; Indels
                                                             0; Gaps
                                                                        0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
             Db
          27 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 86
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Db
          87 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 115
RESULT 13
US-09-646-028-5
; Sequence 5, Application US/09646028
; Patent No. 6562347
; GENERAL INFORMATION:
 APPLICANT: Kwak, Larry
  APPLICANT: Biragyn, Arya
 TITLE OF INVENTION: METHODS AND COMPOSITIONS OF
; TITLE OF INVENTION: CHEMOKINE-TUMOR ANTIGEN FUSION PROTEINS AS CANCER
VACCINES
; FILE REFERENCE: 14014.0316/P
; CURRENT APPLICATION NUMBER: US/09/646,028
  CURRENT FILING DATE: 2000-09-12
  PRIOR APPLICATION NUMBER: 60/077,745
  PRIOR FILING DATE: 1998-03-12
; NUMBER OF SEQ ID NOS: 57
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 5
   LENGTH: 166
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of artificial sequence:/note=synthetic
construct
US-09-646-028-5
```

```
Query Match
                        100.0%; Score 463; DB 2; Length 166;
 Best Local Similarity 100.0%; Pred. No. 2.2e-51;
          89; Conservative
                              0; Mismatches
                                                   Indels
                                                              0; Gaps
                                                                         0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             Db
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qv
             11111111111111111111111111111
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 14
US-08-808-720-1
; Sequence 1, Application US/08808720
; Patent No. 6100387
  GENERAL INFORMATION:
    APPLICANT: Herrmann, Steve
    APPLICANT: Swanberg, Stephen
    TITLE OF INVENTION: CHIMERIC POLYPEPTIDES CONTAINING
    TITLE OF INVENTION: CHEMOKINE DOMAINS
    NUMBER OF SEQUENCES: 10
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genetics Insititute, Inc.
      STREET: 87 CambridgePark
      CITY: Cambridge
      STATE: MA
      COUNTRY: USA
      ZIP: 02140
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/808,720
      FILING DATE:
;
      CLASSIFICATION: 530
;
    ATTORNEY/AGENT INFORMATION:
             Sprunger, Suzanne
      NAME:
      REGISTRATION NUMBER: P-41,323
      REFERENCE/DOCKET NUMBER: GI5291
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (617) 498-8284
      TELEFAX: (617) 876-5851
  INFORMATION FOR SEQ ID NO: 1:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 328 amino acids
      TYPE: amino acid
      STRANDEDNESS:
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-808-720-1
```

Query Match 100.0%; Score 463; DB 2; Length 328;

```
Best Local Similarity 100.0%; Pred. No. 5.1e-51;
          89; Conservative 0; Mismatches 0; Indels
 Matches
                                                           0; Gaps
                                                                       0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Db
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 15
US-09-467-638-1
; Sequence 1, Application US/09467638
; Patent No. 6730296
 GENERAL INFORMATION:
    APPLICANT: Herrmann, Steve
    APPLICANT: Swanberg, Stephen
    TITLE OF INVENTION: CHIMERIC POLYPEPTIDES CONTAINING
    TITLE OF INVENTION: CHEMOKINE DOMAINS
    NUMBER OF SEQUENCES: 10
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genetics Insititute, Inc.
      STREET: 87 CambridgePark
      CITY: Cambridge
      STATE: MA
      COUNTRY: USA
      ZIP: 02140
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/09/467,638
      FILING DATE:
      CLASSIFICATION:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US/08/808,720
      FILING DATE:
    ATTORNEY/AGENT INFORMATION:
      NAME: Sprunger, Suzanne
      REGISTRATION NUMBER: P-41,323
      REFERENCE/DOCKET NUMBER: GI5291
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (617) 498-8284
      TELEFAX: (617) 876-5851
   INFORMATION FOR SEQ ID NO: 1:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 328 amino acids
      TYPE: amino acid
      STRANDEDNESS:
      TOPOLOGY: linear
    MOLECULE TYPE: protein
```

US-09-467-638-1

tch	100.0%;	Score 463;	DB 2;	Length 328;			
al Similarity	100.0%; Pred. No. 5.1e-5			-51;			
89; Conserva	ative 0;	: Mismatche	s 0;	Indels	0;	Gaps	0;
						_	
1 MNAKVVVVLV	LVLTALCLSDO	KPVSLSYRCPC	RFFESHV	ARANVKHLKI:	LNTPNC	ALQIV	60
11111111			1111111		111111	HĨH	
1 MNAKVVVVLVI	LVLTALCLSDO	KPVSLSYRCPC	RFFESHVA	ARANVKHLKI	LNTPNC	ALQIV	60
						-	
61 ARLKNNNROVO	CIDPKLKWIO	EYLEKALNK 89					
-	_						
	al Similarity 89; Conserva 1 MNAKVVVVLVI 1 MNAKVVVVLVI 61 ARLKNNNRQVO	al Similarity 100.0%; 89; Conservative 0; 1 MNAKVVVVLVLVLTALCLSDO	al Similarity 100.0%; Pred. No. 5 89; Conservative 0; Mismatche 1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPC	al Similarity 100.0%; Pred. No. 5.1e-51; 89; Conservative 0; Mismatches 0; 1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVA	al Similarity 100.0%; Pred. No. 5.1e-51; 89; Conservative 0; Mismatches 0; Indels 1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKI	al Similarity 100.0%; Pred. No. 5.1e-51; 89; Conservative 0; Mismatches 0; Indels 0; 1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNC.	89; Conservative 0; Mismatches 0; Indels 0; Gaps 1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV

Search completed: April 26, 2006, 02:39:05 Job time: 47 secs

GenCore version 5.1.7 Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 26, 2006, 02:30:38; Search time 225 Seconds

(without alignments)

279.076 Million cell updates/sec

Title: US-10-785-230-5

Perfect score: 463

Sequence: 1 MNAKVVVLVLTALCLSD......VCIDPKLKWIQEYLEKALNK 89

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt_05.80:*

1: uniprot_sprot:*
2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

			8 .				•	_
R	esult		Query					•
	No.	Score	Match	Length	DB	ID	Descrip	tion
	1	463	100.0	89	2	Q61CW0_HUMAN	Q6icw0	homo sapien
	2	463	100.0	92	2	Q9H554 HUMAN	Q9h554	homo sapien
	3	463	100.0	93	1	SDF1 HUMAN	P48061	homo sapien
	4	463	100.0	119	2	Q5IT36 HUMAN	Q5it36	homo sapien
	5	455	98.3	89	2	Q8HYPO MACMU	Q8hyp0	macaca mula
	6	447	96.5	93	2	Q5R8M6_PONPY	Q5r8m6	pongo pygma
	7	445	96.1	89	2	Q54AJ3 FELCA	Q54aj3	felis silve
	8	445	96.1	93	1	SDF1 FELCA	062657	felis silve
	9	442	95.5	89	1	SDF1 MOUSE	P40224	mus musculu
	10	442	95.5	89	2	Q543V6 MOUSE	Q543v6	mus musculu
	11	442	95.5	93	2	Q4FJL5 MOUSE	Q4fj15	mus musculu
	12	442	95.5	137	2	Q80ZW4 MOUSE	Q80zw4	mus musculu
	13	437	94.4	89	2	Q5XNN9 CANFA	Q5xnn9	canis famil
	14	435	94.0	89	2	Q9QZD1 RAT		rattus norv
	15	435	94.0	119	2	Q80YV8 RAT	Q80yv8	rattus norv

16	428	92.4	116	2	Q6EKW4_PIG	Q6ekw4	sus scrofa
17	359	77.5	89	2	Q6T7C0_CHICK	Q6t7c0	gallus gall
18	359	77.5	131	2	Q6T7B9_CHICK	Q6t7b9	gallus gall
19	341	73.7	93	2	Q5EBF6 XENTR	Q5ebf6	xenopus tro
20	341	73.7	94	2	Q8UUJ9_XENLA		xenopus lae
21	225.5	48.7	99	2	Q4QTK3_ICTPU	Q4qtk3	ictalurus p
22	224.5	48.5	99	2	Q8AV10_BRARE	Q8av10	brachydanio
23	220.5	47.6	97	2	Q6V9B5_BRARE	Q6v9b5	brachydanio
24	209.5	45.2	97	2	Q70V43 CYPCA	Q70v43	cyprinus ca
25	207.5	44.8	98	2	Q4RQF0_TETNG	Q4rqf0	tetraodon n
26	206.5	44.6	99	2	Q5ZP81_CYPCA	Q5zp81	cyprinus ca
27	122	26.3	98	2	Q8QGV8_PAROL	Q8qgv8	paralichthy
28	122	26.3	109	2	Q90Y59_PAROL	Q90y59	paralichthy
29	116	25.1	101	1	IL8_FELCA	Q9xsx5	felis silve
30	113.5	24.5	101	1	IL8_CAVPO	P49113	cavia porce
31	113	24.4	97	2	Q6LAE6_HUMAN	Q6lae6	homo sapien
32	113	24.4	99	1	IL8_HUMAN	P10145	h interleuk
33	113	24.4	99	2	Q6FGF6_HUMAN	Q6fgf6	homo sapien
34	112.5	24.3	96	1	GROA_MOUSE	P12850	mus musculu
35	112.5	24.3	107	2	Q5U5W9_MOUSE	Q5u5w9	mus musculu
36	111.5	24.1	107	2	Q6PUD4_PIG	Q6pud4	sus scrofa
37	111	24.0	98	1	SCYBA_RAT	P48973	rattus norv
38	111	24.0	101	1	IL8_CANFA	P41324	canis famil
39	110.5	23.9	107	2	Q6PUJ1_PIG	Q6puj1	sus scrofa
40	110	23.8	103	1	IL8_CHICK	P08317	gallus gall
41	109.5	23.7	42	2	Q75PL0_ORYLA	Q75p10	oryzias lat
42	109.5	23.7	91	1	CCL5_SIGHI		sigmodon hi
43	109	23.5	98	2	Q6GTC7_RAT	Q6gtc7	rattus norv
44	108.5	23.4	91	1	CCL5_MACMU		macaca mula
45	107	23.1	101	1	IL8_MACMU	P67813	macaca mula

ALIGNMENTS

```
RESULT 1
Q6ICW0 HUMAN
     Q6ICWO HUMAN PRELIMINARY;
                                      PRT;
                                               89 AA.
ΙD
AC
     Q6ICW0;
     10-MAY-2005 (TrEMBLrel. 30, Created)
10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT
DT
DT
     10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE
     CXCL12 protein (Stromal cell-derived factor 1a) (Fragment).
GN
     Name=CXCL12;
     Homo sapiens (Human).
os
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
     Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC
     Homo.
OX.
     NCBI_TaxID=9606;
RN
     [1]
RP
     NUCLEOTIDE SEQUENCE.
     Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RA
RL
     Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
     [2]
RN
RP
     NUCLEOTIDE SEQUENCE.
RA
     Zhao X., Zhang H., Lee S., Wong K., Zheng B.;
     "Polymorphism study of cell-derived factor 1 (SDF1) gene and their
RT
```

```
correlation with HIV infection in a Chinese cohort.";
    Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; CR450283; CAG29279.1; -; mRNA.
DR
DR
    EMBL; AY874118; AAW82036.1; -; mRNA.
FT
    NON TER
                 89
                       89
    SEQUENCE
               89 AA; 10103 MW; 62B44E8D209C3A14 CRC64;
SO
                         100.0%; Score 463; DB 2; Length 89;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 6.2e-44;
           89; Conservative
                               0; Mismatches
                                                0; Indels
                                                              0; Gaps
                                                                          0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             1 \  \, \text{MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV} \  \, 60
Db
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 2
Q9H554 HUMAN
    Q9H554 HUMAN PRELIMINARY;
                                  PRT;
                                          92 AA.
ID
AC
    O9H554;
DT
    01-MAR-2001 (TrEMBLrel. 16, Created)
DT
    01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT
    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE
    Chemokine (C-X-C motif) ligand 12 (Stromal cell-derived factor
DΕ
GN
    Name=CXCL12; ORFNames=RP11-20J15.4-002;
os
    Homo sapiens (Human).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC
    Homo.
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    NUCLEOTIDE SEQUENCE.
RA
    Bird C.;
RL
    Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
    EMBL; AL137026; CAC10202.1; -; Genomic_DNA.
DR
DR
    HSSP; P48061; 1SDF.
DR
    SMR; Q9H554; 23-88.
    GO; GO:0005576; C:extracellular region; IEA.
DR
    GO; GO:0008009; F:chemokine activity; IEA.
DR
    GO; GO:0006955; P:immune response; IEA.
DR
    InterPro; IPR002473; C-X-C/Interlkn 8.
DR
    InterPro; IPR001811; Chemokine IL8.
DR
DR
    Pfam; PF00048; IL8; 1.
    PRINTS; PR00436; INTERLEUKIN8.
DR
    SMART; SM00199; SCY; 1.
DR
    SEQUENCE 92 AA; 10510 MW; AEF0C402B44E8D20 CRC64;
SO
  Query Match
                         100.0%; Score 463; DB 2; Length 92;
  Best Local Similarity
                         100.0%; Pred. No. 6.4e-44;
                             0; Mismatches
 Matches 89; Conservative
                                                 0; Indels
```

```
1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 3
SDF1 HUMAN
    SDF1 HUMAN
ID
                   STANDARD;
                                  PRT;
                                          93 AA.
AC
    P48061;
DT
    01-FEB-1996 (Rel. 33, Created)
DT
    01-FEB-1996 (Rel. 33, Last sequence update)
    10-MAY-2005 (Rel. 47, Last annotation update)
DT
DE
    Stromal cell-derived factor 1 precursor (SDF-1) (CXCL12) (Pre-B cell
DE
    growth stimulating factor) (PBSF) (hIRH) [Contains: SDF-1-beta(3-72);
DE
    SDF-1-alpha(3-67)].
GN
    Name=CXCL12; Synonyms=SDF1;
    Homo sapiens (Human).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC
OC
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    NUCLEOTIDE SEQUENCE.
RA
    Spotila L.D.;
RL
    Submitted (OCT-1994) to the EMBL/GenBank/DDBJ databases.
RN
    NUCLEOTIDE SEQUENCE.
RP
    MEDLINE=96039262; PubMed=7490086;
RA
    Shirozu M., Nakano T., Inazawa J., Tashiro K., Tada H., Shinohara T.,
RA
    Honjo T.;
RT
    "Structure and chromosomal localization of the human stromal cell-
    derived factor 1 (SDF1) gene.";
RL
    Genomics 28:495-500(1995).
RN
     [3]
    NUCLEOTIDE SEQUENCE (ISOFORM ALPHA).
RP
RC
    TISSUE=Liver;
RA
    Begum N.A., Barnard G.F.;
RT
    "Nucleotide sequence of hIRH, human intercrine reduced in hepatomas.";
RL
    Submitted (JAN-1995) to the EMBL/GenBank/DDBJ databases.
RN
    NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RP
RA
    Rieder M.J., Johanson E.J., da Ponte S.H., Hastings N.C., Ahearn M.O.,
RA
    Bertucci C.B., Wong M.W., Yi Q., Nickerson D.A.;
RT
    "SeattleSNPs. NHLBI HL66682 program for genomic applications, UW-
RT
    FHCRC, Seattle, WA (URL: http://pga.gs.washington.edu).";
RL
    Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN
    NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RP
RX
    PubMed=15164054; DOI=10.1038/nature02462;
RA
    Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA
    Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA
    Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA
    Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA
    Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
```

```
Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA
     Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA
     Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA
     Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA
     Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA
RA
     Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
     Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA
     Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA
     Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA
     Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA
     Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA
RA
     Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA
     Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA
     Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
     Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA
RA
     Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA
     Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA
     Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
     Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA
     Siebert R., Fechtel K., Bentley D., Durbin R., Hubbard T.,
RA
     Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RA
     "The DNA sequence and comparative analysis of human chromosome 10.";
RT
RL
     Nature 429:375-381(2004).
RN
     [6]
     NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RP
RC
     TISSUE=Brain;
RX
     MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriquez A.C., Grimwood J., Schmutz J., Myers R.M.,
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
RT
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
RP
     IDENTIFICATION OF SDF-1ALPHA(3-67) AND SDF-1BETA(3-72) BY MASS
RP
     SPECTROMETRY, AND N-TERMINAL AND C-TERMINAL PROCESSING.
     PubMed=14525775; DOI=10.1182/blood-2003-08-2857;
RX
     De La Luz Sierra M., Yang F., Narazaki M., Salvucci O., Davis D.,
RA
     Yarchoan R., Zhang H.H., Fales H., Tosato G.;
RA
     "Differential processing of stromal-derived factor-lalpha and beta
RT
RT
     explains functional diversity.";
RL
     Blood 103:2452-2459(2004).
RN
     [8]
```

```
STRUCTURE BY NMR OF 22-88.
RP
    MEDLINE=98046030; PubMed=9384579; DOI=10.1093/emboj/16.23.6996;
RX
    Crump M.P., Gong J.H., Loetscher P., Rajarathnam K., Amara A.,
RA
    Arenzana-Seisdedos F., Virelizier J.L., Baggiolini M., Sykes B.D.,
RA
RA
    Clark-Lewis I.;
    "Solution structure and basis for functional activity of stromal cell-
RT
    derived factor-1; dissociation of CXCR4 activation from binding and
RT
    inhibition of HIV-1.";
RT
RL
    EMBO J. 16:6996-7007(1997).
RN
    [9]
RP
    X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 22-88.
    MEDLINE=98284037; PubMed=9618518; DOI=10.1073/pnas.95.12.6941;
RX
RA
    Dealwis C., Fernandez E.J., Thompson D.A., Simon R.J., Siani M.A.,
RA
    "Crystal structure of chemically synthesized [N33A] stromal cell-
RT
RT
    derived factor lalpha, a potent ligand for the HIV-1 'fusin'
RT
    coreceptor.";
RL
    Proc. Natl. Acad. Sci. U.S.A. 95:6941-6946(1998).
CC
    -!- FUNCTION: Chemoattractant active on T-lymphocytes, monocytes, but
        not neutrophils. SDF-1-beta(3-72) and SDF-1-alpha(3-67) show a
CC
        reduced chemotactic activity. Binding to cell surface
CC
        proteoglycans seems to inhibit formation of SDF-1-alpha(3-67) and
CC
        thus to preserve activity on local sites.
CC
    -!- SUBCELLULAR LOCATION: Secreted.
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
CC
        Name=Beta; Synonyms=SDF-1-beta(1-72);
CC
          IsoId=P48061-1; Sequence=Displayed;
CC
        Name=Alpha; Synonyms=SDF-1-alpha(1-68);
CC
          IsoId=P48061-2; Sequence=VSP 001056;
CC
    -!- PTM: Processed forms SDF-1-beta(3-72) and SDF-1-alpha(3-67) are
CC
        produced after secretion by proteolytic cleavage of isoforms Beta
CC
        and Alpha, respectively. The N-terminal processing is probably
CC .
        achieved by DPP4. Isoform Alpha is first cleaved at the C-terminus
CC
        to yield a SDF-1-alpha(1-67) intermediate before being processsed
CC
        at the N-terminus. The C-terminal processing of isoform Alpha is
CC
        reduced by binding to heparin and, probably, cell surface
CC
        proteoglycans.
CC
    -!- SIMILARITY: Belongs to the intercrine alpha (chemokine CxC)
CC
        family.
CC
    ______
CC
    This Swiss-Prot entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use as long as its content is in no way modified and this statement is not
CC
    removed.
CC
    ______
DR
    EMBL; U16752; AAA97434.1; -; mRNA.
DR
    EMBL; L36033; AAB39332.1; -; mRNA.
    EMBL; L36034; AAB39333.1; -; mRNA.
DR
    EMBL; U19495; AAB40516.1; -; mRNA.
DR
    EMBL; AY802782; AAV49999.1; -; Genomic DNA.
DR
DR
    EMBL; AL137026; CAC10203.1; -; Genomic_DNA.
    EMBL; BC039893; AAH39893.1; -; mRNA.
DR
DR
    PIR; G01540; G01540.
DR
    PDB; 1A15; X-ray; A/B=22-88.
DR
    PDB; 1QG7; X-ray; A/B=22-88.
```

```
PDB; 1SDF; NMR; @=22-88.
     PDB; 1VMC; NMR; A=20-89.
DR
     PDB; 2SDF; NMR; @=22-88.
DR
     Ensembl; ENSG00000107562; Homo sapiens.
DR
     HGNC; HGNC: 10672; CXCL12.
DR
    MIM; 600835; -.
DR
     GO; GO:0008009; F:chemokine activity; TAS.
     GO; GO:0005102; F:receptor binding; TAS.
DR
     GO; GO:0006874; P:calcium ion homeostasis; TAS.
DR
DR
     GO; GO:0007155; P:cell adhesion; TAS.
DR
     GO; GO:0006935; P:chemotaxis; TAS.
DR
     GO; GO:0008015; P:circulation; TAS.
     GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; TAS.
DR
     GO; GO:0006955; P:immune response; TAS.
DR
     GO; GO:0008064; P:regulation of actin polymerization and/or d. . .; TAS.
DR
     GO; GO:0009615; P:response to virus; TAS.
DR
DR
     GO; GO:0007165; P:signal transduction; TAS.
     InterPro; IPR002473; C-X-C/Interlkn 8.
DR
DR
     InterPro; IPR001811; Chemokine IL8.
     InterPro; IPR001089; CXC chmkine smll.
DR
     Pfam; PF00048; IL8; 1.
DR
     PRINTS; PR00436; INTERLEUKIN8.
DR
     PROSITE; PS00471; SMALL CYTOKINES CXC; FALSE NEG.
KW
     3D-structure; Alternative splicing; Chemotaxis; Cytokine;
     Growth factor; Sensory transduction; Signal.
KW
FT
     SIGNAL
                  1
                        21
                                 Potential.
FT
     CHAIN
                 22
                        93
                                 Stromal cell-derived factor 1.
FT
     CHAIN
                 24
                        93
                                 SDF-1-beta (3-72).
FT
     CHAIN
                 24
                        88
                                 SDF-1-alpha(3-67).
FT
     DISULFID
                 30
                        55
FT
     DISULFID
                 32
                        71
FT
     VARSPLIC
                 90
                        93
                                 Missing (in isoform Alpha).
FT
                                 /FTId=VSP_001056.
\mathbf{FT}
     STRAND
                 36
                        36
\mathbf{FT}
     HELIX
                  41
                        43
FT
     STRAND
                  44
                        50
FT
     TURN
                  53
                        54
FT
     STRAND
                 59
                        63
FT
     TURN
                  64
                        66
  Query Match
                         100.0%; Score 463; DB 1; Length 93;
  Best Local Similarity
                         100.0%; Pred. No. 6.5e-44;
            89; Conservative
                                0; Mismatches
                                                  0; Indels
                                                                0; Gaps
                                                                            0;
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
              1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
           61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
              61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 4
Q5IT36 HUMAN
     O5IT36 HUMAN PRELIMINARY;
                                   PRT;
                                          119 AA.
АÇ
     O5IT36;
```

```
10-MAY-2005 (TrEMBLrel. 30, Created)
DT
    10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT
    10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DT
    Stromal cell-derived factor 1 gamma.
DE
GN
    Name=CXCL12;
os
    Homo sapiens (Human).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC
OC
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    NUCLEOTIDE SEQUENCE.
RA
    Callebaut C., Verdin E.;
    "Inhibition of X4 and R5 HIV-1 by human SDF-1g, a novel chemokine that
RT
    interferes with HIV transcription.";
RT
    Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AY644456; AAT76437.1; -; mRNA.
DR
    GO; GO:0005576; C:extracellular region; IEA.
DR
    GO; GO:0008009; F:chemokine activity; IEA.
    GO; GO:0006955; P:immune response; IEA.
    InterPro; IPR002473; C-X-C/Interlkn 8.
DR
    InterPro; IPR001811; Chemokine IL8.
DR
    Pfam; PF00048; IL8; 1.
DR
    PRINTS; PR00436; INTERLEUKIN8.
DR
    SMART; SM00199; SCY; 1.
SO
    SEQUENCE
              119 AA; 13705 MW; C36297D68341B824 CRC64;
 Query Match
                         100.0%; Score 463; DB 2; Length 119;
 Best Local Similarity
                         100.0%; Pred. No. 8.3e-44;
 Matches 89; Conservative
                              0; Mismatches
                                                0; Indels
                                                              0; Gaps
                                                                          0;
Qу
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 5
O8HYPO MACMU
    08HYPO MACMU PRELIMINARY;
                                  PRT;
                                          89 AA.
    O8HYPO;
AC
DT
    01-MAR-2003 (TrEMBLrel. 23, Created)
    01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DT
DE
    Chemokine CXCL12/SDF-1ALPHA.
os
    Macaca mulatta (Rhesus macaque).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
oc
    Cercopithecidae; Cercopithecinae; Macaca.
OX
    NCBI TaxID=9544;
RN
    [1]
RP
    NUCLEOTIDE SEQUENCE.
    MEDLINE=22123042; PubMed=12126650; DOI=10.1006/cyto.2002.0875;
RX
    Basu S., Schaefer T.M., Ghosh M., Fuller C.L., Reinhart T.A.;
RA
```

```
"Molecular cloning and sequencing of 25 different rhesus macaque
RT
RT
     chemokine cDNAs reveals evolutionary conservation among C, CC, CXC,
     and CX3C families of chemokines.";
RT
     Cytokine 18:140-148(2002).
RL
     EMBL; AF449283; AAN76086.1; -; mRNA.
DR
DR
    HSSP; P48061; 1SDF.
     SMR; Q8HYP0; 23-88.
DR
    GO; GO:0005576; C:extracellular region; IEA.
DR
     GO; GO:0008009; F:chemokine activity; IEA.
DR
     GO; GO:0006955; P:immune response; IEA.
DR
     InterPro; IPR002473; C-X-C/Interlkn 8.
DR
DR
    InterPro; IPR001811; Chemokine IL8.
DR
     Pfam; PF00048; IL8; 1.
DR
    PRINTS; PR00436; INTERLEUKIN8.
DR
    SMART; SM00199; SCY; 1.
SO
    SEQUENCE
               89 AA; 10105 MW; AD531633C6DC2B07 CRC64;
                         98.3%; Score 455; DB 2; Length 89;
 Query Match
 Best Local Similarity
                         97.8%; Pred. No. 4.9e-43;
           87; Conservative
                                0; Mismatches
                                                 2; Indels
                                                               0; Gaps
                                                                           0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLALVLTTLCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 6
Q5R8M6 PONPY
    Q5R8M6 PONPY PRELIMINARY;
                                  PRT;
                                          93 AA.
     Q5R8M6;
     01-FEB-2005 (TrEMBLrel. 29, Created)
DT
DT
     01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
DT
     01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE
     Hypothetical protein DKFZp469G1525.
GN
     Name=DKFZp469G1525;
OS
     Pongo pygmaeus (Orangutan).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC
     Pongo.
     NCBI TaxID=9600;
OX
RN
     [1]
RP
     NUCLEOTIDE SEQUENCE.
RC
     TISSUE=Kidney;
RG
     The German cDNA Consortium;
RA
     Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA
     Fobo G., Han M., Wiemann S.;
     Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RL
DR
     EMBL; CR859725; CAH91884.1; -; mRNA.
DR
     SMR; Q5R8M6; 23-88.
DR
     GO; GO:0005576; C:extracellular region; IEA.
DR
     GO; GO:0008009; F:chemokine activity; IEA.
DR
     GO; GO:0006955; P:immune response; IEA.
DR
     InterPro; IPR002473; C-X-C/Interlkn 8.
```

```
InterPro; IPR001811; Chemokine IL8.
DR
    Pfam; PF00048; IL8; 1.
DR
    PRINTS; PR00436; INTERLEUKIN8.
DR
    SMART; SM00199; SCY; 1.
DR
    Hypothetical protein.
KW
    SEQUENCE 93 AA; 10655 MW; 551D6828FFF9183D CRC64;
SO
                        96.5%; Score 447; DB 2; Length 93;
 Query Match
 Best Local Similarity
                        96.6%; Pred. No. 4.1e-42;
           86; Conservative
                              1; Mismatches
 Matches
                                               2; Indels
                                                            0; Gaps
                                                                       0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVDVLALVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNDNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 7
Q54AJ3 FELCA
    Q54AJ3 FELCA PRELIMINARY;
                                 PRT;
ID
                                         89 AA.
AC
    054AJ3;
DΤ
    13-SEP-2005 (TrEMBLrel. 31, Created)
DT
    13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT
    13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE
    Stromal cell-derived factor-1 a precursor.
GN
    Name=SDF-1a;
OS
    Felis silvestris catus (Cat).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Felidae;
    Felis.
OC
OX
    NCBI TaxID=9685;
RN
RP
    NUCLEOTIDE SEQUENCE.
RC
    TISSUE=Thymus;
RA
    Nishimura Y., Miyazawa T., Ikeda Y., Izumiya Y., Nakamura K., Cai J.,
RA
    Sato E., Kohmoto M., Mikami T.;
     "Molecular cloning and sequencing of feline stromal cell-derived
RT
RT
    factor-1 a and b.";
    Eur. J. Immunogenet. 0:0-0(1998).
RL
    EMBL; AB011965; BAA28601.1; -; mRNA.
KW
    Signal.
    SIGNAL
                               Potential.
FT
                 1
                       18
FT
    CHAIN
                19
                       89
                               stromal cell-derived factor-la.
    SEQUENCE
              89 AA; 10018 MW; 81E9BE373B2F85FD CRC64;
SO
 Query Match
                        96.1%; Score 445; DB 2; Length 89;
  Best Local Similarity
                        95.5%; Pred. No. 6.5e-42;
 Matches
           85; Conservative
                              1; Mismatches
                                               3; Indels
                                                            0;
                                                                        0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
             Db
           1 MDAKVVAVLALVLAALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
```

Qу

```
RESULT 8
SDF1 FELCA
                                 PRT:
    SDF1 FELCA
                   STANDARD:
                                       93 AA.
AC
    062657;
    15-DEC-1998 (Rel. 37, Created)
DT
    15-DEC-1998 (Rel. 37, Last sequence update)
DT
    10-MAY-2005 (Rel. 47, Last annotation update)
DT
    Stromal cell-derived factor 1 precursor (SDF-1) (CXCL12).
DE
GN
    Name=CXCL12; Synonyms=SDF1;
os
    Felis silvestris catus (Cat).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Felidae;
OC
    Felinae; Felis.
OX
    NCBI TaxID=9685;
RN
    [1]
RP
    NUCLEOTIDE SEQUENCE (ISOFORMS ALPHA AND BETA).
RC
    TISSUE=Thymus;
    MEDLINE=98450506; PubMed=9777331;
RX
RX
    DOI=10.1046/j.1365-2370.1998.00107.x;
    Nishimura Y., Miyazawa T., Ikeda Y., Izumiya Y., Nakamura K.,
RA
    Cai J.S., Sato E., Kohmoto M., Mikami T.;
RA
RT
    "Molecular cloning and sequencing of feline stromal cell-derived
RT
    factor-1 alpha and beta.";
RL
    Eur. J. Immunogenet. 25:303-305(1998).
CC
    -!- FUNCTION: Chemoattractant active on T-lymphocytes, monocytes, but
CC
        not neutrophils.
CC
    -!- SUBCELLULAR LOCATION: Secreted.
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
CC
        Name=Beta;
CC
          IsoId=062657-1; Sequence=Displayed;
CC
        Name=Alpha;
CC
          IsoId=062657-2; Sequence=VSP 001055;
CC
    -!- SIMILARITY: Belongs to the intercrine alpha (chemokine CxC)
CC
        family.
CC
     ______
CC
    This Swiss-Prot entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use as long as its content is in no way modified and this statement is not
CC
    removed.
     ______
CC
DR
    EMBL; AB011966; BAA28602.1; -; mRNA.
DR
    HSSP; P48061; 1SDF.
    SMR; 062657; 23-88.
DR
    InterPro; IPR002473; C-X-C/Interlkn 8.
DR
    InterPro; IPR001811; Chemokine IL8.
DR
    InterPro; IPR001089; CXC_chmkine_smll.
DR
DR
    Pfam; PF00048; IL8; 1.
    PRINTS; PR00436; INTERLEUKIN8.
DR
DR
    SMART; SM00199; SCY; 1.
    PROSITE; PS00471; SMALL CYTOKINES CXC; FALSE NEG.
DR
    Alternative splicing; Chemotaxis; Cytokine; Growth factor;
KW
```

```
KW
     Sensory transduction; Signal.
FT
                        21
     SIGNAL
                 1
                                 Potential.
                 22
                        93
FT
    CHAIN
                                 Stromal cell-derived factor 1.
                 30
                        55
FT
    DISULFID
                                 By similarity.
                 32
                                 By similarity.
                        71
FT
    DISULFID
                 90
                        93
FT
    VARSPLIC
                                 Missing (in isoform Alpha).
                                 /FTId=VSP 001055.
FT
                       10581 MW;
SO
    SEQUENCE
               93 AA;
                                 44FC763711E9BE37 CRC64;
 Query Match
                         96.1%; Score 445; DB 1; Length 93;
 Best Local Similarity
                         95.5%; Pred. No. 6.8e-42;
                                1; Mismatches
 Matches
           85; Conservative
                                                3; Indels 0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             Db
           1 MDAKVVAVLALVLAALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 9
SDF1 MOUSE
ID
    SDF1 MOUSE
                   STANDARD;
                                 PRT:
                                         89 AA.
AC
    P40224;
DT
    01-FEB-1995 (Rel. 31, Created)
    01-FEB-1995 (Rel. 31, Last sequence update)
DT
    10-MAY-2005 (Rel. 47, Last annotation update)
    Stromal cell-derived factor 1 precursor (SDF-1) (CXCL12) (Pre-B cell
DE
DE
    growth stimulating factor) (PBSF) (12-O-tetradecanoylphorbol 13-
DΕ
    acetate repressed protein 1) (TPAR1) (Thymic lymphoma cell stimulating
DE
    factor) (TLSF).
GN
    Name=Cxcl12; Synonyms=Sdf1;
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC
OC
    Muroidea; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
    NUCLEOTIDE SEQUENCE.
RX
    MEDLINE=94181581; PubMed=8134392;
RA
    Nagasawa T., Kikutani H., Kishimoto T.;
RT
     "Molecular cloning and structure of a pre-B-cell growth-stimulating
RT
    factor.";
RL
    Proc. Natl. Acad. Sci. U.S.A. 91:2305-2309(1994).
RN
RP
    NUCLEOTIDE SEQUENCE.
RX
    MEDLINE=93342488; PubMed=8342023;
RA
    Tashiro K., Tada H., Heilker R., Shirozu M., Nakano T., Honjo T.;
RT
     "Signal sequence trap: a cloning strategy for secreted proteins and
RT
    type I membrane proteins.";
RL
    Science 261:600-603(1993).
RN
    [3]
RP
    NUCLEOTIDE SEQUENCE.
RX
    MEDLINE=95073497; PubMed=7982471; DOI=10.1006/excr.1994.1344;
RA
    Jiang W., Zhou P., Kahn S.M., Tomita N., Johnson M.D., Weinstein I.B.;
```

```
"Molecular cloning of TPAR1, a gene whose expression is repressed by
RT
     the tumor promoter 12-0-tetradecanoylphorbol 13-acetate (TPA).";
RT
RL
     Exp. Cell Res. 215:284-293(1994).
RN
     [4]
     NUCLEOTIDE SEQUENCE.
RP
RC
     STRAIN=AKR/J;
     Nomura M., Nakata Y., Uzawa A., Nose M., Akashi M., Suzuki G.;
RA
     Submitted (DEC-1994) to the EMBL/GenBank/DDBJ databases.
RL
RN
     NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RP
     STRAIN=C57BL/6J; TISSUE=Kidney;
RC
RX
     MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA
     Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA
     Nikaido I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H.,
     Yaqi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA
     Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA
     Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA
RA
     Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,
     Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA
     Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA
     Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA
     Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA
     Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA
     Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA
     Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA
RA
     Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
     Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA
     Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
RA
     Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
     Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA
RA
     Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
RA
     Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA
     Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
     Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA
     Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA
RA
     Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
     Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA
RA
     Birney E., Hayashizaki Y.;
RT
     "Analysis of the mouse transcriptome based on functional annotation of
RT
     60,770 full-length cDNAs.";
RL
     Nature 420:563-573(2002).
RN
     NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RP
     STRAIN=C57BL/6J; TISSUE=Mammary gland;
RC
     MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RX
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
```

Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,

RA

```
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
CC
    -!- FUNCTION: Chemoattractant active on T-lymphocytes, monocytes, but
CC
         not neutrophils.
CC
     -!- FUNCTION: Stimulates the proliferation of bone marrow-derived b
CC
         progenitor cells in the presence of IL-7 as well as growth of the
CC
         stromal cell-dependent B-cell clone DW34 cells.
CC
     -!- SUBCELLULAR LOCATION: Secreted.
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=2;
CC
        Name=Alpha;
CC
           IsoId=P40224-1; Sequence=Displayed;
CC
        Name=Beta;
          IsoId=P40224-2; Sequence=VSP 001057;
CC
     -!- SIMILARITY: Belongs to the intercrine alpha (chemokine CxC)
CC
         family.
     _____
CC
    This Swiss-Prot entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use as long as its content is in no way modified and this statement is not
CC
    removed.
CC
DR
     EMBL; D21072; BAA04648.1; -; mRNA.
DR
     EMBL; L12029; AAA40100.1; -; mRNA.
    EMBL; L12030; AAA40101.1; -; mRNA.
DR
DR
    EMBL; S74318; AAB32650.1; -; mRNA.
DR
    EMBL; D43804; BAA07862.1; -; mRNA.
     EMBL; D43805; BAA07863.1; -; mRNA.
DR
     EMBL; AK075596; BAC35845.1; -; mRNA.
DR
    EMBL; BC006640; AAH06640.1; -; mRNA.
DR
    PIR; A53497; A53497.
DR
    PIR; I81182; I81182.
DR
    HSSP; P48061; 1SDF.
DR
    SMR; P40224; 23-88.
DR
    Ensembl; ENSMUSG00000061353; Mus musculus.
    MGI; MGI:103556; Cxcl12.
    GO; GO:0005615; C:extracellular space; TAS.
DR
     GO; GO:0008009; F:chemokine activity; IDA.
DR
     GO; GO:0007420; P:brain development; IDA.
DR
     GO; GO:0007281; P:germ cell development; IDA.
DR
DR
     GO; GO:0008354; P:germ cell migration; IDA.
DR
     GO; GO:0050930; P:induction of positive chemotaxis; IDA.
     GO; GO:0030335; P:positive regulation of cell migration; IDA.
     GO; GO:0042098; P:T cell proliferation; IMP.
DR
     InterPro; IPR002473; C-X-C/Interlkn_8.
DR
DR
     InterPro; IPR001811; Chemokine IL8.
DR
     InterPro; IPR001089; CXC chmkine smll.
DR
     Pfam; PF00048; IL8; 1.
DR
     PRINTS; PR00436; INTERLEUKIN8.
     PROSITE; PS00471; SMALL CYTOKINES_CXC; FALSE_NEG.
DR
```

```
Alternative splicing; Chemotaxis; Cytokine; Growth factor;
KW
     Sensory transduction; Signal.
KW
FT
     SIGNAL
                  1
                        21
                                 Potential.
                 22
                                 Stromal cell-derived factor 1.
FT
    CHAIN
                        89
                 30
                        55
                                 By similarity.
FT
    DISULFID
                                 By similarity.
FT
     DISULFID
                 32
                        71
                                 K -> KRLKM (in isoform Beta).
FT
    VARSPLIC
                 89
                        89
                                 /FTId=VSP 001057.
FT
               89 AA; 10032 MW; C4B8AD69078E55FA CRC64;
SQ
     SEQUENCE
                         95.5%; Score 442; DB 1; Length 89;
 Query Match
 Best Local Similarity
                         93.3%; Pred. No. 1.4e-41;
           83; Conservative
                                3; Mismatches
                                                 3; Indels
                                                               0;
                                                                   Gaps
                                                                           0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
              Db
           1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALOIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
              61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 10
Q543V6 MOUSE
ID
    Q543V6 MOUSE PRELIMINARY;
                                   PRT;
                                           89 AA.
AC
     0543V6;
DT
     13-SEP-2005 (TrEMBLrel. 31, Created)
DT
     13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
     13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DT
DE
     9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched
DE
    library, clone:B130032A21 product:stromal cell derived factor 1, full
DE
    insert sequence.
GN
    Name=Cxcl12;
os
    Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC
    Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
    NUCLEOTIDE SEQUENCE.
     STRAIN=C57BL/6J; TISSUE=Parthenogenote;
RC
    MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RX
     Carninci P., Hayashizaki Y.;
RA
     "High-efficiency full-length cDNA cloning.";
RT
RL
    Meth. Enzymol. 303:19-44(1999).
RN
RP
     NUCLEOTIDE SEQUENCE.
     STRAIN=C57BL/6J; TISSUE=Parthenogenote;
RC
     MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RX
     Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA
     Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA
RA
     Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA
     Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
     Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA
RA
     Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
     Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA
```

```
Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA
     Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA
     Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA
     Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA
     Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA
     Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA
    Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA
     Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA
     Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA
RA
    Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA
    Hayashizaki Y.;
     "Functional annotation of a full-length mouse cDNA collection.";
RT
RL
    Nature 409:685-690(2001).
RN
     [3]
RP
    NUCLEOTIDE SEQUENCE.
RC
     STRAIN=C57BL/6J; TISSUE=Parthenogenote;
RX
    MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA
    Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA
    Nikaido I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA
    Yaqi K., Tomaru Y., Hasegawa Y., Noqami A., Schonbach C., Gojobori T.,
RA
     Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA
     Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA
     Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,
RA
     Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA
    Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA
    Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA
     Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA
     Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA
    Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA
    Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA
     Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA
    Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA
     Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
RA
     Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
RA
    Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA
    Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,
RA
    Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA
    Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA
     Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA
    Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA
    Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA
    Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA
     Birney E., Hayashizaki Y.;
RT
     "Analysis of the mouse transcriptome based on functional annotation of
RT
     60,770 full-length cDNAs.";
RL
    Nature 420:563-573(2002).
RN
RP
    NUCLEOTIDE SEQUENCE.
RC
     STRAIN=C57BL/6J; TISSUE=Parthenogenote;
RX
    MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RA
     Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA
     Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT
     "Normalization and subtraction of cap-trapper-selected cDNAs to
RТ
     prepare full-length cDNA libraries for rapid discovery of new genes.";
RL
     Genome Res. 10:1617-1630(2000).
RN
RP
     NUCLEOTIDE SEQUENCE.
```

```
STRAIN=C57BL/6J; TISSUE=Parthenogenote;
RC
     MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RX
     Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA
     Konno H., Akiyama J., Nishi K., Kitsunai T., Tashiro H., Itoh M.,
RA
RA
     Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
     Yamamoto R., Matsumoto H., Sakaquchi S., Ikegami T., Kashiwagi K.,
RA
     Fujiwake S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA
     Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA
     Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RA
RT
     "RIKEN integrated sequence analysis (RISA) system-384-format
RT
     sequencing pipeline with 384 multicapillary sequencer.";
RL
     Genome Res. 10:1757-1771(2000).
RN
RP
     NUCLEOTIDE SEQUENCE.
RC
     STRAIN=C57BL/6J; TISSUE=Parthenogenote;
RA
     Adachi J., Aizawa K., Akimura T., Arakawa T., Bono H., Carninci P.,
RA
     Fukuda S., Furuno M., Hanagaki T., Hara A., Hashizume W.,
RA
     Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,
     Hori F., Imotani K., Ishii Y., Itoh M., Kaqawa I., Kasukawa T.,
RA
     Katoh H., Kawai J., Kojima Y., Kondo S., Konno H., Kouda M., Koya S.,
     Kurihara C., Matsuyama T., Miyazaki A., Murata M., Nakamura M.,
RA
     Nishi K., Nomura K., Numazaki R., Ohno M., Ohsato N., Okazaki Y.,
RA
     Saito R., Saitoh H., Sakai C., Sakai K., Sakazume N., Sano H.,
RA
     Sasaki D., Shibata K., Shinagawa A., Shiraki T., Sogabe Y., Tagami M.,
RA
     Tagawa A., Takahashi F., Takaku-Akahira S., Takeda Y., Tanaka T.,
RA
RA
     Tomaru A., Toya T., Yasunishi A., Muramatsu M., Hayashizaki Y.;
RL
     Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
DR
     EMBL; AK045092; BAC32216.1; -; mRNA.
DR
    MGI; MGI:103556; Cxcl12.
DR
     GO; GO:0005615; C:extracellular space; TAS.
DR
     GO; GO:0008009; F:chemokine activity; IDA.
DR
     GO; GO:0007420; P:brain development; IDA.
DR
     GO; GO:0007281; P:germ cell development; IDA.
DR
     GO; GO:0008354; P:germ cell migration; IDA.
     GO; GO:0050930; P:induction of positive chemotaxis; IDA.
     GO; GO:0030335; P:positive regulation of cell migration; IDA.
DR
     GO; GO:0042098; P:T cell proliferation; IMP.
     SEQUENCE
               89 AA; 10032 MW; C4B8AD69078E55FA CRC64;
SQ
  Query Match
                         95.5%; Score 442; DB 2; Length 89;
  Best Local Similarity
                         93.3%; Pred. No. 1.4e-41;
 Matches
           83; Conservative
                                3; Mismatches
                                                  3; Indels
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
              Db
            1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIV 60
           61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
              61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 11
Q4FJL5 MOUSE
     Q4FJL5 MOUSE PRELIMINARY;
                                   PRT;
                                           93 AA.
ID
AC
     13-SEP-2005 (TrEMBLrel. 31, Created)
```

```
13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
    13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DT
DΕ
    Cxcl12 protein.
GN
    Name=Cxcl12;
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC
    Muroidea; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
RN
     [1]
RP
    NUCLEOTIDE SEQUENCE.
RA
    Ebert L., Muenstermann E., Schatten R., Henze S., Bohn E.,
    Mollenhauer J., Wiemann S., Schick M., Korn B.;
RT
     "Cloning of mouse full open reading frames in Gateway(R) system entry
RT
    vector (pDONR201).";
RL
    Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; CT010389; CAJ18596.1; -; mRNA.
SQ
    SEQUENCE 93 AA; 10561 MW; 625367D344B8AD69 CRC64;
                         95.5%; Score 442; DB 2; Length 93;
 Ouerv Match
 Best Local Similarity
                         93.3%; Pred. No. 1.5e-41;
 Matches
                                3; Mismatches
           83; Conservative
                                                 3; Indels
                                                               0; Gaps
                                                                           0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             Db
           1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 12
Q80ZW4 MOUSE
    Q80ZW4 MOUSE PRELIMINARY;
                                   PRT;
                                         137 AA.
    Q80ZW4;
DT
    01-JUN-2003 (TrEMBLrel. 24, Created)
    01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT
DT
    01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE
    Cxcl12 protein.
GN
    Name=Cxcl12;
os
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC
OC
    Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
    NUCLEOTIDE SEQUENCE.
RC
     STRAIN=C57BL/6; TISSUE=Brain;
    MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RX
RA
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
```

```
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length human
RT
RT
     and mouse cDNA sequences.";
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
RP
    NUCLEOTIDE SEQUENCE.
RC
    STRAIN=C57BL/6; TISSUE=Brain;
RA
    Strausberg R.;
RL
    Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
    EMBL; BC046827; AAH46827.1; -; mRNA.
DR
    HSSP: P48061: 1SDF.
DR
    SMR; Q80ZW4; 23-88.
    MGI; MGI:103556; Cxcl12.
DR
    GO; GO:0005615; C:extracellular space; TAS.
DR
     GO; GO:0008009; F:chemokine activity; IDA.
DR
    GO; GO:0007420; P:brain development; IDA.
DR
DR
    GO; GO:0007281; P:germ cell development; IDA.
DR
     GO; GO:0008354; P:germ cell migration; IDA.
DR
     GO; GO:0050930; P:induction of positive chemotaxis; IDA.
DR
    GO; GO:0030335; P:positive regulation of cell migration; IDA.
    GO; GO:0042098; P:T-cell proliferation; IMP.
DR
    InterPro; IPR002473; C-X-C/Interlkn 8.
DR
    InterPro; IPR001811; Chemokine_IL8.
DR
    Pfam; PF00048; IL8; 1.
     PRINTS; PR00436; INTERLEUKIN8.
DR
DR
     SMART; SM00199; SCY; 1.
SQ
     SEQUENCE
               137 AA; 15529 MW; 04B47DAB6904DF77 CRC64;
                         95.5%; Score 442; DB 2; Length 137;
 Query Match
  Best Local Similarity
                         93.3%;
                                Pred. No. 2.1e-41;
 Matches
           83; Conservative
                                3; Mismatches
                                                 3; Indels
                                                               0: Gaps
                                                                           0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIV 60
Db
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 13
Q5XNN9 CANFA
     Q5XNN9 CANFA PRELIMINARY;
                                   PRT;
ID
                                          89 AA.
AC
     Q5XNN9;
DT
     25-OCT-2004 (TrEMBLrel. 28, Created)
     25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
     25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
```

```
Stromal cell-derived factor-1.
DE
    Canis familiaris (Dog).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Canidae;
OC
OC
    Canis.
OX
     NCBI TaxID=9615;
RN
     [1]
RP
    NUCLEOTIDE SEQUENCE.
RA
     Wei Y., Hu S.;
     "Identification and cloning of dog SDF-1 cDNA.";
RT
     Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; AY746395; AAU89475.2; -; mRNA.
DR
DR
     SMR; Q5XNN9; 23-88.
DR
    GO; GO:0005576; C:extracellular region; IEA.
     GO; GO:0008009; F:chemokine activity; IEA.
DR
DR
     GO; GO:0006955; P:immune response; IEA.
DR
     InterPro; IPR002473; C-X-C/Interlkn 8.
DR
    InterPro; IPR001811; Chemokine IL8.
     Pfam; PF00048; IL8; 1.
DR
     PRINTS; PRO0436; INTERLEUKIN8.
DR
     SMART; SM00199; SCY; 1.
DR
               89 AA; 10005 MW; E9B8AD69078E4020 CRC64;
so
     SEQUENCE
 Query Match
                         94.4%; Score 437; DB 2; Length 89;
  Best Local Similarity
                         92.1%; Pred. No. 5.1e-41;
 Matches
           82; Conservative
                                4; Mismatches
                                                                          0;
                                                 3; Indels
                                                               0; Gaps
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNSRQVCIDPKLKWIQEYLEKALNK 89
RESULT 14
Q9QZD1 RAT
     Q9QZD1 RAT PRELIMINARY;
                                  PRT;
                                         89 AA.
AC
     Q9QZD1;
DT
     01-MAY-2000 (TrEMBLrel. 13, Created)
     01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT
     10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
     Stromal cell-derived factor-1 alpha (Chemokine (C-X-C motif) ligand
DE
DΕ
GN
     Name=Cxcl12; Synonyms=SDF-1;
os
     Rattus norvegicus (Rat).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC
     Muridae; Murinae; Rattus.
OX
    NCBI_TaxID=10116;
RN
     [1]
RP
     NUCLEOTIDE SEQUENCE.
RC
     STRAIN=Spraque-Dawley;
RA
     Ohtani Y., Okada M., Kawaguchi N., Minami M., Satoh M.;
RL
     Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN
     [2]
```

```
NUCLEOTIDE SEQUENCE.
RP
    Pillarisetti K., Gupta S.K.;
RA
     Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
    NUCLEOTIDE SEQUENCE.
RP
RC
    TISSUE=Kidney;
    MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length human
RT
     and mouse cDNA sequences.";
RT
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
     [4]
    NUCLEOTIDE SEQUENCE.
RP
RC
     TISSUE=Kidney;
     Director MGC Project;
RA
RL
     Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
DR
     EMBL; AF189724; AAF01066.1; -; mRNA.
     EMBL; AF209976; AAG43506.1; -; mRNA.
DR
     EMBL; BC078737; AAH78737.1; -; mRNA.
DR
     HSSP; P48061; 1SDF.
DR
     SMR; Q9QZD1; 23-88.
DR
     Ensembl; ENSRNOG00000013589; Rattus norvegicus.
DR
     RGD; 3651; Cxcl12.
DR
     GO; GO:0005576; C:extracellular region; IEA.
DR
     GO; GO:0008009; F:chemokine activity; IEA.
DR
     GO; GO:0006955; P:immune response; IEA.
     InterPro; IPR002473; C-X-C/Interlkn 8.
DR
     InterPro; IPR001811; Chemokine IL8.
DR
DR
     Pfam; PF00048; IL8; 1.
DR
     PRINTS; PRO0436; INTERLEUKIN8.
     SMART; SM00199; SCY; 1.
DR
SQ
               89 AA; 9977 MW;
                                 D86977626A2E35FA CRC64;
     SEQUENCE
                                  Score 435; DB 2;
                                                    Length 89;
  Query Match
                          94.0%;
                                 Pred. No. 8.6e-41;
  Best Local Similarity
                         92.1%;
                                                                0; Gaps
                                                                            0;
                                 4; Mismatches
                                                  3; Indels
  Matches
            82; Conservative
            1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
              1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
```

```
61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKSNNROVCIDPKLKWIQEYLDKALNK 89
RESULT 15
O80YV8 RAT
    Q80YV8 RAT PRELIMINARY;
                                 PRT;
                                       119 AA.
AC
    080YV8;
    01-JUN-2003 (TrEMBLrel. 24, Created)
DT
DΤ
    01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    Stromal cell-derived factor-1 gamma.
OS
    Rattus norvegicus (Rat).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC
OC
    Muridae; Murinae; Rattus.
OX
    NCBI TaxID=10116;
RN
    [1]
RP
    NUCLEOTIDE SEQUENCE.
    Gleichmann M., Gillen C., Mueller H.W.;
RA
    Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AF217564; AAF63712.1; -; mRNA.
DR
DR
    HSSP; P48061; 1SDF.
DR
    SMR; Q80YV8; 23-88.
DR
    GO; GO:0005576; C:extracellular region; IEA.
DR
    GO; GO:0008009; F:chemokine activity; IEA.
    GO; GO:0006955; P:immune response; IEA.
DR
    InterPro; IPR002473; C-X-C/Interlkn 8.
DR
    InterPro; IPR001811; Chemokine IL8.
DR
    Pfam; PF00048; IL8; 1.
DR
    PRINTS; PR00436; INTERLEUKIN8.
    SMART; SM00199; SCY; 1.
DR
SQ
    SEQUENCE 119 AA; 13551 MW; 5E1D99E44DC36FA8 CRC64;
 Query Match
                        94.0%; Score 435; DB 2; Length 119;
  Best Local Similarity
                        92.1%; Pred. No. 1.1e-40;
 Matches
          82; Conservative
                               4; Mismatches
                                                              0; Gaps
                                                                         0;
                                                3; Indels
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Qу
             Db
           1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             1111:111111111111111111111111111111
Db
          61 ARLKSNNRQVCIDPKLKWIQEYLDKALNK 89
```

Search completed: April 26, 2006, 02:37:30 Job time: 228 secs

GenCore version 5.1.7 Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 26, 2006, 02:39:19; Search time 25 Seconds

(without alignments)

156.650 Million cell updates/sec

Title: US-10-785-230-5

Perfect score: 463

Sequence: 1 MNAKVVVLVLTALCLSD......VCIDPKLKWIQEYLEKALNK 89

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 225428 seqs, 44002918 residues

Total number of hits satisfying chosen parameters: 225428

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: Published Applications AA New:*

1: /SIDS5/ptodata/1/pubpaa/US08 NEW PUB.pep:*

2: /SIDS5/ptodata/1/pubpaa/US06_NEW_PUB.pep:*

3: /SIDS5/ptodata/1/pubpaa/US07_NEW_PUB.pep:*

4: /SIDS5/ptodata/1/pubpaa/PCT NEW PUB.pep:*

5: /SIDS5/ptodata/1/pubpaa/US09_NEW_PUB.pep:*

6: /SIDS5/ptodata/1/pubpaa/US10 NEW PUB.pep:*

7: /SIDS5/ptodata/1/pubpaa/US11_NEW_PUB.pep:*

8: /SIDS5/ptodata/1/pubpaa/US60_NEW_PUB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result		% Query				
No.	Score	_	Length	DB	ID	Description
1	463	100.0	89	6	US-10-241-375-22	Sequence 22, Appl
2	463	100.0	89	7	US-11-028-922A-6	Sequence 6, Appli
3	463	100.0	93	6	US-10-241-375-56	Sequence 56, Appl
4	435	94.0	89	7	US-11-028-922A-7	Sequence 7, Appli
5	365	78.8	72	7	US-11-136-097-7	Sequence 7, Appli
6	360	77.8	67	7	US-11-136-097-6	Sequence 6, Appli
7	359	77.5	68	7	US-11-028-922A-5	Sequence 5, Appli
8	351	75.8	67	6	US-10-945-674A-1	Sequence 1, Appli
9	347	74.9	67	6	US-10-945-674A-7	Sequence 7, Appli

11 346 74.7 67 6 US-10-945-674A-6 Sequence 6, Appli 12 345 74.5 67 6 US-10-945-674A-9 Sequence 9, Appli 13 344 74.3 67 6 US-10-945-674A-2 Sequence 2, Appli 14 344 74.3 67 6 US-10-945-674A-5 Sequence 5, Appli 15 343 74.1 67 6 US-10-945-674A-8 Sequence 5, Appli 16 343 74.1 67 6 US-10-945-674A-8 Sequence 8, Appli 16 343 74.1 67 6 US-10-945-674A-10 Sequence 10, Appl 18 341 73.7 67 6 US-10-945-674A-10 Sequence 10, Appl 19 339 73.2 67 6 US-10-945-674A-1 Sequence 11, Appl 20 337 72.8 67 6 US-10-945-674A-1 Sequence 12, Appl 21 127.5 27.5 34 6 US-10-945-674A-12 Sequence 12, Appl 22 127.5 27.5 34 6 US-10-945-674A-12 Sequence 75, Appl 23 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 23 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 100, Appl 25 122.5 26.5 34 6 US-10-945-674A-100 Sequence 100, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-99 Sequence 99, Appl 28 120.5 26.0 34 6 US-10-945-674A-102 Sequence 102, Appl 28 120.5 26.0 34 6 US-10-945-674A-102 Sequence 102, Appl 29 120.5 26.0 34 6 US-10-945-674A-101 Sequence 101, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, Appl 31 118.5 25.6 34 6 US-10-945-674A-116 Sequence 87, Appl 31 118.5 24.5 34 6 US-10-945-674A-115 Sequence 88, Appl 31 118.5 24.5 34 6 US-10-945-674A-116 Sequence 114, Appl 32 117.5 25.4 34 6 US-10-945-674A-116 Sequence 87, Appl 31 118.5 24.5 34 6 US-10-945-674A-116 Sequence 115, Appl 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 115, Appl 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 115, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
13 344 74.3 67 6 US-10-945-674A-2 Sequence 2, Appli 14 344 74.3 67 6 US-10-945-674A-5 Sequence 5, Appli 15 343 74.1 67 6 US-10-945-674A-8 Sequence 8, Appli 16 343 74.1 67 6 US-10-945-674A-133 Sequence 133, Appli 17 342 73.9 67 6 US-10-945-674A-10 Sequence 10, Appli 18 341 73.7 67 6 US-10-945-674A-1 Sequence 11, Appli 19 339 73.2 67 6 US-10-945-674A-1 Sequence 11, Appli 20 337 72.8 67 6 US-10-945-674A-1 Sequence 12, Appli 127.5 27.5 34 6 US-10-945-674A-1 Sequence 12, Appli 127.5 27.5 34 6 US-10-945-674A-1 Sequence 124, Appli 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appli 127.5 27.5 34 6 US-10-945-674A-126 Sequence 124, Appli 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, Appli 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, Appli 127.5 26.7 34 6 US-10-945-674A-100 Sequence 100, Appli 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appli 122.5 26.5 34 6 US-10-945-674A-99 Sequence 84, Appli 122.5 26.5 34 6 US-10-945-674A-10 Sequence 102, Appli 121.5 26.2 34 6 US-10-945-674A-10 Sequence 102, Appli 121.5 26.2 34 6 US-10-945-674A-86 Sequence 86, Appli 120.5 26.0 34 6 US-10-945-674A-86 Sequence 87, Appli 121.5 25.8 34 6 US-10-945-674A-86 Sequence 88, Appli 120.5 25.8 34 6 US-10-945-674A-101 Sequence 101, Appli 121.5 25.6 34 6 US-10-945-674A-101 Sequence 114, Appli 121.5 25.4 34 6 US-10-945-674A-101 Sequence 115, Appli 121.5 24.5 34 6 US-10-945-674A-115 Sequence 115, Appli 121.5 24.5 34 6 US-10-945-674A-116 Sequence 116, Appli 121.5 24.5 34 6 US-10-945-674A-116 Sequence 23, Appli 123.5 24.5 34 6 US-10-945-674A-116 Sequence 23, Appli 123.5 24.5 34 6 US-10-945-674A-116 Sequence 23, Appli 124.4 99 6 US-10-241-375-23 Sequence 23, Appli 124.4 99 6 US-10-241-375-23 Sequence 23, Appli 124.4 99 6 US-10-241-375-23 Sequence 23, Appli 125.5 24.9 34 6 US-10-241-375-23 Sequence 23, Appli 125.5 24.9 34 6 US
14 344 74.3 67 6 US-10-945-674A-5 Sequence 5, Appli 15 343 74.1 67 6 US-10-945-674A-8 Sequence 8, Appli 16 343 74.1 67 6 US-10-945-674A-133 Sequence 10, Appl 17 342 73.9 67 6 US-10-945-674A-10 Sequence 10, Appl 18 341 73.7 67 6 US-10-945-674A-1 Sequence 4, Appli 19 339 73.2 67 6 US-10-945-674A-1 Sequence 11, Appl 20 337 72.8 67 6 US-10-945-674A-12 Sequence 12, Appl 21 127.5 27.5 34 6 US-10-945-674A-12 Sequence 124, Appl 22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 126, App 23 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, App 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 84, Appl 26 122.5 26.5
15 343 74.1 67 6 US-10-945-674A-8 Sequence 8, Appli 16 343 74.1 67 6 US-10-945-674A-133 Sequence 133, Appl 17 342 73.9 67 6 US-10-945-674A-10 Sequence 10, Appl 18 341 73.7 67 6 US-10-945-674A-4 Sequence 1, Appl 19 339 73.2 67 6 US-10-945-674A-11 Sequence 11, Appl 20 337 72.8 67 6 US-10-945-674A-12 Sequence 12, Appl 21 127.5 27.5 34 6 US-10-945-674A-75 Sequence 75, Appl 22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 23 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 126, Appl 25 122.5 26.5 34 6 US-10-945-674A-100 Sequence 100, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 84, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 84, Appl 28 120.5 26.0 34 6 US-10-945-674A-102 Sequence 87, Appl 29 120.5 26.0 34 6 US-10-945-674A-83 Sequence 88, Appl 30 119.5 25.8 34 6 US-10-945-674A-86 Sequence 86, Appl 31 118.5 25.6 34 6 US-10-945-674A-101 Sequence 86, Appl 31 118.5 25.6 34 6 US-10-945-674A-101 Sequence 87, Appl 32 117.5 25.4 34 6 US-10-945-674A-101 Sequence 114, Appl 32 117.5 25.4 34 6 US-10-945-674A-115 Sequence 87, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, Appl 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 115, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 35 113 24.4 99 6 US-10-241-375-23
16 343 74.1 67 6 US-10-945-674A-133 Sequence 133, App 17 342 73.9 67 6 US-10-945-674A-10 Sequence 10, Appl 18 341 73.7 67 6 US-10-945-674A-4 Sequence 4, Appli 19 339 73.2 67 6 US-10-945-674A-11 Sequence 11, Appl 20 337 72.8 67 6 US-10-945-674A-12 Sequence 12, Appl 21 127.5 27.5 34 6 US-10-945-674A-12 Sequence 75, Appl 22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 23 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 24 123.5 26.7 34 6 US-10-945-674A-126 Sequence 126, Appl 25 122.5 26.5 34 6 US-10-945-674A-100 Sequence 100, Appl 26 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, Appl 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 30 119.5 25.8 34 6 US-10-945-674A-86 Sequence 86, Appl 31 118.5 25.6 34 6 US-10-945-674A-101 Sequence 101, Appl 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, Appl 32 117.5 25.4 34 6 US-10-945-674A-115 Sequence 115, Appl 34 113.5 24.5 34 6 US-10-945-674A-115 Sequence 115, Appl 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 115, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 35 24.5 34 6 US-10-945-674A-116 Sequence 23, Appl 36 US-10-241-375-23 Sequence 23, Appl 36 US-10-241-375-23 Sequence 23, Appl 37 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 36 US-10-241-375-23 Sequence 23, Appl 36 US-10-241-375-23 Sequence 23, Appl 37 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 36 US-10-241-375-23 Sequence 23, Appl 37 224.4 99 6 US-10-241-375-23 Sequence 23, Appl 37 224.4 99 6 US-10-241-375-23 Sequence 23, Appl 37 224.4 99 6 US-10-241-375-23 Sequence 23, Appl 38 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
17 342 73.9 67 6 US-10-945-674A-10 Sequence 10, Appl 18 341 73.7 67 6 US-10-945-674A-4 Sequence 4, Appli 19 339 73.2 67 6 US-10-945-674A-11 Sequence 11, Appl 20 337 72.8 67 6 US-10-945-674A-12 Sequence 12, Appl 21 127.5 27.5 34 6 US-10-945-674A-75 Sequence 75, Appl 22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 23 127.5 27.5 34 6 US-10-945-674A-126 Sequence 124, Appl 24 123.5 26.7 34 6 US-10-945-674A-126 Sequence 126, Appl 25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 27 121.5 26.2 34 6 US-10-945-674A-99 Sequence 99, Appl 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 102, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 83, Appl 30 119.5 25.8 34 6 US-10-945-674A-86 Sequence 86, Appl 31 118.5 25.6 34 6 US-10-945-674A-101 Sequence 101, Appl 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, Appl 32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, Appl 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
18 341 73.7 67 6 US-10-945-674A-4 Sequence 4, Appli 19 339 73.2 67 6 US-10-945-674A-11 Sequence 11, Appl 20 337 72.8 67 6 US-10-945-674A-12 Sequence 12, Appl 21 127.5 27.5 34 6 US-10-945-674A-75 Sequence 75, Appl 22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 23 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, Appl 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 100, Appl 25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 101, App 30 119.5 25.8
18 341 73.7 67 6 US-10-945-674A-4 Sequence 4, Appli 19 339 73.2 67 6 US-10-945-674A-11 Sequence 11, Appl 20 337 72.8 67 6 US-10-945-674A-12 Sequence 12, Appl 21 127.5 27.5 34 6 US-10-945-674A-75 Sequence 75, Appl 22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 23 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, Appl 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 100, Appl 25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-102 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8
20 337 72.8 67 6 US-10-945-674A-12 Sequence 12, Appl 21 127.5 27.5 34 6 US-10-945-674A-75 Sequence 75, Appl 22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, Appl 23 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, Appl 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 100, Appl 25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, Appl 28 120.5 26.0 34 6 US-10-945-674A-86 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-101 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-111 Sequence 111, Appl 31 118.5 <t< td=""></t<>
21 127.5 27.5 34 6 US-10-945-674A-75 Sequence 75, Appl 22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, App 23 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, App 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 100, App 25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, App 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-111 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-115 Sequence 85, Appl 33 115.5 2
22 127.5 27.5 34 6 US-10-945-674A-124 Sequence 124, App 23 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, App 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 100, App 25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, App 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 85, Appl 32 117.5 25.4 34 6 US-10-945-674A-115 Sequence 85, Appl 34 113.5
23 127.5 27.5 34 6 US-10-945-674A-126 Sequence 126, App 24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 100, App 25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, App 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, App 32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, App 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, App 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
24 123.5 26.7 34 6 US-10-945-674A-100 Sequence 100, App 25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, App 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, App 32 117.5 25.4 34 6 US-10-945-674A-115 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-116 Sequence 115, App 34 113.5 24.5 34 6 US-10-241-375-23 Sequence 23, Appl
25 122.5 26.5 34 6 US-10-945-674A-84 Sequence 84, Appl 26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, Appl 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, Appl 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, Appl 32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, Appl 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, Appl 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
26 122.5 26.5 34 6 US-10-945-674A-99 Sequence 99, Appl 27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, App 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, App 32 117.5 25.4 34 6 US-10-945-674A-115 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-116 Sequence 115, App 34 113.5 24.5 34 6 US-10-241-375-23 Sequence 23, Appl
27 121.5 26.2 34 6 US-10-945-674A-102 Sequence 102, App 28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, App 32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, App 34 113.5 24.5 34 6 US-10-241-375-23 Sequence 23, Appl
28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, App 32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, App 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, App 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
28 120.5 26.0 34 6 US-10-945-674A-83 Sequence 83, Appl 29 120.5 26.0 34 6 US-10-945-674A-86 Sequence 86, Appl 30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, App 32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, App 34 113.5 24.5 34 6 US-10-241-375-23 Sequence 23, Appl
30 119.5 25.8 34 6 US-10-945-674A-101 Sequence 101, App 31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, App 32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, App 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, App 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
31 118.5 25.6 34 6 US-10-945-674A-114 Sequence 114, App 32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, App 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, App 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
32 117.5 25.4 34 6 US-10-945-674A-85 Sequence 85, Appl 33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, App 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, App 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
33 115.5 24.9 34 6 US-10-945-674A-115 Sequence 115, App 34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, App 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
34 113.5 24.5 34 6 US-10-945-674A-116 Sequence 116, App 35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
35 113 24.4 99 6 US-10-241-375-23 Sequence 23, Appl
• • • • • • • • • • • • • • • • • • • •
36 113 24.4 99 7 US-11-186-284-87 Sequence 87, Appl
37 108 23.3 31 6 US-10-945-674A-74 Sequence 74, Appl
38 108 23.3 31 6 US-10-945-674A-123 Sequence 123, App
39 108 23.3 31 6 US-10-945-674A-125 Sequence 125, App
40 106.5 23.0 91 6 US-10-241-375-21 Sequence 21, Appl
41 106.5 23.0 91 7 US-11-262-284-21 Sequence 21, Appl
42 104 22.5 31 6 US-10-945-674A-96 Sequence 96, Appl
43 103 22.2 31 6 US-10-945-674A-80 Sequence 80, Appl
44 103 22.2 31 6 US-10-945-674A-95 Sequence 95, Appl
45 102 22.0 31 6 US-10-945-674A-98 Sequence 98, Appl

ALIGNMENTS

```
RESULT 1
US-10-241-375-22
; Sequence 22, Application US/10241375
; Publication No. US20060073114A1
; GENERAL INFORMATION:
; APPLICANT: Grainger, David J.
; APPLICANT: Tatalick, Lauen Marie
; APPLICANT: Kanaly, Suzanne T.
  TITLE OF INVENTION: Compounds and methods to inhibit or
; TITLE OF INVENTION: augment an inflammatory response.
  FILE REFERENCE: 295.027US1
  CURRENT APPLICATION NUMBER: US/10/241,375
; CURRENT FILING DATE: 2002-09-11
; PRIOR APPLICATION NUMBER: US/09/150,813
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: US 08/927939
```

```
PRIOR FILING DATE: 1997-09-11
  NUMBER OF SEQ ID NOS: 105
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-241-375-22
 Query Match
                       100.0%; Score 463; DB 6; Length 89;
 Best Local Similarity
                       100.0%; Pred. No. 4.9e-49;
                             0; Mismatches
 Matches
          89; Conservative
                                                 Indels
                                                                     0;
          1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
            Db
          1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
         61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
            61 ARLKNNNROVCIDPKLKWIOEYLEKALNK 89
RESULT 2
US-11-028-922A-6
; Sequence 6, Application US/11028922A
; Publication No. US20050271639A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Marc
  TITLE OF INVENTION: GENETICALLY ENGINEERED FOR THERAPEUTIC APPLICATIONS
  FILE REFERENCE: CCF-7019
  CURRENT APPLICATION NUMBER: US/11/028,922A
  CURRENT FILING DATE: 2005-01-04
; NUMBER OF SEQ ID NOS: 9
  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
US-11-028-922A-6
 Query Match
                       100.0%; Score 463; DB 7; Length 89;
 Best Local Similarity
                       100.0%; Pred. No. 4.9e-49;
          89; Conservative
                             0; Mismatches
                                             0; Indels
                                                             Gaps
                                                                     0;
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
            Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 3
US-10-241-375-56
; Sequence 56, Application US/10241375
; Publication No. US20060073114A1
```

```
; GENERAL INFORMATION:
 APPLICANT: Grainger, David J.
; APPLICANT: Tatalick, Lauen Marie
; APPLICANT: Kanaly, Suzanne T.
; TITLE OF INVENTION: Compounds and methods to inhibit or
 TITLE OF INVENTION: augment an inflammatory response.
; FILE REFERENCE: 295.027US1
 CURRENT APPLICATION NUMBER: US/10/241,375
  CURRENT FILING DATE: 2002-09-11
 PRIOR APPLICATION NUMBER: US/09/150,813
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: US 08/927939
; PRIOR FILING DATE: 1997-09-11
; NUMBER OF SEQ ID NOS: 105
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 56
   LENGTH: 93
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-241-375-56
                        100.0%; Score 463; DB 6; Length 93;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 5.2e-49;
           89; Conservative
                             0; Mismatches
                                              0; Indels
                                                             0; Gaps
                                                                        0:
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 4
US-11-028-922A-7
; Sequence 7, Application US/11028922A
; Publication No. US20050271639A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Marc
; TITLE OF INVENTION: GENETICALLY ENGINEERED FOR THERAPEUTIC APPLICATIONS
; FILE REFERENCE: CCF-7019
; CURRENT APPLICATION NUMBER: US/11/028,922A
; CURRENT FILING DATE: 2005-01-04
; NUMBER OF SEQ ID NOS: 9
  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 7
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Rattus norvegicus
US-11-028-922A-7
 Query Match
                        94.0%; Score 435; DB 7; Length 89;
 Best Local Similarity 92.1%; Pred. No. 1.2e-45;
 Matches 82; Conservative
                               4; Mismatches
                                               3; Indels
Qy
```

```
1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
            61 ARLKSNNRQVCIDPKLKWIQEYLDKALNK 89
Db
RESULT 5
US-11-136-097-7
; Sequence 7, Application US/11136097
; Publication No. US20050265969A1
; GENERAL INFORMATION:
 APPLICANT: Clark-Lewis, Ian
  APPLICANT: Gong, Jiang-Hong
  APPLICANT: Duronio, Vincent
  APPLICANT: The University of British Columbia
 TITLE OF INVENTION: Therapeutic Chemokine Receptor Antagonists
  FILE REFERENCE: 080352-00000US
  CURRENT APPLICATION NUMBER: US/11/136,097
  CURRENT FILING DATE: 2005-05-23
  PRIOR APPLICATION NUMBER: US/09/646,192
  PRIOR FILING DATE: 2000-09-13
  PRIOR APPLICATION NUMBER: CA 2,226,391
 PRIOR FILING DATE: 1998-03-13
  PRIOR APPLICATION NUMBER: CA 2,245,224
  PRIOR FILING DATE: 1998-08-14
  PRIOR APPLICATION NUMBER: WO PCT/CA99/00221
 PRIOR FILING DATE: 1999-03-12
  NUMBER OF SEQ ID NOS: 7
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
   LENGTH: 72
   TYPE: PRT
   ORGANISM: Homo sapiens
   FEATURE:
   OTHER INFORMATION: stromal cell derived factor-1beta (SDF-1beta)
US-11-136-097-7
  Query Match
                       78.8%; Score 365; DB 7; Length 72;
  Best Local Similarity 100.0%; Pred. No. 2.9e-37;
 Matches 68; Conservative 0; Mismatches 0; Indels
                                                                      0;
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
Qу
            1 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
Db
          82 YLEKALNK 89
Qу
            1111111
Db
          61 YLEKALNK 68
RESULT 6
US-11-136-097-6
; Sequence 6, Application US/11136097
; Publication No. US20050265969A1
; GENERAL INFORMATION:
```

```
APPLICANT: Clark-Lewis, Ian
  APPLICANT: Gong, Jiang-Hong
  APPLICANT: Duronio, Vincent
; APPLICANT: The University of British Columbia
; TITLE OF INVENTION: Therapeutic Chemokine Receptor Antagonists
 FILE REFERENCE: 080352-00000US
 CURRENT APPLICATION NUMBER: US/11/136,097
  CURRENT FILING DATE: 2005-05-23
  PRIOR APPLICATION NUMBER: US/09/646,192
  PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: CA 2,226,391
  PRIOR FILING DATE: 1998-03-13
  PRIOR APPLICATION NUMBER: CA 2,245,224
  PRIOR FILING DATE: 1998-08-14
  PRIOR APPLICATION NUMBER: WO PCT/CA99/00221
  PRIOR FILING DATE: 1999-03-12
; NUMBER OF SEQ ID NOS: 7
  SOFTWARE: PatentIn Ver. 2.1
; SEO ID NO 6
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Homo sapiens
   FEATURE:
   OTHER INFORMATION: stromal cell derived factor-lalpha (SDF-lalpha)
US-11-136-097-6
 Query Match
                         77.8%; Score 360; DB 7; Length 67;
  Best Local Similarity
                        100.0%; Pred. No. 1.1e-36;
 Matches
          67; Conservative
                              0; Mismatches
                                               0; Indels
                                                              0; Gaps
                                                                         0;
Qy
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
             Db
           1 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
          82 YLEKALN 88
Qy
             1111111
Db
          61 YLEKALN 67
RESULT 7
US-11-028-922A-5
; Sequence 5, Application US/11028922A
; Publication No. US20050271639A1
; GENERAL INFORMATION:
 APPLICANT: Penn, Marc
  TITLE OF INVENTION: GENETICALLY ENGINEERED FOR THERAPEUTIC APPLICATIONS
; FILE REFERENCE: CCF-7019
; CURRENT APPLICATION NUMBER: US/11/028,922A
; CURRENT FILING DATE: 2005-01-04
; NUMBER OF SEQ ID NOS: 9
  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 5
   LENGTH: 68
   TYPE: PRT
   ORGANISM: Homo sapiens
US-11-028-922A-5
```

```
77.5%; Score 359; DB 7; Length 68;
 Query Match
                        98.5%; Pred. No. 1.5e-36;
 Best Local Similarity
                              0; Mismatches
 Matches 67; Conservative
                                              1; Indels
                                                                        0;
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
Qу
             1 KPVSLLYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
Db
Qy
          82 YLEKALNK 89
             1111111
          61 YLEKALNK 68
Db
RESULT 8
US-10-945-674A-1
; Sequence 1, Application US/10945674A
; Publication No. US20060014682A1
; GENERAL INFORMATION:
; APPLICANT: Tudan, Christopher R.
 APPLICANT: Merzouk, Ahmed
 APPLICANT: Arab, Lakhdar
  APPLICANT: Saxena, Geeta
             Eaves, Connie J.
  APPLICANT:
             Cashman, Joanne
  APPLICANT:
  APPLICANT:
             Clark-Lewis, Ian
  APPLICANT:
             Salari, Hassan
  APPLICANT: Chemokine Therapeutics Corporation
  APPLICANT:
             The University of British Columbia
  TITLE OF INVENTION: CXCR4 Antagonist Treatment of Hematopoietic Cells
  FILE REFERENCE: 080420-000100US
  CURRENT APPLICATION NUMBER: US/10/945,674A
  CURRENT FILING DATE: 2004-09-20
  PRIOR APPLICATION NUMBER: CA 2,305,787
  PRIOR FILING DATE: 2000-05-09
  PRIOR APPLICATION NUMBER: US 60/205,467
  PRIOR FILING DATE: 2000-05-19
  PRIOR APPLICATION NUMBER: US 09/852,424
  PRIOR FILING DATE: 2001-05-09
  NUMBER OF SEO ID NOS: 140
  SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 1
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence:synthetic
   OTHER INFORMATION: SDF-1(1-67)[P2G] CXCR4 receptor antagonist
US-10-945-674A-1
 Query Match
                        75.8%;
                               Score 351; DB 6;
                                                 Length 67;
  Best Local Similarity
                        98.5%; Pred. No. 1.3e-35;
 Matches
           66; Conservative
                              0; Mismatches
                                               1; Indels
                                                             0;
                                                                Gaps
                                                                        0;
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
Qу
             Db
           1 KGVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNROVCIDPKLKWIQE 60
```

```
82 YLEKALN 88
Qу
             61 YLEKALN 67
Db
RESULT 9
US-10-945-674A-7
; Sequence 7, Application US/10945674A
; Publication No. US20060014682A1
; GENERAL INFORMATION:
; APPLICANT: Tudan, Christopher R.
; APPLICANT: Merzouk, Ahmed
; APPLICANT: Arab, Lakhdar
  APPLICANT: Saxena, Geeta
  APPLICANT: Eaves, Connie J.
  APPLICANT: Cashman, Joanne
APPLICANT: Clark-Lewis, Ian
  APPLICANT: Salari, Hassan
  APPLICANT: Chemokine Therapeutics Corporation
; APPLICANT: The University of British Columbia
 TITLE OF INVENTION: CXCR4 Antagonist Treatment of Hematopoietic Cells
 FILE REFERENCE: 080420-000100US
  CURRENT APPLICATION NUMBER: US/10/945,674A
  CURRENT FILING DATE: 2004-09-20
; PRIOR APPLICATION NUMBER: CA 2,305,787
  PRIOR FILING DATE: 2000-05-09
  PRIOR APPLICATION NUMBER: US 60/205,467
  PRIOR FILING DATE: 2000-05-19
  PRIOR APPLICATION NUMBER: US 09/852,424
  PRIOR FILING DATE: 2001-05-09
  NUMBER OF SEQ ID NOS: 140
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence: synthetic
   OTHER INFORMATION: SDF-1[P2G] CXCR4 receptor antagonist analogue
   OTHER INFORMATION: with proline-amino acid chimera (P*) substituted
   OTHER INFORMATION: at residue 6
   FEATURE:
   NAME/KEY: MOD RES
   LOCATION: (6)
   OTHER INFORMATION: Xaa = P* = proline-amino acid chimera (3-aryl-proline,
   OTHER INFORMATION: 3-hydroxyaryl-proline or 3-alkyl-proline)
US-10-945-674A-7
                         74.9%; Score 347; DB 6; Length 67;
  Query Match
  Best Local Similarity
                         97.0%; Pred. No. 4.1e-35;
          65; Conservative
                                0; Mismatches
                                                               0; Gaps
 Matches
                                                 2; Indels
                                                                           0;
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
Qу
             1 KGVSLXYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
Db
```

82 YLEKALN 88

Qу

; Sequence 6, Application US/10945674A

```
RESULT 10
US-10-945-674A-3
; Sequence 3, Application US/10945674A
; Publication No. US20060014682A1
; GENERAL INFORMATION:
  APPLICANT: Tudan, Christopher R.
  APPLICANT: Merzouk, Ahmed
  APPLICANT: Arab, Lakhdar
  APPLICANT: Saxena, Geeta
  APPLICANT: Eaves, Connie J.
  APPLICANT: Cashman, Joanne
  APPLICANT: Clark-Lewis, Ian
  APPLICANT: Salari, Hassan
  APPLICANT: Chemokine Therapeutics Corporation
              The University of British Columbia
  APPLICANT:
  TITLE OF INVENTION: CXCR4 Antagonist Treatment of Hematopoietic Cells
  FILE REFERENCE: 080420-000100US
  CURRENT APPLICATION NUMBER: US/10/945,674A
  CURRENT FILING DATE: 2004-09-20
  PRIOR APPLICATION NUMBER: CA 2,305,787
  PRIOR FILING DATE: 2000-05-09
  PRIOR APPLICATION NUMBER: US 60/205,467
  PRIOR FILING DATE: 2000-05-19
  PRIOR APPLICATION NUMBER: US 09/852,424
  PRIOR FILING DATE: 2001-05-09
  NUMBER OF SEQ ID NOS: 140
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Artificial Sequence
    FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence:synthetic
   OTHER INFORMATION: SDF-1(1-67)[P2G] CXCR4 receptor antagonist
    OTHER INFORMATION: analogue with proline (P) substituted at residue 6
US-10-945-674A-3
                                Score 346; DB 6; Length 67;
  Query Match
                         74.78;
  Best Local Similarity
                         97.0%; Pred. No. 5.4e-35;
  Matches
           65; Conservative
                                0; Mismatches
                                                 2; Indels
                                                               0; Gaps
                                                                          0;
Qу
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
             Dh
           1 KGVSLPYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
          82 YLEKALN 88
Qу
             1111111
          61 YLEKALN 67
Db
RESULT 11
US-10-945-674A-6
```

```
; Publication No. US20060014682A1
; GENERAL INFORMATION:
  APPLICANT: Tudan, Christopher R.
  APPLICANT: Merzouk, Ahmed
  APPLICANT: Arab, Lakhdar
  APPLICANT: Saxena, Geeta
  APPLICANT: Eaves, Connie J.
  APPLICANT: Cashman, Joanne
  APPLICANT: Clark-Lewis, Ian
  APPLICANT: Salari, Hassan
  APPLICANT: Chemokine Therapeutics Corporation
  APPLICANT: The University of British Columbia
  TITLE OF INVENTION: CXCR4 Antagonist Treatment of Hematopoietic Cells
  FILE REFERENCE: 080420-000100US
  CURRENT APPLICATION NUMBER: US/10/945,674A
  CURRENT FILING DATE: 2004-09-20
  PRIOR APPLICATION NUMBER: CA 2,305,787
  PRIOR FILING DATE: 2000-05-09
  PRIOR APPLICATION NUMBER: US 60/205,467
  PRIOR FILING DATE: 2000-05-19
  PRIOR APPLICATION NUMBER: US 09/852,424
  PRIOR FILING DATE: 2001-05-09
  NUMBER OF SEQ ID NOS: 140
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence:synthetic
   OTHER INFORMATION: SDF-1[P2G] CXCR4 receptor antagonist analogue
   OTHER INFORMATION: with proline-amino acid chimera (P*) substituted
   OTHER INFORMATION: at residue 5
   FEATURE:
   NAME/KEY: MOD RES
   LOCATION: (5)
   OTHER INFORMATION: Xaa = P* = proline-amino acid chimera (3-aryl-proline,
   OTHER INFORMATION: 3-hydroxyaryl-proline or 3-alkyl-proline)
US-10-945-674A-6
                                Score 346; DB 6; Length 67;
 Query Match
                         74.7%;
                         97.0%; Pred. No. 5.4e-35;
 Best Local Similarity
          65; Conservative
                                0; Mismatches
                                                 2; Indels
                                                              0; Gaps
                                                                          0;
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81 ·
Qу
             1 KGVSXSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
Db
          82 YLEKALN 88
Qy
             111111
          61 YLEKALN 67
Db
RESULT 12
US-10-945-674A-9
; Sequence 9, Application US/10945674A
; Publication No. US20060014682A1
```

```
; GENERAL INFORMATION:
  APPLICANT: Tudan, Christopher R.
  APPLICANT: Merzouk, Ahmed
  APPLICANT: Arab, Lakhdar
  APPLICANT: Saxena, Geeta
  APPLICANT: Eaves, Connie J.
  APPLICANT: Cashman, Joanne
  APPLICANT: Clark-Lewis, Ian
  APPLICANT: Salari, Hassan
  APPLICANT: Chemokine Therapeutics Corporation
  APPLICANT: The University of British Columbia
  TITLE OF INVENTION: CXCR4 Antagonist Treatment of Hematopoietic Cells
  FILE REFERENCE: 080420-000100US
  CURRENT APPLICATION NUMBER: US/10/945,674A
  CURRENT FILING DATE: 2004-09-20
  PRIOR APPLICATION NUMBER: CA 2,305,787
  PRIOR FILING DATE: 2000-05-09
  PRIOR APPLICATION NUMBER: US 60/205,467
  PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: US 09/852,424
; PRIOR FILING DATE: 2001-05-09
 NUMBER OF SEQ ID NOS: 140
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence:synthetic
   OTHER INFORMATION: SDF-1[P2G] CXCR4 receptor antagonist analogue
   OTHER INFORMATION: with proline-amino acid chimera (P*) substituted
   OTHER INFORMATION: at residue 8
   FEATURE:
   NAME/KEY: MOD RES
   LOCATION: (8)
   OTHER INFORMATION: Xaa = P* = proline-amino acid chimera (3-aryl-proline,
   OTHER INFORMATION: 3-hydroxyaryl-proline or 3-alkyl-proline)
US-10-945-674A-9
  Query Match
                         74.5%; Score 345; DB 6; Length 67;
  Best Local Similarity
                        97.0%; Pred. No. 7.1e-35;
                               0; Mismatches 2; Indels
 Matches 65; Conservative
                                                                          0;
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
Qу
             Db
           1 KGVSLSYXCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
          82 YLEKALN 88
Qу
             111111
          61 YLEKALN 67
RESULT 13
US-10-945-674A-2
; Sequence 2, Application US/10945674A
; Publication No. US20060014682A1
; GENERAL INFORMATION:
```

```
APPLICANT: Tudan, Christopher R.
  APPLICANT: Merzouk, Ahmed
  APPLICANT: Arab, Lakhdar
  APPLICANT: Saxena, Geeta
  APPLICANT: Eaves, Connie J.
  APPLICANT: Cashman, Joanne
  APPLICANT: Clark-Lewis, Ian
  APPLICANT: Salari, Hassan
  APPLICANT: Chemokine Therapeutics Corporation
  APPLICANT: The University of British Columbia
  TITLE OF INVENTION: CXCR4 Antagonist Treatment of Hematopoietic Cells
  FILE REFERENCE: 080420-000100US
  CURRENT APPLICATION NUMBER: US/10/945,674A
  CURRENT FILING DATE: 2004-09-20
  PRIOR APPLICATION NUMBER: CA 2,305,787
  PRIOR FILING DATE: 2000-05-09
  PRIOR APPLICATION NUMBER: US 60/205,467
 PRIOR FILING DATE: 2000-05-19
 PRIOR APPLICATION NUMBER: US 09/852,424
 PRIOR FILING DATE: 2001-05-09
 NUMBER OF SEQ ID NOS: 140
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Artificial Sequence
   OTHER INFORMATION: Description of Artificial Sequence: synthetic
   OTHER INFORMATION: SDF-1(1-67)[P2G] CXCR4 receptor antagonist
   OTHER INFORMATION: analogue with proline (P) substituted at residue 5
US-10-945-674A-2
                        74.3%; Score 344; DB 6; Length 67;
 Query Match
 Best Local Similarity
                        97.0%; Pred. No. 9.4e-35;
         65; Conservative
                               0; Mismatches
                                               2; Indels
                                                              0;
                                                                 Gaps
                                                                         0;
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
Qy
             1 KGVSPSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
          82 YLEKALN 88
             61 YLEKALN 67
RESULT 14
US-10-945-674A-5
; Sequence 5, Application US/10945674A
; Publication No. US20060014682A1
; GENERAL INFORMATION:
 APPLICANT: Tudan, Christopher R.
  APPLICANT: Merzouk, Ahmed
  APPLICANT: Arab, Lakhdar
; APPLICANT: Saxena, Geeta
; APPLICANT: Eaves, Connie J.
; APPLICANT: Cashman, Joanne
; APPLICANT: Clark-Lewis, Ian
```

```
APPLICANT: Salari, Hassan
  APPLICANT: Chemokine Therapeutics Corporation
  APPLICANT: The University of British Columbia
  TITLE OF INVENTION: CXCR4 Antagonist Treatment of Hematopoietic Cells
 FILE REFERENCE: 080420-000100US
  CURRENT APPLICATION NUMBER: US/10/945,674A
 CURRENT FILING DATE: 2004-09-20
  PRIOR APPLICATION NUMBER: CA 2,305,787
  PRIOR FILING DATE: 2000-05-09
 PRIOR APPLICATION NUMBER: US 60/205,467
 PRIOR FILING DATE: 2000-05-19
 PRIOR APPLICATION NUMBER: US 09/852,424
 PRIOR FILING DATE: 2001-05-09
 NUMBER OF SEQ ID NOS: 140
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence:synthetic
   OTHER INFORMATION: SDF-1(1-67)[P2G] CXCR4 receptor antagonist
   OTHER INFORMATION: analogue with proline (P) substituted at residue 8
US-10-945-674A-5
                         74.3%;
                                 Score 344; DB 6; Length 67;
 Query Match
 Best Local Similarity
                         97.0%; Pred. No. 9.4e-35;
          65; Conservative
                                0; Mismatches
                                                2; Indels
                                                               0; Gaps
                                                                           0;
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
Qу
             1 KGVSLSYPCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
          82 YLEKALN 88
Qу
             111111
          61 YLEKALN 67
RESULT 15
US-10-945-674A-8
; Sequence 8, Application US/10945674A
; Publication No. US20060014682A1
: GENERAL INFORMATION:
  APPLICANT: Tudan, Christopher R.
  APPLICANT: Merzouk, Ahmed
  APPLICANT: Arab, Lakhdar
  APPLICANT: Saxena, Geeta
  APPLICANT: Eaves, Connie J.
  APPLICANT: Cashman, Joanne
  APPLICANT: Clark-Lewis, Ian
  APPLICANT: Salari, Hassan
  APPLICANT: Chemokine Therapeutics Corporation APPLICANT: The University of British Columbia
; TITLE OF INVENTION: CXCR4 Antagonist Treatment of Hematopoietic Cells
; FILE REFERENCE: 080420-000100US
; CURRENT APPLICATION NUMBER: US/10/945,674A
; CURRENT FILING DATE: 2004-09-20
```

```
PRIOR APPLICATION NUMBER: CA 2,305,787
  PRIOR FILING DATE: 2000-05-09
  PRIOR APPLICATION NUMBER: US 60/205,467
; PRIOR FILING DATE: 2000-05-19
; PRIOR APPLICATION NUMBER: US 09/852,424
; PRIOR FILING DATE: 2001-05-09
  NUMBER OF SEO ID NOS: 140
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
   LENGTH: 67
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence:synthetic
   OTHER INFORMATION: SDF-1[P2G] CXCR4 receptor antagonist analogue
   OTHER INFORMATION: with proline-amino acid chimera (P*) substituted
   OTHER INFORMATION: at residue 7
   FEATURE:
   NAME/KEY: MOD RES
   LOCATION: (7)
   OTHER INFORMATION: Xaa = P* = proline-amino acid chimera (3-aryl-proline,
   OTHER INFORMATION: 3-hydroxyaryl-proline or 3-alkyl-proline)
US-10-945-674A-8
 Query Match
                        74.1%; Score 343; DB 6; Length 67;
  Best Local Similarity
                        97.0%; Pred. No. 1.2e-34;
 Matches
         65; Conservative
                               0; Mismatches
                                               2; Indels
                                                                         0;
Qу
          22 KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 81
             Db
           1 KGVSLSXRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQE 60
          82 YLEKALN 88
Qу
             111111
Db
          61 YLEKALN 67
```

Search completed: April 26, 2006, 02:42:27

Job time : 26 secs

GenCore version 5.1.7 Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 26, 2006, 02:38:29; Search time 165 Seconds

(without alignments)

225.375 Million cell updates/sec

Title: US-10-785-230-5

Perfect score: 463

Sequence: 1 MNAKVVVLVLTALCLSD......VCIDPKLKWIQEYLEKALNK 89

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA Main:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*

2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*

3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*

4: /cgn2_6/ptodata/1/pubpaa/US10A PUBCOMB.pep:*

5: /cgn2 6/ptodata/1/pubpaa/US10B PUBCOMB.pep:*

6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

D14		8				
Result No.				DB	ID	Description
1	463	100.0	89	2	US-08-927-939-22	Sequence 22, Appl
2	463	100.0	89	3	US-09-953-692-4	Sequence 4, Appli
3	463	100.0	89	3	US-09-953-717-4	Sequence 4, Appli
4	463	100.0	89	3	US-09-792-793A-32	Sequence 32, Appl
5	463	100.0	89	4	US-10-375-209A-32	Sequence 32, Appl
6	463	100.0	89	4	US-10-785-230-5	Sequence 5, Appli
7	463	100.0	89	5	US-10-924-029-1	Sequence 1, Appli
8	463	100.0	89	5	US-10-985-324-4	Sequence 4, Appli
9	463	100.0	89	5	US-10-773-236-280	Sequence 280, App
10	463	100.0	89	5	US-10-921-235-43	Sequence 43, Appl
11	463	100.0	93	2	US-08-927-939-56	Sequence 56, Appl

12	463	100.0	93	3	US-09-144-838-7	Sequence 7, Appli
13	463	100.0	93	3	US-09-919-497-95	Sequence 95, Appl
14	463	100.0	93	3	US-09-835-107-2	Sequence 2, Appli
15	463	100.0	93	3	US-09-835-107-3	Sequence 3, Appli
16	463	100.0	93	3	US-09-792-793A-93	Sequence 93, Appl
17	463	100.0	93	4	US-10-086-177A-2	Sequence 2, Appli
18	463	100.0	93	4	US-10-086-177A-3	Sequence 3, Appli
19	463	100.0	93	4	US-10-375-209A-93	Sequence 93, Appl
20	463	100.0	93	4	US-10-447-315-25	Sequence 25, Appl
21	463	100.0	93	4	US-10-706-265-6	Sequence 6, Appli
22	463	100.0	93	4	US-10-788-792-193	Sequence 193, App
23	463	100.0	93	5	US-10-723-860-2672	Sequence 2672, Ap
24	463	100.0	93	5	US-10-924-029-2	Sequence 2, Appli
25	463	100.0	93	5	US-10-222-703A-3	Sequence 3, Appli
26	463	100.0	93	5	US-10-222-703A-4	Sequence 4, Appli
27	463	100.0	93	5	US-10-849-989-28	Sequence 28, Appl
28	463	100.0	93	5	US-10-756-149-5439	Sequence 5439, Ap
29	463	100.0	93	5	US-10-287-436A-522	Sequence 522, App
30	463	100.0	93	5	US-10-287-436A-1213	Sequence 1213, Ap
31	463	100.0	119	4	US-10-308-322-12	Sequence 12, Appl
32	463	100.0	166	4	US-10-335-394-5	Sequence 5, Appli
33	442	95.5	89	4	US-10-785-230-7	Sequence 7, Appli
34	435	94.0	93	4	US-10-308-322-17	Sequence 17, Appl
35	435	94.0	119	4	US-10-308-322-13	Sequence 13, Appl
36	428	92.4	136	4	US-10-264-049-3373	Sequence 3373, Ap
37	427	92.2	90	4	US-10-308-322-7	Sequence 7, Appli
38	427	92.2	119	4	US-10-308-322-4	Sequence 4, Appli
39	377	81.4	74	4	US-10-050-902-238	Sequence 238, App
40	377	81.4	74	4	US-10-050-898-238	Sequence 238, App
41	377	81.4	101	4	US-10-308-322-22	Sequence 22, Appl
42	377	81.4	177	4	US-10-335-394-54	Sequence 54, Appl
43	377	81.4	339	4	US-10-335-394-55	Sequence 55, Appl
44	376	81.2	70	4	US-10-050-902-239	Sequence 239, App
45	376	81.2	70	4	US-10-050-898-239	Sequence 239, App

ALIGNMENTS

```
RESULT 1
US-08-927-939-22
; Sequence 22, Application US/08927939
; Publication No. US20010006640A1
; GENERAL INFORMATION:
; APPLICANT: Grainger, David J.
; APPLICANT: Tatalick, Lauen Marie
; TITLE OF INVENTION: Compounds and methods to inhibit or
; TITLE OF INVENTION: augment an inflammatory response.
; FILE REFERENCE: 295.022US1
; CURRENT APPLICATION NUMBER: US/08/927,939
; CURRENT FILING DATE: 1997-09-11
; NUMBER OF SEQ ID NOS: 83
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
  LENGTH: 89
   TYPE: PRT
  ORGANISM: Homo sapiens
```

```
100.0%; Score 463; DB 2; Length 89;
  Query Match
  Best Local Similarity
                              Pred. No. 1.2e-47;
                       100.0%;
 Matches
          89; Conservative
                            0: Mismatches
                                             0; Indels
                                                          0;
                                                             Gaps
                                                                     0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Qу
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
            61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 2
US-09-953-692-4
; Sequence 4, Application US/09953692
; Patent No. US20020107195A1
; GENERAL INFORMATION:
; APPLICANT: Shalley, Gupta K.
  TITLE OF INVENTION: Method for Inducing Chemotaxis in Endothelial Cells by
  TITLE OF INVENTION: Administering Stromal Cell Derived Factor-1(
  FILE REFERENCE: P50676C1
  CURRENT APPLICATION NUMBER: US/09/953,692
  CURRENT FILING DATE: 2001-09-17
  PRIOR APPLICATION NUMBER: 09/358,624
  PRIOR FILING DATE: 1999-07-21
 PRIOR APPLICATION NUMBER: 60/093,596
  PRIOR FILING DATE: 1998-07-21
  NUMBER OF SEQ ID NOS: 6
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 4
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Human
US-09-953-692-4
  Query Match
                       100.0%;
                               Score 463; DB 3; Length 89;
  Best Local Similarity
                       100.0%; Pred. No. 1.2e-47;
                             0; Mismatches
 Matches
          89; Conservative
                                           0; Indels
                                                                     0;
                                                          0; Gaps
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Qy
            Db
          1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
            61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 3
US-09-953-717-4
; Sequence 4, Application US/09953717
; Patent No. US20020107196A1
; GENERAL INFORMATION:
; APPLICANT: Shalley, Gupta K.
```

```
TITLE OF INVENTION: Method for Inducing Chemotaxis in Endothelial Cells by
  TITLE OF INVENTION: Administering Stromal Cell Derived Factor-1(
  FILE REFERENCE: P50676D1
; CURRENT APPLICATION NUMBER: US/09/953,717
  CURRENT FILING DATE: 2001-09-17
  PRIOR APPLICATION NUMBER: 09/358,624
  PRIOR FILING DATE: 1999-07-21
  PRIOR APPLICATION NUMBER: 60/093,596
  PRIOR FILING DATE: 1998-07-21
 NUMBER OF SEQ ID NOS: 6
 SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 4
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Human
US-09-953-717-4
 Query Match
                        100.0%; Score 463; DB 3; Length 89;
  Best Local Similarity 100.0%; Pred. No. 1.2e-47;
           89; Conservative
                              0: Mismatches
                                                0; Indels
                                                             0; Gaps
                                                                         0:
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 4
US-09-792-793A-32
; Sequence 32, Application US/09792793A
; Patent No. US20020168370A1
; GENERAL INFORMATION:
; APPLICANT: McDonald, John R.
  APPLICANT: Coggins, Philip
  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING SECONDARY TISSUE
DAMAGE AND
; TITLE OF INVENTION: OTHER INFLAMMATORY CONDITIONS AND DISORDERS
  FILE REFERENCE: 25020-601D
  CURRENT APPLICATION NUMBER: US/09/792,793A
  CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 93
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 32
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
   FEATURE:
   OTHER INFORMATION: Human Chemokine Polypeptide: Stromal cell-derived
   OTHER INFORMATION: Factor-1-Alpha (SDF-1-Alpha)
   PUBLICATION INFORMATION:
   JOURNAL: Genomics
   VOLUME: 28
   PAGES: 495-500
   DATE: 1995
```

```
100.0%; Score 463; DB 3; Length 89;
 Query Match
 Best Local Similarity
                              Pred. No. 1.2e-47;
                      100.0%;
 Matches
          89; Conservative 0; Mismatches
                                            0: Indels
                                                         0;
                                                                    0;
                                                             Gaps
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Qу
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
         61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
            61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 5
US-10-375-209A-32
; Sequence 32, Application US/10375209A
; Publication No. US20030215421A1
; GENERAL INFORMATION:
; APPLICANT: McDonald, John R.
 APPLICANT: Coggins, Philip
  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING SECONDARY TISSUE
DAMAGE AND
; TITLE OF INVENTION: OTHER INFLAMMATORY CONDITIONS AND DISORDERS
  FILE REFERENCE: 25020-601E
; CURRENT APPLICATION NUMBER: US/10/375,209A
; CURRENT FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 93
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 32
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
   OTHER INFORMATION: Human Chemokine Polypeptide: Stromal cell-derived
   OTHER INFORMATION: Factor-1-Aplha (SDF-1-Alpha)
  PUBLICATION INFORMATION:
   JOURNAL: Genomics
   VOLUME: 28
   PAGES: 495-500
   DATE: 1995
US-10-375-209A-32
                       100.0%; Score 463; DB 4; Length 89;
 Query Match
                      100.0%; Pred. No. 1.2e-47;
 Best Local Similarity
          89; Conservative
                            0; Mismatches
                                            0; Indels
                                                         0; Gaps
                                                                    0;
          1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
            Db
          1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
            Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
```

```
RESULT 6
US-10-785-230-5
; Sequence 5, Application US/10785230
; Publication No. US20040209837A1
; GENERAL INFORMATION:
; APPLICANT: KISHIMOTO, Tadamitsu
  APPLICANT: NAGASAWA, Takashi
  APPLICANT: TACHIBANA, Kazunobu
  APPLICANT: CHUGAI SEIYAKU KABUSIKI KAISHA
  TITLE OF INVENTION: Vascularization Inhibitors
  FILE REFERENCE: 46124-5042-US
  CURRENT APPLICATION NUMBER: US/10/785,230
  CURRENT FILING DATE: 2004-02-25
  PRIOR APPLICATION NUMBER: PCT/JP99/01448
  PRIOR FILING DATE: 1999-03-23
  PRIOR APPLICATION NUMBER: JP10/95448
  PRIOR FILING DATE: 1998-03-24
; NUMBER OF SEQ ID NOS: 12
; SEQ ID NO 5
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Ligand peptide
US-10-785-230-5
 Query Match
                        100.0%; Score 463; DB 4; Length 89;
 Best Local Similarity
                        100.0%; Pred. No. 1.2e-47;
 Matches
          89; Conservative
                              0; Mismatches
                                               0; Indels
                                                             0; Gaps
                                                                         0:
Qу
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 7
US-10-924-029-1
; Sequence 1, Application US/10924029
; Publication No. US20050020528A1
   GENERAL INFORMATION:
        APPLICANT: Herrmann, Stephen H.
                   Lu, Zhijian
                   McCoy, John M.
                   Swanberg, Stephen L.
                   Walker, Bruce
                   Yang, Otto
        TITLE OF INVENTION: CHEMOKINES WITH AMINO-TERMINAL MODIFICATIONS
        NUMBER OF SEQUENCES: 15
        CORRESPONDENCE ADDRESS:
             ADDRESSEE: Genetics Institute, Inc.
             STREET: 87 CambridgePark Drive
             CITY: Cambridge
             STATE: MA
```

```
COUNTRY: U.S.A.
             ZIP: 02140
        COMPUTER READABLE FORM:
             MEDIUM TYPE: Floppy disk
             COMPUTER: IBM PC compatible
             OPERATING SYSTEM: PC-DOS/MS-DOS
             SOFTWARE: PatentIn Release #1.0, Version #1.30
        CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/10/924,029
             FILING DATE: 23-Aug-2004
             CLASSIFICATION: <Unknown>
        PRIOR APPLICATION DATA:
             APPLICATION NUMBER: US/09/175,713
             FILING DATE: 20-Oct-1998
        ATTORNEY/AGENT INFORMATION:
             NAME: Sprunger, Suzanne A.
             REGISTRATION NUMBER: 41,323
        TELECOMMUNICATION INFORMATION:
             TELEPHONE: (617) 498-8284
             TELEFAX: (617) 876-5851
   INFORMATION FOR SEO ID NO: 1:
        SEQUENCE CHARACTERISTICS:
             LENGTH: 89 amino acids
             TYPE: amino acid
             STRANDEDNESS: <Unknown>
             TOPOLOGY: linear
        MOLECULE TYPE: protein
        SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-924-029-1
 Query Match
                         100.0%; Score 463; DB 5; Length 89;
                                Pred. No. 1.2e-47;
  Best Local Similarity
                        100.0%;
                              0: Mismatches
 Matches
           89; Conservative
                                                0; Indels
                                                              0;
                                                                 Gaps
                                                                         0:
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 8
US-10-985-324-4
; Sequence 4, Application US/10985324
; Publication No. US20050202019A1
; GENERAL INFORMATION:
; APPLICANT: Northwest Biotherapeutics, Inc.
  APPLICANT: Murphy, Gerald P.
  APPLICANT: Boynton, Alton L.
  APPLICANT:
              Sehgal, Anil
  TITLE OF INVENTION: THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE
  TITLE OF INVENTION: ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS
  FILE REFERENCE: 20093-000600PC
; CURRENT APPLICATION NUMBER: US/10/985,324
; CURRENT FILING DATE: 2004-11-09
```

```
PRIOR APPLICATION NUMBER: US/09/647,501
  PRIOR FILING DATE: 2001-06-15
  PRIOR APPLICATION NUMBER: 60/079,916
  PRIOR FILING DATE: 1998-03-30
  PRIOR APPLICATION NUMBER: 60/104,656
  PRIOR FILING DATE: 1998-10-16
  NUMBER OF SEQ ID NOS: 28
  SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 4
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-985-324-4
 Query Match
                         100.0%; Score 463; DB 5; Length 89;
                        100.0%; Pred. No. 1.2e-47;
 Best Local Similarity
          89; Conservative
                              0; Mismatches
                                               0;
                                                    Indels
                                                              0;
                                                                  Gaps
                                                                          0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 9
US-10-773-236-280
; Sequence 280, Application US/10773236
; Publication No. US20050208602A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et. al.
  TITLE OF INVENTION: 89 Human Secreted Proteins
  FILE REFERENCE: PS751P1
  CURRENT APPLICATION NUMBER: US/10/773,236
  CURRENT FILING DATE: 2004-02-09
  PRIOR APPLICATION NUMBER: 60/311,085
   PRIOR FILING DATE: 2001-08-10
  PRIOR APPLICATION NUMBER: 60/325,209
  PRIOR FILING DATE: 2001-09-28
  PRIOR APPLICATION NUMBER: PCT/US02/25107
  PRIOR FILING DATE: 2002-08-08
  PRIOR APPLICATION NUMBER: 60/330,629
  PRIOR FILING DATE: 2001-10-26
   PRIOR APPLICATION NUMBER: PCT/US02/33985
  PRIOR FILING DATE: 2002-10-24
  PRIOR APPLICATION NUMBER: 60/331,046
   PRIOR FILING DATE: 2001-11-07
   PRIOR APPLICATION NUMBER: PCT/US02/35606
   PRIOR FILING DATE: 2002-11-06
   PRIOR APPLICATION NUMBER: 60/358,554
   PRIOR FILING DATE: 2002-02-22
  PRIOR APPLICATION NUMBER: PCT/US03/04819
   PRIOR FILING DATE: 2003-02-20
  PRIOR APPLICATION NUMBER: 60/358,714
 PRIOR FILING DATE: 2002-02-25
```

```
Remaining Prior Application data removed - See File Wrapper or PALM.
  NUMBER OF SEQ ID NOS: 396
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 280
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-773-236-280
 Query Match
                       100.0%; Score 463; DB 5; Length 89;
 Best Local Similarity 100.0%; Pred. No. 1.2e-47;
          89; Conservative
 Matches
                           0; Mismatches
                                             0; Indels
                                                                      0;
          1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
            1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
            Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 10
US-10-921-235-43
; Sequence 43, Application US/10921235
; Publication No. US20050214786A1
; GENERAL INFORMATION:
; APPLICANT: Birse et al.
 TITLE OF INVENTION: 26 Human Secreted Proteins
 FILE REFERENCE: PS741P1
  CURRENT APPLICATION NUMBER: US/10/921,235
  CURRENT FILING DATE: 2004-08-19
 PRIOR APPLICATION NUMBER: US03/04819
 PRIOR FILING DATE: 2003-02-20
 PRIOR APPLICATION NUMBER: US03/04818
 PRIOR FILING DATE: 2003-02-20
 PRIOR APPLICATION NUMBER: 60/358,554
 PRIOR FILING DATE: 2002-02-22
  PRIOR APPLICATION NUMBER: 60/358,714
  PRIOR FILING DATE: 2002-02-25
 NUMBER OF SEQ ID NOS: 76
 SOFTWARE: PatentIn Ver. 2.0
; SEO ID NO 43
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-921-235-43
 Query Match
                       100.0%; Score 463; DB 5; Length 89;
 Best Local Similarity
                       100.0%; Pred. No. 1.2e-47;
          89; Conservative
                             0; Mismatches
                                              0; Indels
                                                           0; Gaps
                                                                      0;
Qу
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
            Db
          1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
```

TYPE: PRT

```
RESULT 11
US-08-927-939-56
; Sequence 56, Application US/08927939
; Publication No. US20010006640A1
; GENERAL INFORMATION:
; APPLICANT: Grainger, David J.
; APPLICANT: Tatalick, Lauen Marie
 TITLE OF INVENTION: Compounds and methods to inhibit or
; TITLE OF INVENTION: augment an inflammatory response.
; FILE REFERENCE: 295.022US1
 CURRENT APPLICATION NUMBER: US/08/927,939
  CURRENT FILING DATE: 1997-09-11
; NUMBER OF SEQ ID NOS: 83
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEO ID NO 56
   LENGTH: 93
   TYPE: PRT
   ORGANISM: Homo sapiens
US-08-927-939-56
 Query Match
                        100.0%; Score 463; DB 2; Length 93;
 Best Local Similarity
                        100.0%; Pred. No. 1.3e-47;
 Matches
           89; Conservative
                            0; Mismatches
                                              0; Indels
                                                                         0;
Qу
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 12
US-09-144-838-7
; Sequence 7, Application US/09144838A
; Patent No. US20020051996A1
; GENERAL INFORMATION:
; APPLICANT: Siani, Michael A.
 APPLICANT: Wilken, Jill
 APPLICANT: Simon, Reyna
  APPLICANT: Kent, Stephen B.H.
  TITLE OF INVENTION: Modular Protein Libraries and Methods of Preparation
  FILE REFERENCE: GRFN-020/01US
  CURRENT APPLICATION NUMBER: US/09/144,838A
  CURRENT FILING DATE: 1998-08-31
  EARLIER APPLICATION NUMBER: US 60/057,620
  EARLIER FILING DATE: 1997-09-04
  NUMBER OF SEQ ID NOS: 54
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
   LENGTH: 93
```

```
ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-144-838-7
 Query Match
                       100.0%; Score 463; DB 3; Length 93;
 Best Local Similarity 100.0%; Pred. No. 1.3e-47;
                            0; Mismatches
          89; Conservative
                                             0; Indels
                                                          0; Gaps
                                                                     0;
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Qy
            Db
          1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
         61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
            61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Dh
RESULT 13
US-09-919-497-95
; Sequence 95, Application US/09919497
; Patent No. US20020106662A1
; GENERAL INFORMATION:
; APPLICANT: Mutter, George L.
 TITLE OF INVENTION: PROGNOSTIC CLASSIFICATION OF ENDOMETRIAL CANCER
; FILE REFERENCE: B0801/7225
; CURRENT APPLICATION NUMBER: US/09/919,497
; CURRENT FILING DATE: 2001-07-31
; PRIOR APPLICATION NUMBER: US 60/221,735
 PRIOR FILING DATE: 2000-07-31
; NUMBER OF SEQ ID NOS: 100
  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 95
   LENGTH: 93
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-919-497-95
  Query Match
                       100.0%; Score 463; DB 3; Length 93;
 Best Local Similarity 100.0%; Pred. No. 1.3e-47;
          89; Conservative
                            0; Mismatches
 Matches
                                            0; Indels
                                                          0; Gaps
                                                                     0;
Qy
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
            Db
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
         61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
            Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 14
US-09-835-107-2
; Sequence 2, Application US/09835107
; Patent No. US20020165123A1
; GENERAL INFORMATION:
; APPLICANT: Tudan, Christopher R.
```

```
APPLICANT: Merzouk, Ahmed
  APPLICANT: Arab, Lakhdar
  APPLICANT: Saxena, Geeta
 APPLICANT: Eaves, Connie J.
  APPLICANT: Cashman, Johanne
  APPLICANT: Clark-Lewis
 APPLICANT: Salari, Hassan
 TITLE OF INVENTION: CXCR4 AGONIST TREATMENT OF HEMATOPOIETIC CELLS
 FILE REFERENCE: SMAR012
 CURRENT APPLICATION NUMBER: US/09/835,107
; CURRENT FILING DATE: 2001-08-20
 PRIOR APPLICATION NUMBER: CA 2,305,036
  PRIOR FILING DATE: 2000-04-12
  PRIOR APPLICATION NUMBER: US 60/232,425
  PRIOR FILING DATE: 2000-09-14
  PRIOR APPLICATION NUMBER: CA 2,335,109
 PRIOR FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 34
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
   LENGTH: 93
   TYPE: PRT
   ORGANISM: Homo sapiens
   FEATURE:
   OTHER INFORMATION: SDF-1 Precursor, PBSF
US-09-835-107-2
 Query Match
                        100.0%; Score 463; DB 3; Length 93;
 Best Local Similarity 100.0%; Pred. No. 1.3e-47;
 Matches 89; Conservative 0; Mismatches
                                              0; Indels
                                                            0; Gaps
                                                                       0;
Qу
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Dh
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 15
US-09-835-107-3
; Sequence 3, Application US/09835107
: Patent No. US20020165123A1
; GENERAL INFORMATION:
 APPLICANT: Tudan, Christopher R.
; APPLICANT: Merzouk, Ahmed
; APPLICANT: Arab, Lakhdar
; APPLICANT: Saxena, Geeta
; APPLICANT: Eaves, Connie J.
; APPLICANT: Cashman, Johanne
 APPLICANT: Clark-Lewis
 APPLICANT: Salari, Hassan
  TITLE OF INVENTION: CXCR4 AGONIST TREATMENT OF HEMATOPOIETIC CELLS
; FILE REFERENCE: SMAR012
; CURRENT APPLICATION NUMBER: US/09/835,107
; CURRENT FILING DATE: 2001-08-20
```

```
; PRIOR APPLICATION NUMBER: CA 2,305,036
 PRIOR FILING DATE: 2000-04-12
 PRIOR APPLICATION NUMBER: US 60/232,425
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: CA 2,335,109
 PRIOR FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 34
 SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
   LENGTH: 93
   TYPE: PRT
   ORGANISM: Homo sapiens
   OTHER INFORMATION: SDF-1 beta
US-09-835-107-3
 Query Match
                      100.0%; Score 463; DB 3; Length 93;
                      100.0%; Pred. No. 1.3e-47;
 Best Local Similarity
 Matches 89; Conservative 0; Mismatches 0; Indels
                                                         0; Gaps
                                                                   0;
          1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
         61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
            Db
         61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
```

Search completed: April 26, 2006, 02:41:56

Job time : 165 secs

GenCore version 5.1.7 Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 26, 2006, 02:30:09; Search time 187 Seconds

(without alignments)

209.116 Million cell updates/sec

Title: US-10-785-230-5

Perfect score: 463

;

Sequence: 1 MNAKVVVLVLTALCLSD......VCIDPKLKWIQEYLEKALNK 89

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 segs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: A_Geneseq_21:*

1: geneseqp1980s:*

2: geneseqp1990s:*

3: geneseqp2000s:*

4: geneseqp2001s:*

5: geneseqp2002s:*

6: geneseqp2003as:*

7: geneseqp2003bs:*

8: geneseqp2004s:*

9: geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

F	esult		o Query						
_	No.	Score		Length	DB	ID	Descripti	Description	
	1	463	100.0	89	2	AAR75419	Aar75419	Human SDF	
	2	463	100.0	89	2	AAY26177	Aay26177	Stromal c	
	3	463	100.0	89	2	AAY39995	Aay39995	Human SDF	
	4	463	100.0	89	3	AAY52508	Aay52508	Human str	
	5	463	100.0	89	3	AAY93603	Aay93603 .	A human B	
	6	463	100.0	89	3	AAB15791	Aab15791	Human che	
	7	463	100.0	89	5	ABG32978	Abg32978	Human str	
	8	463	100.0	89	5	ABG33066	Abg33066	Human str	

9	463	100.0	89	7	ADC78236	Adc78236	Human sec
10	463	100.0	89	9	ADW64706	Adw64706	Human che
11	463	100.0	93	2	AAR75420	Aar75420	Human SDF
12	463	100.0	93	2	AAW50766	Aaw50766	Human SDF
13	463	100.0	93	2	AAY26178	Aay26178	Stromal c
14	463	100.0	93	2	AAY06725		Amino aci
15	463	100.0	93	3	AAB15812		Human che
16	463	100.0	93	5	AAU84305	Aau84305	Human end
17	463	100.0	93	5	AAB47691	Aab47691	SDF-1-bet
18	463	100.0	93	5	AAB47690	Aab47690	SDF-1 pre
19	463	100.0	93	5	AAE23952		Human str
20	463	100.0	93	7	ADN95190		Human BEC
21	463	100.0	93	7	ADP65272	Adp65272	Human str
22	463	100.0	93	8	ADN07719	Adn07719	Human str
23	463	100.0	93	8	ADP12445	Adp12445	Protein e
24	463	100.0	93	8	ADQ19853	Adq19853	Human sof
25	463	100.0	93	8	ADQ14484	Adq14484	Human che
26	463	100.0	93	8	ADR99187	Adr99187	Chemokine
27	463	100.0	93	9	ADW64707	Adw64707	Human che
28	463	100.0	93	9	ADY76111	Ady76111	Human str
29	463	100.0	93	9	ADY76110	Ady76110	Human str
30	463	100.0	93	9	ADZ21672	Adz21672	Human str
31	463	100.0	119	5	AAM48047	Aam48047	Human SDF
32	463	100.0	166	2	AAY29899	Aay29899	Human SDF
33	463	100.0	328	2	AAW76220	Aaw76220	Human che
34	454	98.1	93	8	ADN36543	Adn36543	Chemokine
35	447.5	96.7	92	8	ADN36544	Adn36544	Chemokine
36	442	95.5	89	2	AAR70994	Aar70994	Protein e
37	442	95.5	89	2	AAW50764		Peptide #
38	442	95.5	89	2	AAY39996	Aay39996	Mouse SDF
39	442	95.5	89	6	AAE14828	Aae14828	Mouse str
40	442	95.5	93	2	AAW50765	Aaw50765	Peptide #
41	440	95.0	326	2	AAW76221	Aaw76221	Human che
42	435	94.0	93	5	AAM48049	Aam48049	Rat SDF-1
43	435	94.0	119	5	AAM48048	Aam48048	Rat SDF-1
44	428	92.4	136	5	ABP42241		Human ova
45	427	92.2	90	5	AAM48043	Aam48043	Generic S

ALIGNMENTS

```
RESULT 1
    AAR75419 standard; protein; 89 AA.
XX
AC
    AAR75419;
XX
DT
    15-NOV-1995 (first entry)
XX
DE
     Human SDF-1-alpha.
XX
KW
     SDF-1-alpha; stromal derived factor; hematopoietic cell;
KW
     inflammatory disease; infectious disease; AIDS;
KW
     neurodegenerative disease.
XX
OS
     Homo sapiens.
```

```
XX
FH
                    Location/Qualifiers
    Key
FΤ
                    1. .21
    Peptide
FT
                    /label= Sig peptide
XX
PN
    CA2117953-A.
XX
    15-APR-1995.
PD
XX
PF
    12-OCT-1994;
                   94CA-02117953.
XX
PR
    14-OCT-1993;
                   93JP-00280505.
XX
PA
    (ONOY ) ONO PHARM CO LTD.
XX
PI
    Honjo T, Shirozu M,
                        Tada H;
XX
DR
    WPI; 1995-207311/28.
    N-PSDB; AAQ74088, AAQ74089.
DR
XX
PT
    Polypeptide(s) used for treating diseases relating to undergrown or
    abnormal proliferation of haematopoietic cells - e.g. inflammatory
PT
PT
    diseases, infectious diseases, AIDS or neuro: degenerative diseases.
XX
PS
    Claim 2; Page 22; 43pp; English.
XX
CC
    A cDNA library prepared from human pro-B cell line FLEB14 cells was
CC
    screened with 32P-labeled mouse SDF-1-alpha cDNA. A positive clone
CC
    contained an insert of 1.9 kb (AAQ74089), including an ORF (AAQ74088)
    encoding human SDF-1-alpha (AAR75419). Recombinant hSDF-1-alpha was
CC
CC
    produced in E. coli and COS cells
XX
SQ
    Sequence 89 AA;
 Query Match
                         100.0%; Score 463; DB 2;
                                                   Length 89;
 Best Local Similarity
                         100.0%; Pred. No. 1.4e-49;
 Matches
           89; Conservative
                               0; Mismatches
                                                0; Indels
                                                              0; Gaps
                                                                         0;
Qу
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             Db
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 2
AAY26177
    AAY26177 standard; protein; 89 AA.
XX
AC
    AAY26177;
XX
DT
    29-SEP-1999 (first entry)
XX
DE
    Stromal cell derived factor 1a.
XX
```

```
Stromal cell derived factor 1a; SDF 1a; vaccine; immune response;
KW
KW
     antigen; humoral response; cell-mediated response; PCR;
     immunostimulatory; expression plasmid vector.
KW
XX
OS
    Homo sapiens.
XX
                    Location/Qualifiers
FH
     Kev
    Peptide
                    1. .21
FT
                    /note= "signal peptide"
FT
FT
     Protein
                    22. .89
FT
                    /label= SDF la
FT
                    /note= "Stromal cell-derived factor-1a"
XX
PN
    WO9929728-A1.
XX
PD
    17-JUN-1999.
XX
                   98WO-US026291.
PF
    11-DEC-1998;
XX
PR
    11-DEC-1997;
                   97US-0069281P.
XX
PA
     (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PΙ
     Gallo RC, Devico AL,
                           Garzino-Demo A;
XX
DR
    WPI; 1999-385578/32.
DR
    N-PSDB; AAX80632.
XX
PT
    Methods of enhancing vaccine efficacy.
XX
PS
    Claim 4; Page 102; 134pp; English.
XX
CC
    The present sequence is stromal cell derived factor-la. This belongs to
    the CXC class of chemokines. This is chemotactic for mature dendritic
CC
CC
     cells. The efficacy of a vaccine is enhanced by combining it with one or
CC
    more chemokines to enhance the immune response to an antigen. This can be
CC
    humoral or cell-mediated immune response. The purified chemokines,
CC
     fragments, derivatives or analogues are administered either concurrently
CC
    with one or more purified antigens against which an immune response is
CC
    desired or within a time period either before or after antigen
    administration. The chemokine gene is isolated by PCR, and administered
CC
    by constructing an expression plasmid vector which can be expressed in a
CC
CC
     coordinated manner upon introduction in a suitable cell. The vaccines are
CC
     immunostimulatory and can be used to treat microbial diseases especially
CC
XX
SQ
     Sequence 89 AA;
 Query Match
                         100.0%;
                                 Score 463; DB 2;
                                                    Length 89;
 Best Local Similarity
                         100.0%;
                                  Pred. No. 1.4e-49;
 Matches
           89; Conservative
                                0; Mismatches
                                                 0;
                                                     Indels
                                                                           0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
              Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
```

Best Local Similarity

```
RESULT 3
AAY39995
     AAY39995 standard; protein; 89 AA.
XX
AC
     AAY39995;
XX
DT
     16-DEC-1999 (first entry)
XX
DΕ
     Human SDF-1-alpha protein sequence.
XX
KW
     CXCR4; human; neovascularisation; inhibitor; solid cancer; therapy;
KW
     tissue repairing agent; vascularisation; SDF-1-alpha.
XX
OS
     Homo sapiens.
XX
PN
     WO9948528-A1.
XX
PD
     30-SEP-1999.
XX
PF
     23-MAR-1999;
                    99WO-JP001448.
XX
PR
     24-MAR-1998;
                    98JP-00095448.
XX
PA
     (CHUS ) CHUGAI SEIYAKU KK.
PA
     (KISH/) KISHIMOTO T.
XX
ΡI
     Kishimoto T, Nagasawa T, Tachibana K;
XX
     WPI; 1999-591042/50.
DR
DR
     N-PSDB; AAZ27612.
XX
PT
     CXCR4-potentiating agents and methods useful for inhibiting
PT
     neovascularization, and treating solid cancers.
XX
PS
     Disclosure; Page 51-52; 63pp; Japanese.
XX
CC
     This sequence is the human SDF-1-alpha protein. The invention relates to
CC
     remedies inhibiting neovascularisation, remedies for solid cancer,
CC
     remedies for diseases pathologically caused by neovascularisation and
CC
     tissue repairing agents containing as the active ingredient a substance
CC
     capable of potentiating CXCR4. Based on a finding that vascularisation is
CC
     inhibited in a CXCR4 knockout mouse, it becomes possible to prepare
CC
     remedies inhibiting vascularisation which contain as the active
CC
     ingredient a substance capable of potentiating CXCR4, remedies for solid
CC
     cancer, remedies for diseases pathologically caused by neovascularisation
CC
     and tissue repairing agents containing as the active ingredient a
CC
     substance capable of potentiating CXCR4. It is also possible to establish
CC
     methods for treatment with the use of these remedies
XX
SO
     Sequence 89 AA;
                          100.0%; Score 463; DB 2; Length 89;
  Query Match
```

100.0%; Pred. No. 1.4e-49;

```
89; Conservative
                               0; Mismatches
                                                 0; Indels
 Matches
                                                               0; Gaps
                                                                          0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 4
AAY52508
ID
    AAY52508 standard; protein; 89 AA.
XX
AC
    AAY52508;
XX
DT
    22-FEB-2000 (first entry)
XX
DΕ
    Human stromal cell derived factor-1 (SDF-1).
XX
KW
    CXC-chemokine receptor-4; CXCR-4; stromal cell derived factor-1; SDF-1;
    ligand; chemotaxis; inflammation; G-protein-coupled receptor;
KW
KW
    signal transduction; CD4-independent; HIV-1; infection; proliferation;
KW
    transformation; tumorigenesis; cancer; tumour; overexpression; brain;
KW
    breast; colon; lung; melanoma; glioblastoma; inhibition; growth arrest;
KW
    diagnosis; prognosis; marker; proliferative disorders; antisense;
KW
    therapy; treatment; premalignant condition; hypertrophy;
    degenerative disorder; Parkinson's disease; Alzheimer's disease;
KW
KW
    growth deficiency; hypoproliferative disorder; physical trauma; lesion;
KW
    ischaemia; wound.
XX
os
    Homo sapiens.
XX
PN
    WO9950461-A1.
XX
    07-OCT-1999.
PD
XX
PF
    29-MAR-1999;
                   99WO-US007431.
XX
PR
    30-MAR-1998;
                   98US-0079916P.
                   98US-0104656P.
PR
    16-OCT-1998;
XX
PA
     (NWBI-) NORTHWEST BIOTHERAPEUTICS INC.
XX
PΙ
    Murphy GP, Boynton AL,
                            Sehgal A;
XX
DR
    WPI; 2000-052634/04.
DR
    N-PSDB; AAZ38554.
XX
PT
    Use of CXCR-4 and SDF-1 as markers for diagnosis and treatment of e.g.
PT
    tumors, degenerative disorders, growth deficiencies, hyper- and
PT
    hypoproliferative disorders, physical trauma, lesions and wounds.
XX
PS
    Disclosure; Fig 15; 138pp; English.
XX
CC
    This sequence represents stromal cell derived factor-1 (SDF-1) cDNA. SDF-
```

```
1 is the ligand for CXC-chemokine receptor-4 (CXCR-4, AAY52507).
CC
     Chemokine receptors play an important role in the chemotaxis of T-cells
CC
CC
     and phagocytic cells to areas of inflammation. CXCR-4 is a member of the
     G-protein-coupled receptor family, which is involved in signal
CC
     transduction. CXCR-4 also mediates CD4-independent infection by HIV-1.
CC
     CXCR-4 has now been found to have a role in the aberrant proliferative
CC
     behaviour of a number of cell types, including numerous primary tumours
CC
CC
     and derived cell lines. CXCR-4 is involved in cell transformation and
CC
     tumorigenesis, particularly in brain, breast and colon tumours. It was
CC
     found to be overexpressed in several brain tumour derived cell lines and
CC
     primary brain tumour tissues, breast tumour tissues, colorectal
CC
     adenocarcinoma, lung carcinoma and melanoma cell lines. CXCR-4 expression
CC
     was required for the continuous proliferation of glioblastoma cancer
CC
     cells, and inhibition of its gene function resulted in growth arrest.
CC
     Conversely, overexpression resulted in enhanced and rapid cellular
CC
     proliferation. CXCR-4 and SDF-1 can be used as markers for the diagnosis
CC
     and prognosis of cell proliferative disorders, and antisense
CC
     oligonucleotides complementary to at least a portion of an RNA transcript
CC
     of a CXCR-4 gene can be used to inhibit hyperproliferation of a tumour
CC
     cell. Agents that inhibit CXCR-4 function can be used for treating or
CC
     preventing a disease or disorder involving cell overproliferation, e.g.,
CC
     brain cancer, breast cancer, colon cancer, prostate cancer and B cell
CC
     lymphoma, and also premalignant conditions, benign tumours,
CC
     hyperproliferative disorders, and benign dysproliferative disorders. They
CC
     can also be used for treating e.g., cirrhosis of the liver, keloid
CC
     formation, psoriasis, benign tumors, fibrocystic conditions and tissue
CC
     hypertrophy. Compounds that promote CXCR-4 function can also be used for
CC
     preventing or treating a disease or disorder involving a deficiency in
CC
     cell proliferation, or treating a condition where cell proliferation
CC
     would be desirable. Such diseases include degenerative disorders (e.g.,
CC
     Parkinson's disease, Alzheimer's disease), growth deficiencies,
CC
     hypoproliferative disorders, physical trauma, lesions (e.g., those caused
CC
     by ischaemia), and wounds
XX
SO
     Sequence 89 AA;
  Query Match
                         100.0%;
                                  Score 463; DB 3; Length 89;
  Best Local Similarity
                         100.0%;
                                  Pred. No. 1.4e-49;
           89; Conservative
                                0; Mismatches
                                                 0; Indels
                                                               0; Gaps
                                                                           0;
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
              Db
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
           61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
              Db
           61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 5
AAY93603
ID
     AAY93603 standard; protein; 89 AA.
XX
    AAY93603;
AC
XX
DΤ
     25-SEP-2000 (first entry)
XX
```

```
A human B-cell stimulating factor homologue (SDFla).
DE
XX
KW
     Differentially expressed human gene; cardiac disease; kidney disease;
     inflammatory disease; I-8U; prostacyclin-stimulating factor; isf-2;
KW
     tissue specific mRNA; insulin-like growth factor binding protein 6;
KW
     OSF-1; gas-1; YMP; BTG2; pre-B cell stimulating factor homologue; SDF1a;
KW
     peripheral benzodiazepine receptor; annexin II cellular ligand; p11;
KW
KW
     congenital heart failure; dilated congestive cardiomyopathy;
KW
     hypertrophic cardiomyopathy; restrictive cardiomyopathy;
KW
     mitral valve disease; aortic valve disease; tricuspid valve disease;
KW
     angina pectoris; myocardial infarction; cardiac arrhythmia;
KW
     pulmonary hypertension; arterial hypertension; renovascular hypertension;
KW
     arteriosclerosis; atherosclerosis; cardiac tumour.
XX
os
     Homo sapiens.
XX
PN
     WO200035473-A2.
XX
PD
     22-JUN-2000.
XX
PF
     15-DEC-1999;
                    99WO-US029941.
XX
PR
     18-DEC-1998;
                    98US-0113008P.
XX
PA
     (SCIO-) SCIOS INC.
XX
PΙ
     Stanton LW, White RT, Damm DL, Lewicki JA, Joly A, Schreiner GF;
XX
DR
     WPI; 2000-451904/39.
DR
     N-PSDB; AAA46677.
XX
PT
     Preventing, diagnosing and treating cardiac, kidney and inflammatory
PT
     disorders using cardiac genes that are differentially expressed in
PT
     disease states such as cardiac arrhythmia and arteriosclerosis.
XX
PS
     Disclosure; Fig 8J; 170pp; English.
XX
CC
     AAY93594-Y93605 are encoded by differentially expressed human genes,
     associated with disease states and disorders. The specification describes
CC
     methods preventing, diagnosing and treating cardiac, kidney and
CC
CC
     inflammatory diseases associated with inappropriate expression of
CC
     differentially expressed cardiac, kidney and inflammatory genes (e.g.
CC
     AAA46668-79). These genes include I-8U, prostacyclin-stimulating factor,
CC
     isf-2, tissue specific mRNA, insulin-like growth factor binding protein
CC
     6, OSF-1, gas-1, YMP, BTG2, pre-B cell stimulating factor homologue
CC
     (SDFla), peripheral benzodiazepine receptor, and cellular ligand of
CC
     annexin II (pl1), respectively. These diseases include congenital heart
CC
     failure, dilated congestive cardiomyopathy, hypertrophic cardiomyopathy,
CC
     restrictive cardiomyopathy, mitral valve disease, aortic valve disease,
CC
     tricuspid valve disease, angina pectoris, myocardial infarction, cardiac
CC
     arrhythmia, pulmonary hypertension, arterial hypertension, renovascular
CC
     hypertension, arteriosclerosis, atherosclerosis and/or cardiac tumours
XX
SQ
     Sequence 89 AA;
                          100.0%; Score 463; DB 3; Length 89;
  Query Match
  Best Local Similarity 100.0%; Pred. No. 1.4e-49;
```

```
Matches
           89; Conservative
                                0; Mismatches
                                                  0; Indels
                                                                0;
                                                                    Gaps
                                                                            0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
              Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
           61 ARLKNNNROVCIDPKLKWIQEYLEKALNK 89
Qу
              111111111111111111111111111111111111
           61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 6
AAB15791
     AAB15791 standard; protein; 89 AA.
ID
XX
AC
     AAB15791;
XX
DT
     17-JAN-2001 (first entry)
XX
DE
     Human chemokine SDF1alpha SEQ ID NO: 22.
XX
KW
     Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
KW
     monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
KW
     AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
KW
     basophil-mediated disease; myocardial infarction; acute ischaemia;
KW
     rheumatoid arthritis; contraception.
XX
OS
     Homo sapiens.
XX
PN
     WO200042071-A2.
XX
     20-JUL-2000.
PD
XX
PF
     12-JAN-2000; 2000WO-US000821.
XX
PR
     12-JAN-1999;
                   99US-00229071.
PR
     17-MAR-1999:
                   99US-00271192.
     01-DEC-1999;
                   99US-00452406.
PR
XX
PA
     (NEOR-) NEORX CORP.
XX
PΙ
     Grainger DJ, Tatalick LM;
XX
DR
     WPI: 2000-499101/44.
DR
     N-PSDB: AAA74883.
XX
PT
     New peptide 3, amide and heterocyclic compounds and saccharide conjugates
PT
     used for inhibiting chemokine induced activity and for treating e.g.
PT
     stroke, vascular diseases, autoimmune diseases and tumor growth.
XX
PS
     Example 1; Page 134; 387pp; English.
XX
CC
     The present invention concerns the identification of a number of
CC
     chemokines which can be used to produce derivatives, agonists and
CC
     antagonists which are then useful in disease treatment. The chemokines
CC
     include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
CC
     These chemokine derivatives can be used to treat diseases such as
```

```
autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
CC
    AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated
CC
    diseases, endotoxaemia, myocardial infarction, acute ischaemia and
CC
    rheumatoid arthritis, and can be used to prevent strokes and as
CC
    contraceptives. The coding sequences for the chemokines can be used in
CC
    gene therapy for the same diseases, as well as in the production of
CC
CC
    animal models
XX
SO
    Sequence 89 AA;
                         100.0%;
                                 Score 463; DB 3; Length 89;
 Query Match
                         100.0%;
                                 Pred. No. 1.4e-49;
 Best Local Similarity
           89; Conservative
                                0; Mismatches
                                                 0; Indels
                                                                   Gaps
                                                                          0;
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qy
             Db
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 7
ABG32978
    ABG32978 standard; protein; 89 AA.
XX
AC
    ABG32978;
XX
DΤ
    02-DEC-2002 (first entry)
XX
DE
    Human stromal cell derived factor 1-alpha (SDF 1-alpha).
XX
    CXC chemokine receptor 4; CXCR4; chemotaxis induction; SDFlalpha;
KW
KW
    stromal cell-derived factor lalpha; angiogenesis; atherosclerosis;
KW
    restenosis; ischaemic stroke; spinal cord injury; infection; ulcer;
KW
    human immunodeficiency virus; HIV; acquired immunodeficiency syndrome;
    AIDS; pain; cancer; benign prostatic hypertrophy; diabetes; obesity;
KW
KW
    anorexia; bulimia; asthma; Parkinson's disease; acute heart failure;
KW
    hypotension; hypertension; urinary retention; osteoporosis; stroke;
KW
    anginal pectoris; myocardial infarction; benign prostatic hypertrophy;
    migraine; vomiting; psychotic disorder; neurological disorder; anxiety;
KW
    schizophrenia; dyskinesia; Huntingdon's disease; restenosis;
KW
KW
    inflammatory disease; rheumatoid arthritis; diabetic retinopathy;
    inflammatory bowel disease; atherosclerosis; Alzheimer's disease;
KW
    congestive heart failure; cardiac remodeling; angiogenic diseases;
KW
    solid tumour; Kaposi Sarcoma; human.
KW
XX
os
    Homo sapiens.
XX
    US2002107195-A1.
PN
XX
PD
    08-AUG-2002.
XX
PF
    17-SEP-2001; 2001US-00953692.
XX
                   98US-0093596P.
    21-JUL-1998;
PR
```

```
PR
    21-JUL-1999;
                   99US-00358624.
XX
PA
     (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PΙ
    Gupta SK;
XX
    WPI: 2002-697879/75.
DR
    N-PSDB; ABS53989.
DR
XX
PΤ
    Inducing chemotaxis of endothelial cells, useful for regulating
PT
    angiogenesis, e.g. for treating cancer, comprises treatment with stromal
PT
    cell-derived factor 1 alpha.
XX
PS
    Claim 1; Fig 2; 26pp; English.
XX
CC
    The invention describes a method of inducing chemotaxis of endothelial
CC
    cells by treatment with stromal cell-derived factor lalpha (SDFla). The
CC
    method is used for stimulating EC chemotaxis, and thus angiogenesis, and
    is used for treating atherosclerosis, restenosis, ischaemic stroke and
CC
    spinal cord injury. Inhibition of this process is useful in treatment and
CC
CC
    prevention of a very wide range of diseases, such as, infection (by
CC
    bacteria, fungi, protozoa or viruses such as human immunodeficiency virus
CC
     (HIV) and acquired immunodeficiency syndrome (AIDS)), pain, cancer and
CC
    benign prostatic hypertrophy, diabetes, obesity, anorexia, bulimia,
CC
    asthma, Parkinson's disease, acute heart failure, hypotension,
    hypertension, urinary retention, osteoporosis, anginal pectoris,
CC
CC
    myocardial infarction, stroke, ulcers, benign prostatic hypertrophy,
CC
    migraine, vomiting, psychotic and neurological disorders (e.g. anxiety,
CC
    schizophrenia) and dyskinesias (e.g. Huntingdon's disease), inflammatory
CC
    diseases, rheumatoid arthritis, diabetic retinopathy, inflammatory bowel
CC
    disease, atherosclerosis, restenosis, Alzheimer's disease, congestive
CC
    heart failure, cardiac remodeling, angiogenic diseases, solid tumours,
CC
    and Kaposi Sarcoma. This is the amino acid sequence of human stromal cell
CC
    derived factor 1-alpha (SDF 1-alpha)
XX
SQ
    Sequence 89 AA;
 Query Match
                         100.0%; Score 463; DB 5; Length 89;
  Best Local Similarity
                         100.0%; Pred. No. 1.4e-49;
 Matches
           89; Conservative
                               0; Mismatches
                                                 0; Indels
                                                               0; Gaps
                                                                          0;
Qy
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 8
ABG33066
ID
    ABG33066 standard; protein; 89 AA.
XX
AC
    ABG33066;
XX
DT
    28-NOV-2002 (first entry)
```

XX DΕ Human stromal cell derived factor-la (SDF-lalpha). XX KW Chemotaxis; endothelial cell; EC; angiogenesis; atherosclerosis; KW restenosis; ischaemic stroke; spinal cord injury; infection; bacteria; KW fungi; protozoa; virus; pain; cancer; benign prostatic hypertrophy; KW diabetes; obesity; anorexia; bulimia; asthma; allergy; hypertension; KW Parkinson's disease; acute heart failure; hypotension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; dyskinesia; KW KW migraine; vomiting; psychotic disorder; neurological disorder; ulcer; KW inflammatory disorder; rheumatoid arthritis; diabetic retinopathy; ΚW inflammatory bowel disease; atherosclerosis; restenosis; Kaposi sarcoma; KW Alzheimer's disease; congestive heart failure; cardiac remodelling; angiogenic disease; solid tumour; human; stromal cell derived factor-la; KW KW SDF-lalpha. XX OS Homo sapiens. XX PN US2002107196-A1. XX PD 08-AUG-2002. XX 17-SEP-2001; 2001US-00953717. PFXX PR 21-JUL-1998; 98US-0093596P. PR 21-JUL-1999; 99US-00358624. XX PA (SMIK) SMITHKLINE BEECHAM CORP. XX PΙ Gupta SK; XX DR WPI; 2002-706230/76. DR N-PSDB; ABS53747. XX PTInducing chemotaxis of endothelial cells, useful for regulating PTangiogenesis, e.g. for treating cancer, comprises treatment with stromal PΤ cell-derived factor 1 alpha. XX PS Claim 1; Fig 2; 26pp; English. XX CC The present invention relates to a new method for inducing chemotaxis of CC endothelial cells (EC). The method of the invention involves treatment CC with a stromal cell-derived factor la (SDF1alpha). The method is used for CC stimulating EC chemotaxis, and thus angiogenesis, and is used for CC treating atherosclerosis, restenosis, ischaemic stroke and spinal cord CC injury, while inhibition of this process is useful in treatment and CC prevention of a very wide range of diseases, e.g. infection (by bacteria, CC fungi, protozoa or viruses), pain, cancer and benign prostatic CC hypertrophy, diabetes, obesity, anorexia, bulimia, asthma, allergies, CC Parkinson's disease, acute heart failure, hypotension, hypertension, CC urinary retention, osteoporosis, angina pectoris, myocardial infarction, CC stroke, ulcers, migraine, vomiting, psychotic and neurological disorders CC and dyskinesias, inflammatory disorders, rheumatoid arthritis, diabetic CC retinopathy, inflammatory bowel disease, atherosclerosis, restenosis, CC Alzheimer's disease, congestive heart failure, cardiac remodelling, CC angiogenic diseases, solid tumours, and Kaposi sarcoma. The present amino

acid sequence represents the human stromal cell derived factor-la (SDF-

CC

```
CC
     lalpha) protein of the invention
XX
SO
     Sequence 89 AA;
                         100.0%;
                                 Score 463; DB 5; Length 89;
  Query Match
                         100.0%;
                                 Pred. No. 1.4e-49;
  Best Local Similarity
                               0; Mismatches
  Matches
           89; Conservative
                                                 0: Indels
                                                              0; Gaps
                                                                          0;
Qу
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
              61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 9
ADC78236
    ADC78236 standard; protein; 89 AA.
XX
AC
    ADC78236;
XX
DT
     01-JAN-2004 (first entry)
XX
DE
    Human secreted protein SEQ ID NO:43.
XX
KW
     human; secreted protein; neuroprotective; nootropic; antiparkinsonian;
KW
     immunosuppressive; dermatological; antiinflammatory; antirheumatic;
KW
     antiarthritic; antithyroid; antianaemic; antidiabetic; hepatotropic;
KW
     antiasthmatic; antiallergic; nephrotropic; antiarteriosclerotic;
KW
     cardiant; anti-HIV; virucide; antibacterial; fungicide; gynaecological;
KW
     cytostatic; gene therapy; neural disorder; immune system disorder;
     muscular disorder; reproductive disorder; gastrointestinal disorder;
KW
KW
     pulmonary disorder; cardiovascular disorder; renal disorder;
KW
    proliferative disorders; cancer; systemic lupus erythematosus;
KW
     rheumatoid arthritis; multiple sclerosis; thyroiditis; anaemia;
KW
     Grave's disease; diabetes; hepatitis; asthma; allergy; nephritis;
KW
     Parkinson's disease; Alzheimer's disease; atherosclerosis;
KW
    myocardial infarction; AIDS; infection.
XX
os
    Homo sapiens.
XX
PN
    WO2003072761-A1.
XX
PD
     04-SEP-2003.
XX
PF
     20-FEB-2003; 2003WO-US004819.
XX
PR
     22-FEB-2002; 2002US-0358554P.
XX
PA
     (HUMA-) HUMAN GENOME SCI INC.
XX
PΙ
     Birse CE, Komatsoulis G, Choi GH, Olsen H, Ni J, Baker KP;
XX
DR
     WPI; 2003-721771/68.
DR
     P-PSDB; ADC78210.
```

```
New secreted polypeptides and nucleic acid molecules for diagnosing,
PT
PT
     preventing or treating diseases associated with aberrant expression or
     activity of the polypeptide, e.g. cancer, asthma, AIDS, Parkinson's
PT
PT
     disease or diabetes.
XX
     Claim 11; SEQ ID NO 43; 572pp; English.
PS
XX
CC
     The present invention describes an isolated nucleic acid molecule (I)
CC
     encoding a human secreted protein. Also described: (1) a recombinant
CC
     vector comprising (I); (2) making a recombinant host cell comprising (I);
CC
     (3) an isolated polypeptide (II) comprising a sequence that is at least
CC
     95% identical to the polypeptide or its fragment, domain, epitope,
CC
     (allelic) variant or homologue encoded by (I); (4) an isolated antibody
CC
     that binds specifically to (II); (5) a recombinant host cell produced by
CC
     the above method and that expresses (II); (6) making an isolated
     polypeptide; (7) preventing, treating or ameliorating a medical condition
CC
CC
     ; (8) diagnosing a pathological condition or a susceptibility to a
CC
     pathological condition in a subject; (9) identifying a binding partner to
CC
     the above polypeptide; (10) identifying an activity in a biological assay
CC
     ; and (11) the product produced by method (9). (I) and (II) have
CC
     neuroprotective, nootropic, antiparkinsonian, immunosuppressive,
CC
     dermatological, antiinflammatory, antirheumatic, antiarthritic,
CC
     antithyroid, antianaemic, antidiabetic, hepatotropic, antiasthmatic,
CC
     antiallergic, nephrotropic, antiarteriosclerotic, cardiant, anti-HIV,
CC
     virucide, antibacterial, fungicide, gynaecological and cytostatic
CC
     activities, and can be used in gene therapy. The nucleic acid molecule
CC
     (I) and polypeptide (II) can be used in diagnosing, preventing,
CC
     prognosing or treating diseases or disorders associated with aberrant
CC
     expression and/or activity of the above polypeptide, such as neural
CC
     disorders, immune system disorders, muscular disorders, reproductive
CC
     disorders, gastrointestinal disorders, pulmonary disorders,
CC
     cardiovascular disorders, renal disorders, proliferative disorders and/or
CC
     cancers. In particular, these diseases are systemic lupus erythematosus,
CC
     rheumatoid arthritis, multiple sclerosis, thyroiditis, anaemia, Grave's
CC
     disease, diabetes, hepatitis, asthma, allergies, nephritis, Parkinson's
CC
     disease, Alzheimer's disease, atherosclerosis, myocardial infarction,
     AIDS, or infections. The methods may be used for identifying agonists and
CC
CC
     antagonists of the polynucleotide and polypeptide. The present sequence
CC
     represents a human secreted protein from the present invention.
XX
SQ
     Sequence 89 AA;
                         100.0%; Score 463; DB 7; Length 89;
  Query Match
                                  Pred. No. 1.4e-49;
  Best Local Similarity
                         100.0%;
 Matches
           89; Conservative
                                0; Mismatches
                                                 0;
                                                      Indels
            1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
              Db
            1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
           61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
              Db
           61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
```

XX

```
ADW64706
     ADW64706 standard; protein; 89 AA.
ID
XX
     ADW64706;
AC
XX
     07-APR-2005 (first entry)
DT
XX
     Human chemokine SDF-lalpha protein sequence SeqID1.
DE
XX
KW
     chemokine; virucide; anti-HIV; antiinflammatory; immunosuppressive;
KW
     HIV infection; inflammation; autoimmune disease; veterinary;
KW
     gene therapy; SDF-lalpha.
XX
os
    Homo sapiens.
XX
PN
     US2005020528-A1.
XX
PD
     27-JAN-2005.
XX
PF
     23-AUG-2004; 2004US-00924029.
XX
PR
     28-FEB-1997;
                    97US-00808720.
                    97US-0113672P.
PR
     22-OCT-1997;
     20-OCT-1998;
                    98US-00175713.
PR
XX
PA
     (HERR/) HERRMANN S H.
PA
     (LUZZ/) LU Z.
PA
     (MCCO/) MCCOY J M.
PΑ
     (SWAN/) SWANBERG S L.
PA
     (WALK/) WALKER B.
PA
     (YANG/) YANG O.
XX
     Herrmann SH, Lu Z, Mccoy JM, Swanberg SL, Walker B, Yang O;
PΙ
XX
DR
     WPI; 2005-100856/11.
DR
     N-PSDB; ADW64708.
XX
PT
     New composition comprises isolated polynucleotide encoding an amino-
PT
     terminal-modified chemokine or an amino-terminal-modified chemokine,
     useful for preventing, treating, or ameliorating HIV infection,
PT
PT
     inflammatory, or autoimmune condition.
XX
PS
     Example 1; SEQ ID NO 1; 29pp; English.
XX
CC
     This invention relates to a novel composition which comprises an isolated
     polynucleotide encoding an amino-terminal-modified chemokine or comprises
CC
CC
     an amino-terminal-modified chemokine. The invention may be useful for the
CC
     production of compounds with a virucide, anti-HIV, antiinflammatory or
CC
     immunosuppressive activity. The composition is useful for preventing,
CC
     treating, or ameliorating an HIV infection, an inflammatory condition, or
CC
     an autoimmune condition. The composition is also useful for veterinary
CC
     applications. The amino-terminal-modified chemokine are useful as tolls
     for identifying cells expressing receptor for the chemokine, or for
CC
CC
     studying binding of chemokine to isolated receptor molecules. They can
     also be used as vaccine adjuvants or to affect the chemotactic
CC
CC
     recruitment of migratory cells. The polynucleotides can also be used in
CC
     gene therapy. The amino-terminal-modified chemokine is a more successful
```

```
inhibitor of HIV infection than the corresponding unmodified chemokine.
    The present sequence is that of wild-type human chemokine SDF-lalpha
CC
    which was used during the development of the composition of the
CC
CC
    invention.
XX
    Sequence 89 AA;
SO
 Query Match
                        100.0%; Score 463; DB 9; Length 89;
                        100.0%; Pred. No. 1.4e-49;
 Best Local Similarity
 Matches
           89; Conservative
                              0; Mismatches
                                                0;
                                                    Indels
                                                              0; Gaps
                                                                         0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 11
AAR75420
    AAR75420 standard; protein; 93 AA.
ID
XX
AC
    AAR75420;
XX
DT
    15-NOV-1995 (first entry)
XX
DE
    Human SDF-1-beta.
XX
KW
    SDF-1-beta; stromal derived factor; hematopoietic cell;
KW
    inflammatory disease; infectious disease; AIDS;
    neurodegenerative disease.
KW
XX
os
    Homo sapiens.
XX
                   Location/Qualifiers
FΗ
    Key
                    1. .21
\mathbf{FT}
    Peptide
FT
                    /label= Sig peptide
XX
PN
    CA2117953-A.
XX
PD
    15-APR-1995.
XX
PF
    12-OCT-1994;
                   94CA-02117953.
XX
PR
    14-OCT-1993;
                   93JP-00280505.
XX
PA
     (ONOY ) ONO PHARM CO LTD.
XX
PΙ
    Honjo T, Shirozu M,
                         Tada H;
XX
DR
    WPI; 1995-207311/28.
DR
    N-PSDB; AAQ74090, AAQ74091.
XX
PT
    Polypeptide(s) used for treating diseases relating to undergrown or
PT
     abnormal proliferation of haematopoietic cells - e.g. inflammatory
```

```
diseases, infectious diseases, AIDS or neuro:degenerative diseases.
PT
XX
PS
    Claim 12; Page 26-27; 43pp; English.
XX
    A cDNA library prepared from human pro-B cell line FLEB14 cells was
CC
    screened with 32P-labeled mouse SDF-1-alpha cDNA. A positive clone
CC
    contained an insert of 3.5 kb (AAQ74091), including an ORF (AAQ74090)
CC
    encoding human SDF-1-beta (AAR75420). Recombinant hSDF-1-beta was
CC
    produced in E. coli and COS cells
CC
XX
SQ
    Sequence 93 AA;
 Query Match
                        100.0%; Score 463; DB 2; Length 93;
 Best Local Similarity
                        100.0%; Pred. No. 1.5e-49;
                                               0; Indels
           89; Conservative
                              0; Mismatches
                                                             0; Gaps
                                                                         0;
Qу
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 12
AAW50766
    AAW50766 standard; peptide; 93 AA.
XX
AC
    AAW50766;
XX
DT
    27-JUL-1998 (first entry)
XX
DΕ
    Human SDF-1 which is useful for treating HIV.
XX
KW
    Stromal cell-derived chemokine; SDF-1; human immunodeficiency virus; HIV;
KW
    CXCR4 receptor; leukocyte-expressed transmembrane domain receptor.
XX
OS
    Homo sapiens.
XX
PN
    FR2751658-A1.
XX
PD
    30-JAN-1998.
XX
PF
    26-JUL-1996;
                   96FR-00009477.
XX
PR
    26-JUL-1996;
                   96FR-00009477.
XX
PA
     (INSP ) INST PASTEUR.
XX
ΡI
    Arenzana SF, Virelizier JL, Baggiolini M, Moser B, Clark LI;
XX
    WPI; 1998-123039/12.
DR
DR
    P-PSDB; AAV07076.
XX
PT
    Human stromal cell-derived chemokine, SDF-1 - useful for treating human
PT
    immunodeficiency virus infection.
```

```
XX
PS
     Claim 4; Fig 5; 48pp; French.
XX
CC
     The invention relates to peptides which bind to a cellular receptor for
     CXC chemokines, namely the CXCR4 receptor (also known as leukocyte-
CC
     expressed transmembrane domain receptor), especially where the peptide is
CC
CC
     human chemokine SDF-1. The peptide can be used to treat or prevent HIV
     infections, optionally together with reverse transcriptase inhibitors,
CC
     viral protease inhibitors, soluble CD4 receptors, CD4 receptor
CC
CC
     antagonists, immunotherapy agents, agents for treating HIV- associated
CC
     opportunistic infections and/or other CXC or CC chemokines, especially
     RANTES, MIP1- alpha , MIP1- beta or MCP1. The peptide can be used to
CC
    detect anti-SDF-1 antibodies in biological fluids. This sequence
CC
CC
     represents human SDF-1
XX
SQ
    Sequence 93 AA;
 Query Match
                         100.0%;
                                  Score 463; DB 2;
                                                    Length 93;
                                  Pred. No. 1.5e-49;
 Best Local Similarity
                         100.0%;
 Matches
           89; Conservative
                                0; Mismatches
                                                 0;
                                                     Indels
                                                               0;
                                                                   Gaps
                                                                           0;
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             1:11:11:11:11:11
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 13
AAY26178
ID
     AAY26178 standard; protein; 93 AA.
XX
AC
    AAY26178;
XX
DT
     29-SEP-1999
                (first entry)
XX
DE
     Stromal cell derived factor 1b.
XX
KW
     Stromal cell derived factor 1b; SDF 1b; vaccine; immune response;
KW
     antigen; humoral response; cell-mediated response; PCR;
KW
     immunostimulatory; expression plasmid vector.
XX
os
     Homo sapiens.
XX
FH
                    Location/Qualifiers
     Key
FT
     Peptide
                    1. .21
                    /note= "Signal peptide"
FT
FT
     Protein
                    22. .93
FT
                    /label= SDF 1b
FT
                    /note= "Stromal cell-derived factor 1b"
XX
PN
     W09929728-A1.
XX
PD
     17-JUN-1999.
XX
```

```
11-DEC-1998;
                   98WO-US026291.
PF
XX
PR
    11-DEC-1997;
                   97US-0069281P.
XX
     (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
PA
XX
PΙ
    Gallo RC, Devico AL, Garzino-Demo A;
XX
DR
    WPI; 1999-385578/32.
DR
    N-PSDB; AAX80633.
XX
PT
    Methods of enhancing vaccine efficacy.
XX
    Claim 4; Page 103; 134pp; English.
PS
XX
CC
    The present sequence is stromal cell derived factor-lb. This belongs to
CC
    the CXC class of chemokines. This is chemotactic for mature dendritic
CC
    cells. The efficacy of a vaccine is enhanced by combining it with one or
CC
    more chemokines to enhance the immune response to an antigen. This can be
CC
    humoral or cell-mediated immune response. The purified chemokines,
CC
    fragments, derivatives or analogues are administered either concurrently
CC
    with one or more purified antigens against which an immune response is
CC
    desired or within a time period either before or after antigen
CC
    administration. The chemokine gene is isolated by PCR, and administered
CC
    by constructing an expression plasmid vector which can be expressed in a
CC
    coordinated manner upon introduction in a suitable cell. The vaccines are
CC
    immunostimulatory and can be used to treat microbial diseases especially
CC
XX
SQ
    Sequence 93 AA;
  Query Match
                         100.0%;
                                 Score 463; DB 2; Length 93;
                                 Pred. No. 1.5e-49;
  Best Local Similarity
                         100.0%;
 Matches
           89; Conservative
                               0; Mismatches
                                                 0;
                                                    Indels
                                                               0;
                                                                  Gaps
                                                                          0;
Qу
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 14
AAY06725
    AAY06725 standard; protein; 93 AA.
XX
AC
    AAY06725;
XX
DT
    18-JUN-1999 (first entry)
XX
DE
    Amino acid sequence of native SDF-1 alpha.
XX
KW
    Chemokine; cross-over protein; pharmaceutical; inflammatory; AIDS; viral;
KW
    infectious disease; hematopoiesis; chemoprotection; asthma; RANTES; vMIP;
KW
     allergic rhinitis; atopic dermatitis; rheumatoid arthritis; SDF-1; MPAV;
```

```
KW
    stromal cell derived factor 1; Macrophage Inflammatory protein.
XX
os
    Homo sapiens.
XX
PN
    WO9911655-A1.
XX
PD
    11-MAR-1999.
XX
                   98WO-US018096.
PF
    31-AUG-1998;
XX
PR
    04-SEP-1997;
                   97US-0057620P.
XX
PA
     (GRYP-) GRYPHON SCI.
XX
PΙ
    Kent SBH, Siani MA, Simon R, Wilken J;
XX
DR
    WPI; 1999-205128/17.
XX
PT
    New cross-over proteins for treatment of inflammation and infections e.g.
PT
    AIDS - prepared by ligation of two functional protein modules derived
PT
    from two different parent molecules.
XX
PS
    Example 4; Page 41; 75pp; English.
XX
CC
    The invention relates to a cross-over protein produced by chemical
CC
    ligation of at least two functional protein modules derived from at least
    two parent protein molecules. The cross-over proteins can be used in
CC
CC
    pharmaceutical compositions for therapy of inflammatory and infectious
CC
    diseases including AIDS, and for indications of hematopoiesis and
CC
    chemoprotection. They are also useful for treatment of asthma, allergic
    rhinitis, atopic dermatitis and rheumatoid arthritis. A library
CC
CC
    comprising a collection of cross-over proteins is useful for screening
CC
    for cross-over proteins that are receptor ligands. The libraries comprise
CC
    functionally diverse compounds therefore improving the drug discovery
CC
    process. The proteins and libraries are exemplified by the preparation of
CC
    cross-over chemokines comprising various combinations of peptide segments
CC
    derived from RANTES, SDF-1 (stromal cell derived factor 1), vMIP (viral
CC
    Macrophage Inflammatory protein) and other such chemokines. The present
CC
    sequence represents a native amino acid fragment of SDF-1 alpha
XX
SO
    Sequence 93 AA;
  Query Match
                         100.0%;
                                 Score 463; DB 2; Length 93;
  Best Local Similarity
                         100.0%; Pred. No. 1.5e-49;
           89; Conservative
                               0; Mismatches
                                                 0; Indels
                                                              0; Gaps
                                                                          0;
Qy
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             Db
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
```

```
ID
     AAB15812 standard; protein; 93 AA.
XX
AC
     AAB15812;
XX
DT
     17-JAN-2001 (first entry)
XX
DE
     Human chemokine SDF1beta SEQ ID NO: 56.
XX
KW
     Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
KW
     monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
KW
     AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
     basophil-mediated disease; myocardial infarction; acute ischaemia;
KW
KW
     rheumatoid arthritis; contraception.
XX
OS
     Homo sapiens.
XX
PN
     WO200042071-A2.
XX
PD
     20-JUL-2000.
XX
     12-JAN-2000; 2000WO-US000821.
PF
XX
PR
     12-JAN-1999;
                    99US-00229071.
PR
     17-MAR-1999;
                    99US-00271192.
PR
     01-DEC-1999;
                    99US-00452406.
XX
PA
     (NEOR-) NEORX CORP.
XX
PΙ
     Grainger DJ, Tatalick LM;
XX
DR
     WPI; 2000-499101/44.
DR
     N-PSDB; AAA74869.
XX
PT
     New peptide 3, amide and heterocyclic compounds and saccharide conjugates
PT
     used for inhibiting chemokine induced activity and for treating e.g.
PT
     stroke, vascular diseases, autoimmune diseases and tumor growth.
XX
PS
     Disclosure; Page 366; 387pp; English.
XX
CC
     The present invention concerns the identification of a number of
     chemokines which can be used to produce derivatives, agonists and
CC
CC
     antagonists which are then useful in disease treatment. The chemokines
CC
     include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
CC
     These chemokine derivatives can be used to treat diseases such as
CC
     autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
CC
     AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated
CC
     diseases, endotoxaemia, myocardial infarction, acute ischaemia and
CC
     rheumatoid arthritis, and can be used to prevent strokes and as
CC
     contraceptives. The coding sequences for the chemokines can be used in
CC
     gene therapy for the same diseases, as well as in the production of
CC
     animal models
XX
SO
     Sequence 93 AA;
  Query Match
                          100.0%;
                                   Score 463; DB 3; Length 93;
  Best Local Similarity
                          100.0%; Pred. No. 1.5e-49;
  Matches
            89; Conservative
                                 0; Mismatches
                                                   0; Indels
```

Qу	1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Db	1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу	61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db	61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89

Search completed: April 26, 2006, 02:33:39 Job time: 190 secs

GenCore version 5.1.7 Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: April 26, 2006, 02:33:59; Search time 38 Seconds

(without alignments)

225.350 Million cell updates/sec

Title: US-10-785-230-5

Perfect score: 463

Sequence: 1 MNAKVVVVLVLVLTALCLSD......VCIDPKLKWIQEYLEKALNK 89

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: PIR_80:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		8				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
	463	100.0	93	 2	G01540	cytokine SDF-1-bet
2	442	95.5	89	2	153416	interleukin-8 homo
3	442	95.5	89	2	A53497	pre-B-cell growth-
4	442	95.5	93	2	I81182	cytokine - mouse
5	113.5	24.5	101	2	I48148	Neutrophil attract
6	113	24.4	99	2	A37034	interleukin-8 prec
7	112.5	24.3	96	2	A32954	gro-alpha precurso
8	111	24.0	95	2	JN0841	interleukin-8 - do
9	111	24.0	98	2	I59277	Mob-1 - rat
10	110	23.8	103	2	A26736	transformation-ind
11	108	23.3	103	2	I50417	RSV-induced protei
12	107	23.1	101	2	S42496	interleukin-8 prec
13	106.5	23.0	91	1	A28815	monocyte chemoattr

106.5	23.0	91	1	A46539	monocyte chemoattr
106.5	23.0	101	2	B28414	growth-regulated p
104.5	22.6	100	2	JH0200	macrophage inflamm
103.5	22.4	107	2	B38290	GRO-gamma precurso
102.5	22.1	100	2	I55614	macrophage inflamm
102.5	22.1	100	2	S21467	macrophage inflamm
102	22.0	101	2	146871	interleukin-8 - ra
101.5	21.9	96	2	JN0572	neutrophil chemo-a
100.5	21.7	107	2	JH0281	macrophage inflamm
99	21.4	98	2	A45492	IP-10 precursor -
98.5	21.3	120	2	JE0177	lymphocyte and mon
98	21.2	103	2	A53096	interleukin-8 prec
97	21.0	119	2	S42881	platelet basic pro
96.5	20.8	107	2	A28414	melanoma growth-st
96.5	20.8	120	2	I48147	monocyte chemoattr
95	20.5	148	1	S07723	immediate-early se
94.5	20.4	92	2	152322	macrophage inflamm
94.5	20.4	128	1	TGHU	beta-thromboglobul
93	20.1	109	2	A54678	monocyte chemotact
87.5	18.9	126	2	A35766	platelet factor 4,
86	18.6	98	1	TGHUGI	interferon gamma-i
86	18.6	100	2	S46198	cytokine-induced n
84.5	18.3	148	1	A30209	PDGF-inducible JE
84	18.1	75	2	A54188	granulocyte chemot
83.5	18.0	114	2	A55010	neutrophil-activat
83	17.9	117	2	B44253	alveolar macrophag
83	17.9	125	2	JN0470	interferon gamma-i
82.5	17.8	132	2	A57325	C-X-C chemokine LI
82	17.7	113	2	JC7800	neutrophil activat
82	17.7	870	2	A41130	dystrophin homolog
81.5	17.6	75	2	B54188	granulocyte chemot
79	17.1	92	2	146730	immune activation
	106.5 104.5 103.5 102.5 102.5 102.5 100.5 99 98.5 96.5 96.5 94.5 94.5 94.5 94.5 94.5 94.5 94.5 94	106.5 23.0 104.5 22.6 103.5 22.4 102.5 22.1 102.5 22.1 102 22.0 101.5 21.9 100.5 21.7 99 21.4 98.5 21.3 98 21.2 97 21.0 96.5 20.8 96.5 20.8 95 20.5 94.5 20.4 94.5 20.4 93 20.1 87.5 18.9 86 18.6 84 18.1 83.5 18.0 83 17.9 83 17.9 83 17.9 81.5 17.6	106.5 23.0 101 104.5 22.6 100 103.5 22.4 107 102.5 22.1 100 102.5 22.1 100 102.5 22.1 100 102.5 22.1 100 102.5 22.1 107 96 100.5 21.7 107 99 21.4 98 98.5 21.3 120 98 21.2 103 97 21.0 119 96.5 20.8 107 96.5 20.8 120 95 20.5 148 94.5 20.4 92 94.5 20.4 92 94.5 20.4 128 93 20.1 109 87.5 18.9 126 86 18.6 98 86 18.6 100 84.5 18.3 148 84 18.1 75 83.5 18.0 114	106.5 23.0 101 2 104.5 22.6 100 2 103.5 22.4 107 2 102.5 22.1 100 2 102.5 22.1 100 2 102.5 22.1 100 2 102.5 22.1 100 2 102.5 21.9 96 2 100.5 21.7 107 2 99 21.4 98 2 98.5 21.3 120 2 98.5 21.3 120 2 98.5 21.3 120 2 98.5 20.8 107 2 96.5 20.8 107 2 95.5 20.8 120 2 95.5 20.8 120 2 95.5 20.8 120 2 94.5 20.4 92 2 94.5 20.4 92 2 94.5 20.4 128 1 93 <td< td=""><td>106.5 23.0 101 2 B28414 104.5 22.6 100 2 JH0200 103.5 22.4 107 2 B38290 102.5 22.1 100 2 I55614 102.5 22.1 100 2 S21467 102 22.0 101 2 I46871 101.5 21.9 96 2 JN0572 100.5 21.7 107 2 JH0281 99 21.4 98 2 A45492 98.5 21.3 120 2 JE0177 98 21.2 103 2 A53096 97 21.0 119 2 S42881 96.5 20.8 107 2 A28414 96.5 20.8 120 2 I48147 95 20.5 148 1 S07723 94.5 20.4 92 2 I52322 94.5 20.4 128 1 TGHU 93 20.1</td></td<>	106.5 23.0 101 2 B28414 104.5 22.6 100 2 JH0200 103.5 22.4 107 2 B38290 102.5 22.1 100 2 I55614 102.5 22.1 100 2 S21467 102 22.0 101 2 I46871 101.5 21.9 96 2 JN0572 100.5 21.7 107 2 JH0281 99 21.4 98 2 A45492 98.5 21.3 120 2 JE0177 98 21.2 103 2 A53096 97 21.0 119 2 S42881 96.5 20.8 107 2 A28414 96.5 20.8 120 2 I48147 95 20.5 148 1 S07723 94.5 20.4 92 2 I52322 94.5 20.4 128 1 TGHU 93 20.1

ALIGNMENTS

```
RESULT 1
G01540
cytokine SDF-1-beta - human
C; Species: Homo sapiens (man)
C;Date: 21-Dec-1996 #sequence revision 06-Jun-1997 #text change 09-Jul-2004
C; Accession: G01540
R;Spotila, L.D.
submitted to the EMBL Data Library, October 1994
A; Reference number: G07697
A; Accession: G01540
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-93 <SPO>
A; Cross-references: UNIPROT: P48061; UNIPARC: UPI000003092F; EMBL: U16752;
NID:g1272194; PID:g571508
C; Superfamily: beta-thromboglobulin
                          100.0%; Score 463; DB 2; Length 93;
  Query Match
  Best Local Similarity 100.0%; Pred. No. 4.2e-45;
  Matches 89; Conservative 0; Mismatches 0; Indels
                                                                            0;
```

```
1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
             1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALOIV 60
Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qy
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Dh
RESULT 2
I53416
interleukin-8 homolog - mouse
C; Species: Mus sp. (mouse)
C;Date: 02-Aug-1996 #sequence revision 02-Aug-1996 #text_change 05-Nov-1999
C; Accession: I53416
R; Jiang, W.; Zhou, P.; Kahn, S.M.; Tomita, N.; Johnson, M.D.; Weinstein, I.B.
Exp. Cell Res. 215, 284-293, 1994
A; Title: Molecular cloning of TPAR1, a gene whose expression is repressed by the
tumor promoter 12-0-tetradecanovlphorbol 13-acetate (TPA).
A; Reference number: I53416; MUID: 95073497; PMID: 7982471
A; Accession: I53416
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-89 < RES>
A; Cross-references: UNIPARC: UPI00000018A3; GB: S74318; NID: g786393;
PIDN:AAB32650.1; PID:g786394
C; Genetics:
A; Gene: TPAR1
C; Superfamily: beta-thromboglobulin
 Query Match
                        95.5%; Score 442; DB 2; Length 89;
 Best Local Similarity
                        93.3%; Pred. No. 9.5e-43;
 Matches
          83; Conservative
                              3; Mismatches
                                              3; Indels
                                                            0; Gaps
                                                                       0;
Qу
           1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             Db
           1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIV 60
Qv
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             Db
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 3
A53497
pre-B-cell growth-stimulating factor precursor - mouse
C; Species: Mus musculus (house mouse)
C;Date: 02-Jun-1994 #sequence revision 02-Jun-1994 #text change 09-Jul-2004
C; Accession: A53497; I59582
R; Nagasawa, T.; Kikutani, H.; Kishimoto, T.
Proc. Natl. Acad. Sci. U.S.A. 91, 2305-2309, 1994
A; Title: Molecular cloning and structure of a pre-B-cell growth-stimulating
factor.
A; Reference number: A53497; MUID: 94181581; PMID: 8134392
A; Accession: A53497
A; Status: preliminary
```

```
A; Molecule type: mRNA
A; Residues: 1-89 < NAG>
A; Cross-references: UNIPROT: P40224; UNIPARC: UPI00000018A3; GB: D21072;
NID: g413905; PIDN: BAA04648.1; PID: g468457
R; Tashiro, K.; Tada, H.; Heilker, R.; Shirozu, M.; Nakano, T.; Honjo, T.
Science 261, 600-603, 1993
A; Title: Signal sequence trap: a cloning strategy for secreted proteins and type
I membrane proteins.
A; Reference number: I59582; MUID: 93342488; PMID: 8342023
A; Accession: I59582
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-89 < RES>
A; Cross-references: UNIPARC: UPI00000018A3; GB: L12029; NID: q393179;
PIDN:AAA40100.1; PID:g393180
C; Genetics:
A; Gene: SDF-1-alpha
C; Superfamily: beta-thromboglobulin
C; Keywords: cytokine
                         95.5%; Score 442; DB 2; Length 89;
 Ouerv Match
 Best Local Similarity
                         93.3%; Pred. No. 9.5e-43;
           83; Conservative
 Matches
                                3; Mismatches
                                                 3; Indels
                                                               0; Gaps
                                                                           0;
Qу
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
             Db
           1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIV 60
Qу
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Db
RESULT 4
I81182
cytokine - mouse
C; Species: Mus musculus (house mouse)
C;Date: 02-Aug-1996 #sequence revision 02-Aug-1996 #text change 09-Jul-2004
C; Accession: I81182
R; Tashiro, K.; Tada, H.; Heilker, R.; Shirozu, M.; Nakano, T.; Honjo, T.
Science 261, 600-603, 1993
A; Title: Signal sequence trap: a cloning strategy for secreted proteins and type
I membrane proteins.
A; Reference number: 159582; MUID: 93342488; PMID: 8342023
A; Accession: I81182
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-93 < RES>
A; Cross-references: UNIPROT: P40224; UNIPARC: UPI000002A125; GB: L12030;
NID:g393181; PIDN:AAA40101.1; PID:g393182
C; Genetics:
A; Gene: SDF-1-beta
C; Superfamily: beta-thromboglobulin
  Query Match
                         95.5%; Score 442; DB 2; Length 93;
  Best Local Similarity
                         93.3%; Pred. No. 9.9e-43;
 Matches 83; Conservative
                               3; Mismatches
                                                3; Indels
                                                                           0;
```

```
1 MNAKVVVVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIV 60
Qу
              Db
           1 MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIV 60
          61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
             61 ARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
RESULT 5
I48148
Neutrophil attractant protein-1 - guinea pig
C; Species: Cavia porcellus (quinea pig)
C; Date: 02-Jul-1996 #sequence revision 02-Jul-1996 #text change 09-Jul-2004
C; Accession: I48148
R; Yoshimura, T.; Johnson, D.G.
J. Immunol. 151, 6225-6236, 1993
A; Title: cDNA cloning and expression of guinea pig neutrophil attractant
protein-1 (NAP-1): NAP-1 is highly conserved in guinea pig.
A; Reference number: I48148; MUID: 94065176; PMID: 7504015
A; Accession: I48148
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-101 <RES>
A; Cross-references: UNIPROT: P49113; UNIPARC: UPI000012D4F8; GB: L04986;
NID:g459764; PIDN:AAA37049.1; PID:g459765
C; Genetics:
A; Gene: NAP-1
C; Superfamily: beta-thromboglobulin
                         24.5%; Score 113.5; DB 2; Length 101; 32.6%; Pred. No. 1.3e-05;
  Query Match
  Best Local Similarity
 Matches
           30; Conservative 20; Mismatches
                                                 31; Indels
                                                              11; Gaps
                                                                           6;
           6 VVVLVLTALCLSDGKPVS---LSYRCPCRFFESHVARAN---VKHLKILNT-PNCA-L 57
Qу
             | | | | : | : | : |
                                      \square
                                                  : :| ||:: : | ||
Db
           7 VAVLAAFLLSAVLCEGMVVTKLVSELRCQC--IKIHTTPFHPKFIKELKVIESGPRCANS 64
Qу
          58 QIVARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
             :1: :1 ::111:1:111 11:1: :
Db
          65 EIIVKL-SDNRQLCLDPKKKWVQDVVSMFLKR 95
RESULT 6
A37034
interleukin-8 precursor - human
N; Alternate names: beta-thromboglobulin-like protein; fibroblast-derived
neutrophil-activating factor alpha; lung carcinoma-derived chemotaxin;
lymphocyte-derived neutrophil-activating factor; monocyte-derived neutrophil
chemotactic factor; monocyte-derived neutrophil-activating factor
C; Species: Homo sapiens (man)
C;Date: 08-Dec-1992 #sequence revision 08-Dec-1992 #text change 09-Jul-2004
C; Accession: A37034; JL0041; A32791; S37634; PL0107; A28598; A27488; A39960;
A60401; A60591; S15827; S04216; A60567; A60847; S15417; S03975; I54560; I55992;
I37902; S67519
R; Mukaida, N.; Shiroo, M.; Matsushima, K.
```

```
J. Immunol. 143, 1366-1371, 1989
A; Title: Genomic structure of the human monocyte-derived neutrophil chemotactic
factor IL-8.
A; Reference number: A37034; MUID: 89309826; PMID: 2663993
A; Accession: A37034
A; Molecule type: DNA
A; Residues: 1-99 <MUK>
A; Cross-references: UNIPROT: P10145; UNIPARC: UPI0000000DD0; GB: M28130;
NID:g186367; PIDN:AAA59158.1; PID:g186368
A; Note: the authors failed to translate the last thirty-six nucleotides of the
second exon
R; Matsushima, K.; Morishita, K.; Yoshimura, T.; Lavu, S.; Kobayashi, Y.; Lew,
W.; Appella, E.; Kung, H.F.; Leonard, E.J.; Oppenheim, J.J.
J. Exp. Med. 167, 1883-1893, 1988
A; Title: Molecular cloning of a human monocyte-derived neutrophil chemotactic
factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor
necrosis factor.
A; Reference number: JL0041; MUID: 88258376; PMID: 3260265
A; Accession: JL0041
A; Molecule type: mRNA
A; Residues: 1-99 <MA1>
A; Cross-references: UNIPARC: UPI0000000DD0; EMBL: Y00787; NID: q34518;
PIDN:CAA68742.1; PID:q34519
A; Note: the sequence shows similarity to several platelet-derived factors, a v-
src-induced protein, a growth-regulated gene product (gro), and an IFN-gamma-
inducible protein
R; Kowalski, J.; Denhardt, D.T.
Mol. Cell. Biol. 9, 1946-1957, 1989
A; Title: Regulation of the mRNA for monocyte-derived neutrophil-activating
peptide in differentiating HL60 promyelocytes.
A; Reference number: A32791; MUID: 89313739; PMID: 2664463
A; Accession: A32791
A; Molecule type: mRNA
A; Residues: 1-99 <KOW>
A;Cross-references: UNIPARC:UPI000000DDD0; GB:M26383; NID:g188627;
PIDN:AAA36323.1; PID:g188628
R; King, C.H.; Gordon, G.S.; Konieczkowski, M.; Sedor, J.R.
submitted to the EMBL Data Library, February 1992
A; Reference number: S37634
A; Accession: S37634
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-97 <KIN>
A; Cross-references: UNIPARC: UPI000000077C; EMBL: Z11686; NID: q33958;
PIDN:CAA77745.1; PID:q33959
R; Suzuki, K.; Miyasaka, H.; Ota, H.; Yamakawa, Y.; Taqawa, M.; Kuramoto, A.;
Mizuno, S.
J. Exp. Med. 169, 1895-1901, 1989
A; Title: Purification and partial primary sequence of a chemotactic protein for
polymorphonuclear leukocytes derived from human lung giant cell carcinoma LU65C
cells.
A; Reference number: PL0107; MUID: 89279141; PMID: 2659722
A; Accession: PL0107
A; Molecule type: protein
A; Residues: 23-32, 'XR', 35, 'X', 37-52, 'L', 54 <SUZ>
A; Cross-references: UNIPARC: UPI0000177BEA
A; Experimental source: lung giant cell carcinoma LU65C
```

```
R; Gregory, H.; Young, J.; Schroeder, J.M.; Mrowietz, U.; Christophers, E.
Biochem. Biophys. Res. Commun. 151, 883-890, 1988
A; Title: Structure determination of a human lymphocyte derived neutrophil
activating peptide (LYNAP).
A; Reference number: A28598; MUID: 88162914; PMID: 3279957
A; Accession: A28598
A; Molecule type: protein
A; Residues: 28-99 <GRE>
A; Cross-references: UNIPARC: UPI000003094C
R; Walz, A.; Peveri, P.; Aschauer, H.; Baggiolini, M.
Biochem. Biophys. Res. Commun. 149, 755-761, 1987
A; Title: Purification and amino acid sequencing of NAF, a novel neutrophil-
activating factor produced by monocytes.
A; Reference number: A27488; MUID: 88106502; PMID: 3322281
A; Accession: A27488
A; Molecule type: protein
A; Residues: 28-59 <WAL>
A; Cross-references: UNIPARC: UPI0000177BEB
R; Yoshimura, T.; Matsushima, K.; Tanaka, S.; Robinson, E.A.; Appella, E.;
Oppenheim, J.J.; Leonard, E.J.
Proc. Natl. Acad. Sci. U.S.A. 84, 9233-9237, 1987
A; Title: Purification of a human monocyte-derived neutrophil chemotactic factor
that has peptide sequence similarity to other host defense cytokines.
A; Reference number: A39960; MUID: 88097462; PMID: 3480540
A; Accession: A39960
A; Molecule type: protein
A; Residues: 28-69 <YOS>
A; Cross-references: UNIPARC: UPI0000177BEC
R; Schroeder, J.M.; Sticherling, M.; Henneicke, H.H.; Preissner, W.C.;
Christophers, E.
J. Immunol. 144, 2223-2232, 1990
A; Title: IL-lalpha or tumor necrosis factor-alpha stimulate release of three
NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts.
A; Reference number: A60401; MUID: 90187866; PMID: 2179408
A; Accession: A60401
A; Molecule type: protein
A; Residues: 23-32 <SCH>
A; Cross-references: UNIPARC: UPI0000158437
A; Experimental source: dermal fibroblasts
A; Note: a minor component of this material (15%) includes an additional two
amino acids at the amino end
R; Van Damme, J.; Decock, B.; Conings, R.; Lenaerts, J.P.; Opdenakker, G.;
Billiau, A.
Eur. J. Immunol. 19, 1189-1194, 1989
A; Title: The chemotactic activity for granulocytes produced by virally infected
fibroblasts is identical to monocyte-derived interleukin 8.
A; Reference number: A60591; MUID: 89338542; PMID: 2668011
A; Accession: A60591
A; Molecule type: protein
A; Residues: 23-33, 'X', 35, 'X', 37-42 <VAN>
A; Cross-references: UNIPARC: UPI000006F8F7
R; Nakagawa, H.; Hatakeyama, S.; Ikesue, A.; Miyai, H.
FEBS Lett. 282, 412-414, 1991
A; Title: Generation of interleukin-8 by plasmin from AVLPR-interleukin-8, the
human fibroblast-derived neutrophil chemotactic factor.
A; Reference number: S15827; MUID: 91243843; PMID: 1828038
A; Accession: S15827
```

```
A; Molecule type: protein
A; Residues: 23-33, 'X', 35, 'X', 37-47 < FEB>
A; Cross-references: UNIPARC: UPI000006D6FA
R; van Damme, J.; van Beeumen, J.; Conings, R.; Decock, B.; Billiau, A.
Eur. J. Biochem. 181, 337-344, 1989
A; Title: Purification of granulocyte chemotactic peptide/interleukin-8 reveals
N-terminal sequence heterogeneity similar to that of beta-thromboglobulin.
A; Reference number: S04216; MUID: 89231715; PMID: 2523801
A; Accession: S04216
A; Molecule type: protein
A; Residues: 21-67 <VA2>
A; Cross-references: UNIPARC: UPI0000177BED
R; Yoshimura, T.; Robinson, E.A.; Appella, E.; Matsushima, K.; Showalter, S.D.;
Skeel, A.; Leonard, E.J.
Mol. Immunol. 26, 87-93, 1989
A; Title: Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF)
distinguished by different lengths of the amino-terminal sequence.
A; Reference number: A60567; MUID: 89181632; PMID: 2648135
A; Accession: A60567
A; Molecule type: protein
A; Residues: 21-33, 'X', 35, 'X', 37-47 < YO2>
A; Cross-references: UNIPARC: UPI0000177BEE
A; Note: the forms starting from positions 21, 23, and 28 represented 8%, 47%,
and 45%, respectively, of total interleukin-8
R; Van Damme, J.; Van Beeumen, J.; Opdenakker, G.; Billiau, A.
J. Exp. Med. 167, 1364-1376, 1988
A; Title: A novel, NH-2-terminal sequence-characterized human monokine possessing
neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity.
A; Reference number: A60847; MUID: 88187604; PMID: 3258625
A; Accession: A60847
A; Molecule type: protein
A; Residues: 28-47 < VA3>
A; Cross-references: UNIPARC: UPI0000177BEF
R; Car, B.D.; Baggiolini, M.; Walz, A.
Biochem. J. 275, 581-584, 1991
A; Title: Formation of neutrophil-activating peptide 2 from platelet-derived
connective-tissue-activating peptide III by different tissue proteinases.
A; Reference number: S15417; MUID: 91248085; PMID: 2039437
A; Accession: S15417
A; Status: preliminary
A; Molecule type: protein
A; Residues: 28-99 <CAR>
A; Cross-references: UNIPARC: UPI000003094C
R; Golds, E.E.; Mason, P.; Nyirkos, P.
Biochem. J. 259, 585-588, 1989
A; Title: Inflammatory cytokines induce synthesis and secretion of gro protein
and a neutrophil chemotactic factor but not beta-2--microglobulin in human
synovial cells and fibroblasts.
A; Reference number: S03975; MUID: 89246368; PMID: 2655583
A; Accession: S03975
A; Molecule type: protein
A; Residues: 23-46 <GOL>
A; Cross-references: UNIPARC: UPI0000177BF0
R; Hotta, K.; Hayashi, K.; Ishikawa, J.; Tagawa, M.; Hashimoto, K.; Mizumo, S.;
Suzuki, K.
Immunol. Lett. 24, 165-170, 1990
```

```
A; Title: Coding region structure of interleukin-8 gene of human lung giant cell
carcinoma LU65C cells that produce LUCT/interliukin-8: homogeneity in
interleuki-8 genes.
A; Reference number: I54560; MUID: 90346419; PMID: 2200751
A; Accession: I54560
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-99 < RES>
A; Cross-references: UNIPARC: UPI000000DD0; GB: D14283; NID: q219915;
PIDN:BAA03245.1; PID:q219916
R; Schmid, J.; Weissmann, C.
J. Immunol. 139, 250-256, 1987
A; Title: Induction of mRNA for a serine protease and a beta-thromboglobulin-like
protein in mitogen-stimulated human leukocytes.
A; Reference number: I55992; MUID:87224164; PMID:2953813
A; Accession: I55992
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-99 <RE2>
A; Cross-references: UNIPARC: UPI000000DDD0; GB:M17017; NID:g179579;
PIDN: AAA35611.1; PID: g179580
R; Kusner, D.J.; Luebbers, E.L.; Nowinski, R.J.; Konieczkowski, M.; King, C.H.;
Sedor, J.R.
Kidney Int. 39, 1240-1248, 1991
A; Title: Cytokine- and LPS-induced synthesis of interleukin-8 from human
mesangial cells.
A; Reference number: I37902; MUID: 91374977; PMID: 1895676
A; Accession: I37902
A; Status: translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-97 < RE3>
A; Cross-references: UNIPARC: UPI000000077C; EMBL: Z11686; NID: q33958;
PIDN:CAA77745.1; PID:g33959
R; Alouani, S.; Gaertner, H.F.; Mermod, J.J.; Power, C.A.; Bacon, K.B.; Wells,
T.N.C.; Proudfoot, A.E.I.
Eur. J. Biochem. 227, 328-334, 1995
A; Title: A fluorescent interleukin-8 receptor probe produced by targetted
labelling at the amino terminus.
A; Reference number: S67519; MUID: 95154308; PMID: 7851404
A; Accession: S67519
A; Molecule type: mRNA
A; Residues: 1-99 <ALO>
A; Cross-references: UNIPARC: UPI000000DD0
C; Comment: This secretory protein is chemotactic for polymorphonuclear
leukocytes.
C; Comment: This protein is variably processed at the amino end. The major form
differs in different cell types.
C: Genetics:
A; Gene: GDB: IL8
A; Cross-references: GDB:120099; OMIM:146930
A; Map position: 4q13-4q21
A; Introns: 22/1; 67/2; 95/2
C; Superfamily: beta-thromboglobulin
C; Keywords: chemotaxis; cytokine; inflammation
F;1-20/Domain: signal sequence #status predicted <SIG>
F;21-99/Product: interleukin-8, minor form #status experimental <MATA>
```

```
F;23-99/Product: interleukin-8, major fibroblast-derived form #status
experimental <MATB>
F;28-99/Product: interleukin-8, major lymphocyte/monocyte-derived form #status
experimental <MATC>
  Query Match
                          24.4%; Score 113; DB 2; Length 99;
  Best Local Similarity
                          31.2%; Pred. No. 1.4e-05;
            30; Conservative 23; Mismatches
                                                  35; Indels
                                                                  8; Gaps
                                                                              6;
            1 MNAKVVVVLV---LVLTALCLSDGKPVSL-SYRCPC-RFFESHVARANVKHLKILNT-PN 54
Qy
              | :|: | |:
                          1: |||
                                       1 1
                                              11 1 : :
                                                              : | |::: : |:
Db
            1 MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPFHPKFIKELRVIESGPH 60
           55 CA-LQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
              || :|: :| :: |::|:|| |:| :|| :|| :
Db
           61 CANTEIIVKL-SDGRELCLDPKENWVQRVVEKFLKR 95
RESULT 7
A32954
gro-alpha precursor - mouse
N; Alternate names: gro protein; growth regulated protein; melanoma growth-
stimulating activity factor; melanoma mitogenic protein; secretory protein N51
C; Species: Mus musculus (house mouse)
C;Date: 20-Oct-1989 #sequence revision 20-Oct-1989 #text change 09-Jul-2004
C; Accession: A32954; JH0081
R; Oquendo, P.; Alberta, J.; Wen, D.; Graycar, J.L.; Derynck, R.; Stiles, C.D.
J. Biol. Chem. 264, 4133-4137, 1989
A; Title: The platelet-derived growth factor-inducible KC gene encodes a
secretory protein related to platelet alpha-granule proteins.
A; Reference number: A32954; MUID: 89139485; PMID: 2917992
A; Accession: A32954
A; Molecule type: mRNA
A; Residues: 1-96 < OQU>
A; Cross-references: UNIPROT: P12850; UNIPARC: UPI0000028840; GB: J04596;
NID:g201042; PIDN:AAA40131.1; PID:g201043
R; Ryseck, R.P.; MacDonald-Bravo, H.; Mattei, M.G.; Bravo, R.
Exp. Cell Res. 180, 266-275, 1989
A; Title: Cloning and sequence of a secretory protein induced by growth factors
in mouse fibroblasts.
A; Reference number: JH0081; MUID: 89078502; PMID: 2909392
A; Accession: JH0081
A; Molecule type: mRNA
A: Residues: 1-96 < RYS>
A; Cross-references: UNIPARC: UPI0000028840
C; Comment: This protein is basic and lacks threonine, phenylalanine, and
tyrosine.
C; Genetics:
A; Map position: 5
C; Superfamily: beta-thromboglobulin
C; Keywords: extracellular protein
F;1-24/Domain: signal sequence #status predicted <SIG>
F;25-96/Product: gro-alpha #status predicted <MAT>
                          24.3%; Score 112.5; DB 2; Length 96;
  Query Match
  Best Local Similarity
                          31.2%; Pred. No. 1.6e-05;
           25; Conservative 22; Mismatches 30; Indels
                                                                  3; Gaps
                                                                              3;
```

```
10 VLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKIL-NTPNCA-LQIVARLKNNN 67
Qу
                      1: 1 1::
                                11 1
                                        : :
                                               1:: ||:| : |:|
                                                               :::| || |
Db
           13 LLLLATSRLATGAPIANELRCQCLQTMAGIHLKNIQSLKVLPSGPHCTQTEVIATLK-NG 71
           68 RQVCIDPKLKWIQEYLEKAL 87
Qy
              1: 1:11:
                        :|: ::| |
           72 REACLDPEAPLVQKIVQKML 91
Db
RESULT 8
JN0841
interleukin-8 - dog
C; Species: Canis lupus familiaris (dog)
C;Date: 19-May-1994 #sequence revision 19-May-1994 #text change 12-Apr-1995
C; Accession: JN0841
R; Ishikawa, J.; Suzuki, S.; Hotta, K.; Hirota, Y.; Mizuno, S.; Suzuki, K.
Gene 131, 305-306, 1993
A; Title: Cloning of a canine gene homologous to the human interleukin-8-encoding
A; Reference number: JN0841; MUID: 94010328; PMID: 7916715
A; Accession: JN0841
A; Molecule type: DNA
A; Residues: 1-95 <ISH>
A; Cross-references: UNIPARC: UPI0000177BDC
C; Comment: This protein is a polymorphonuclear leukocyles chemotactic factor and
is involved in the host defense function.
C; Genetics:
A; Introns: 22/1; 67/2
C; Superfamily: beta-thromboglobulin
                          24.0%; Score 111; DB 2; Length 95; 33.7%; Pred. No. 2.3e-05;
  Query Match
  Best Local Similarity
  Matches 34; Conservative 20; Mismatches
                                                  29; Indels
                                                                18;
                                                                      Gaps
                                                                              7;
Qу
            1 MNAKVVVVLV---LVLTALC----LSDGKPVSLSYRCPCRFFESHVARANVKHLKILNT- 52
              11
                                                11 1 ::1
                                                              : |::| |
Db
            1 MTSKLAVALLAAFVLSAALCEAAVLS---RVSSELRCQC--IKTHSTPFHPKYIKELRVI 55
Qу
           53 --- PNCA-LQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
                      :|: :| | | :||:||| ||:|: :: | |
Db
           56 DSGPHCENSEIIVKLFNGN-EVCLDPKEKWVQKVVQIFLKK 95
RESULT 9
I59277
Mob-1 - rat
C; Species: Rattus sp. (rat)
C;Date: 02-Jul-1996 #sequence revision 02-Jul-1996 #text change 20-Aug-1999
C; Accession: I59277
R; Liang, P.; Averboukh, L.; Zhu, W.; Pardee, A.B.
Proc. Natl. Acad. Sci. U.S.A. 91, 12515-12519, 1994
A; Title: Ras activation of genes: Mob-1 as a model.
A; Reference number: I59277; MUID: 95107988; PMID: 7809069
A; Accession: I59277
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
```

```
A; Residues: 1-98 < RES>
A; Cross-references: UNIPARC: UPI0000136774; EMBL: U17035; NID: q763535;
PIDN:AAB60485.1; PID:g602432
C; Genetics:
A; Gene: mob-1
C; Superfamily: beta-thromboglobulin
                         24.0%; Score 111; DB 2; Length 98;
  Query Match
                         33.0%; Pred. No. 2.4e-05;
 Best Local Similarity
 Matches
           31; Conservative 22; Mismatches
                                                33; Indels
                                                               8; Gaps
           1 MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARAN-VKHLKI----LNTPNC 55
Qу
                   | : |:|
Db
           1 MNPSAAVVLCLVLLSLSGTQGIPLARTVRCTCIDFHEQTLRPRAIGKLEIIPASLSCPH- 59
          56 ALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
Qу
              ::|:| :| || || : |::|: : |: | || ||:::
          60 -VEIIATMKKNNEKRCLNPESEAIKSLL-KAVSQ 91
Db
RESULT 10
A26736
transformation-induced protein precursor (clone 9E3) - chicken
C; Species: Gallus gallus (chicken)
C; Date: 19-Nov-1988 #sequence revision 19-Nov-1988 #text change 09-Jul-2004
C; Accession: A26736
R; Sugano, S.; Stoeckle, M.Y.; Hanafusa, H.
Cell 49, 321-328, 1987
A; Title: Transformation by Rous sarcoma virus induces a novel gene with homology
to a mitogenic platelet protein.
A; Reference number: A26736; MUID: 87187628; PMID: 3032449
A; Accession: A26736
A; Molecule type: mRNA
A; Residues: 1-103 <SUG>
A; Cross-references: UNIPROT: P08317; UNIPARC: UPI000000031A; GB: M16199;
NID:g211735; PIDN:AAA48758.1; PID:g211736
C; Superfamily: beta-thromboglobulin
C; Keywords: growth factor
F;1-17/Domain: signal sequence #status predicted <SIG>
F;18-103/Product: transformation-induced protein #status predicted <MAT>
 Query Match
                         23.8%; Score 110; DB 2; Length 103;
 Best Local Similarity
                         32.3%; Pred. No. 3.2e-05;
 Matches
           30; Conservative 23; Mismatches
                                                32; Indels
                                                               8; Gaps
                                                                           6;
           1 MNAKVVVVLVLVLTALCLSDGKP-VSLSYRCPCRFFESH---VARANVKHLKIL-NTPNC 55
Qу
             1: :1
                                                     :
                                                         ::: :|: : |:|
Db
           1 MNGKLGAVLALLLVSAALSQGRTLVKMGNELRCQCISTHSKFIHPKSIQDVKLTPSGPHC 60
          56 A-LQIVARLKNNNRQVCIDPKLKWIQEYLEKAL 87
Qу
               ::|:| || : |:||:||
                                   |:| : |||
Db
          61 KNVEIIATLK-DGREVCLDPTAPWVQ-LIVKAL 91
RESULT 11
I50417
RSV-induced protein - chicken
```

```
C; Species: Gallus gallus (chicken)
C; Date: 13-Sep-1996 #sequence revision 13-Sep-1996 #text change 09-Jul-2004
C; Accession: I50417
R; Bedard, P.
Proc. Natl. Acad. Sci. U.S.A. 84, 6715-6719, 1987
A; Title: Constitutive expression of a gene encoding a polypeptide homologous to
biologically active human platelet protein in Rous sarcoma virus-transformed
fibroblasts virus transformed fibroblasts.
A; Reference number: I50417; MUID: 88016162; PMID: 2821543
A; Accession: I50417
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-103 <BED>
A; Cross-references: UNIPROT: P08317; UNIPARC: UPI00001713A9; GB: J02975;
NID:g212643; PIDN:AAA49059.1; PID:g212644
C; Superfamily: beta-thromboglobulin
  Query Match
                          23.3%; Score 108; DB 2; Length 103;
  Best Local Similarity
                          32.3%; Pred. No. 5.4e-05;
  Matches 30; Conservative 22; Mismatches
                                                  33; Indels
            1 MNAKVVVVLVLVLTALCLSDGKP-VSLSYRCPCRFFESH---VARANVKHLKIL-NTPNC 55
Qу
                                                       11 1:1: 1: :
                                             1: :1
Db
            1 MNGKFGAVLALLLVSAALSQGRTLVKMGNELRCQCISTHSKFIHPKSIQDVKLTPSGPHC 60
           56 A-LQIVARLKNNNRQVCIDPKLKWIQEYLEKAL 87
Qу
                ::|:| || : |:||:||
                                    1:1 : 111
Db
           61 KNVEIIATLK-DGREVCLDPTAPWVQ-LIVKAL 91
RESULT 12
S42496
interleukin-8 precursor [similarity] - sheep
C; Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)
C;Date: 06-Jan-1995 #sequence revision 06-Jan-1995 #text change 09-Jul-2004
C; Accession: S42496; I46997
R; Legastelois, I.; Greenland, T.; Arnaud, P.; Mornex, J.F.; Cordier, G.
submitted to the EMBL Data Library, March 1994
A; Description: Nucleotide sequence of ovine interleukin 8 cDNA using polymerase
chain reaction.
A; Reference number: $42496
A; Accession: S42496
A; Molecule type: mRNA
A; Residues: 1-101 <LEG>
A; Cross-references: UNIPROT: P36925; UNIPARC: UPI000012D4FE; EMBL: X78306;
NID:q463253; PIDN:CAA55115.1; PID:q463254
R; Seow, H.F.; Yoshimura, T.; Wood, P.R.; Colditz, I.G.
Immunol. Cell Biol. 72, 398-405, 1994
A; Title: Cloning, sequencing, expression and inflammatory activity in skin of
ovine interleukin-8.
A; Reference number: I46997; MUID:95137691; PMID:7835984
A; Accession: I46997
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-101 <SEO>
A; Cross-references: UNIPARC: UPI000012D4FE; GB: S74436; NID: g786590;
PIDN:AAB33241.1; PID:g786591
```

```
C; Genetics:
A;Gene: IL-8
C; Superfamily: beta-thromboglobulin
C; Keywords: chemotaxis; cytokine; inflammation
F;1-20/Domain: signal sequence #status predicted <SIG>
F;21-101/Product: interleukin-8 #status predicted <MAT>
                         23.1%; Score 107; DB 2; Length 101;
  Query Match
  Best Local Similarity 30.7%; Pred. No. 6.9e-05;
            31; Conservative 25; Mismatches
                                                 27; Indels
                                                               18; Gaps
                                                                            8;
            1 MNAKVVVVLV---LVLTALC----LSDGKPVSLSYRCPCRFFESHVARAN---VKHLKIL 50
Qу
              1:1:1:
                         1: |||
                                     -11
                                           : 1
                                               | | | | | | | | |
                                                            :
Db
            1 MTSKLAVALLAAFLLSAALCEAAVLS---RMSTELRCQC--IKTHSTPFHPKFIKELRVI 55
Qу
           51 NT-PNCA-LQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK 89
               : |:| :|: | | ::||:||| ||:|: :: | :
Db
           56 ESGPHCENSEIIVKL-TNGKEVCLDPKEKWVQKVVQAFLKR 95
RESULT 13
A28815
monocyte chemoattractant cytokine RANTES precursor - human
N; Alternate names: small inducible cytokine A5; T-cell specific cytokine RANTES
C; Species: Homo sapiens (man)
C;Date: 30-Jun-1989 #sequence_revision 16-Aug-1996 #text change 09-Jul-2004
C; Accession: A28815
R; Schall, T.J.; Jongstra, J.; Dyer, B.J.; Jorgensen, J.; Clayberger, C.; Davis,
M.M.; Krensky, A.M.
J. Immunol. 141, 1018-1025, 1988
A; Title: A human T cell-specific molecule is a member of a new gene family.
A; Reference number: A28815; MUID: 88285659; PMID: 2456327
A; Accession: A28815
A; Molecule type: mRNA
A; Residues: 1-91 <SCH>
A; Cross-references: UNIPROT: P13501; UNIPARC: UPI000004A187; GB: M21121
C; Comment: The acronym RANTES reflects the description "Regulated upon
Activation, Normal T Expressed, Secreted".
C; Genetics:
A; Gene: GDB: SCYA5; D17S136E
A; Cross-references: GDB:120749; OMIM:187011
A; Map position: 17q11.2-17q12
C; Superfamily: macrophage inflammatory protein
C; Keywords: chemotaxis; cytokine; immediate-early protein; inflammation; T-cell
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-91/Product: T-cell protein RANTES #status predicted <MAT>
  Query Match
                         23.0%; Score 106.5; DB 1; Length 91;
  Best Local Similarity
                         33.3%; Pred. No. 7.1e-05;
 Matches
           27; Conservative 18; Mismatches
                                                 29; Indels
                                                                7; Gaps
                                                                            5;
Qу
            7 VVLVLVLTALCL-SDGKPVSLSYRCPCRFFESHVARANVK-HLK--ILNTPNCALQIVAR 62
              Db
            8 LAVILIATALCAPASASPYS-SDTTPCCF--AYIARPLPRAHIKEYFYTSGKCSNPAVVF 64
           63 LKNNNRQVCIDPKLKWIQEYL 83
Qу
              : ||||| :|: ||::||:
```

```
RESULT 14
A46539
monocyte chemoattractant cytokine RANTES precursor - mouse
N; Alternate names: MuRantes
C; Species: Mus musculus (house mouse)
C; Date: 18-Jun-1993 #sequence revision 16-Aug-1996 #text change 09-Jul-2004
C; Accession: I48875; A46539; I48654; I56970
R; Danoff, T.M.; Lalley, P.A.; Chang, Y.S.; Heeger, P.S.; Neilson, E.G.
J. Immunol. 152, 1182-1189, 1994
A; Title: Cloning, genomic organization, and chromosomal localization of the
Scya5 gene encoding the murine chemokine RANTES.
A; Reference number: I48875; MUID: 94132613; PMID: 7507961
A; Accession: I48875
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-91 < DAN>
A; Cross-references: UNIPROT: P30882; UNIPARC: UPI000000028C; EMBL: U02298;
NID:q460090; PIDN:AAA18302.1; PID:q460091
R; Schall, T.J.; Simpson, N.J.; Mak, J.Y.
Eur. J. Immunol. 22, 1477-1481, 1992
A; Title: Molecular cloning and expression of the murine RANTES cytokine:
structural and functional conservation between mouse and man.
A; Reference number: A46539; MUID: 92289805; PMID: 1376260
A; Accession: A46539
A; Molecule type: mRNA
A; Residues: 1-18, 'A', 20-91 <SCH>
A; Cross-references: UNIPARC: UPI0000151811; GB: S37648; NID: q250207;
PIDN:AAB22330.1; PID:g250208
A; Experimental source: macrophage cell line PU5-1.8
A; Note: sequence extracted from NCBI backbone (NCBIN:106768, NCBIP:106770)
R; Shin, H.S.; Drysdale, B.E.; Shin, M.L.; Noble, P.W.; Fisher, S.N.; Paznekas,
W.A.
Mol. Cell. Biol. 14, 2914-2925, 1994
A;Title: Definition of a lipopolysaccharide-responsive element in the 5'-
flanking regions of MuRantes and crg-2.
A; Reference number: I48654; MUID: 94217689; PMID: 7513046
A; Accession: I48654
A; Status: translation not shown; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-91 <SHI>
A; Cross-references: UNIPARC: UPI000000028C; EMBL: X70675; NID: q475205;
PIDN:CAA50011.1; PID:q475206
R; Neilson, E.G.; Krensky, A.
Kidney Int. 41, 220-225, 1992
A; Title: Isolation and characterization of cDNA from renal tubular epithelium
encoding murine Rantes: A small intercrine from the Scy superfamily.
A; Reference number: I56970; MUID: 92277990; PMID: 1375672
A; Accession: I56970
A; Status: translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-40, 'E', 42-91 <NEI>
A; Cross-references: UNIPARC: UPI000016380F; GB:M77747; NID:g200649;
PIDN:AAA40029.1; PID:g200650
```

```
C; Comment: This chemoattractant for monocytes but not neutrophils is an
immediate-early response protein to LPS stimulation.
C; Genetics:
A; Introns: 26/1; 63/2
C; Superfamily: macrophage inflammatory protein
C; Keywords: chemotaxis; cytokine; immediate-early protein; inflammation
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-91/Product: monocyte chemoattractant cytokine RANTES #status predicted
<TAM>
 Query Match
                          23.0%; Score 106.5; DB 1; Length 91;
  Best Local Similarity
                          36.7%; Pred. No. 7.1e-05;
 Matches
           29; Conservative 11; Mismatches
                                                 34; Indels
                                                                5; Gaps
                                                                            3;
            9 LVLVLTALCLSDGKPVSL--SYRCPCRFFESHVA--RANVKHLKILNTPNCALQIVARLK 64
Qу
                                             :1 11:11
                           8 LTIILTAAALCTPAPASPYGSDTTPCCFAYLSLALPRAHVKEY-FYTSSKCSNLAVVFVT 66
Db
           65 NNNRQVCIDPKLKWIQEYL 83
Qy
                Db
           67 RRNRQVCANPEKKWVQEYI 85
RESULT 15
B28414
growth-regulated protein precursor - Chinese hamster
C; Species: Cricetulus griseus (Chinese hamster)
C;Date: 30-Jun-1989 #sequence_revision 30-Jun-1989 #text_change 09-Jul-2004
C; Accession: B28414
R; Anisowicz, A.; Bardwell, L.; Sager, R.
Proc. Natl. Acad. Sci. U.S.A. 84, 7188-7192, 1987
A; Title: Constitutive overexpression of a growth-regulated gene in transformed
Chinese hamster and human cells.
A; Reference number: A94184; MUID: 88041072; PMID: 2890161
A; Accession: B28414
A; Molecule type: mRNA
A; Residues: 1-101 <ANI>
A; Cross-references: UNIPROT: P09340; UNIPARC: UPI000012BAF7; GB: J03560;
NID:g191088; PIDN:AAA36985.1; PID:g304509
A; Note: the authors translated the codon CAG for residue 52 as Glu
C; Superfamily: beta-thromboglobulin
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-101/Product: growth-regulated protein #status predicted <MAT>
  Query Match
                          23.0%; Score 106.5; DB 2; Length 101;
                         29.8%; Pred. No. 7.8e-05;
  Best Local Similarity
 Matches 25; Conservative 24; Mismatches
                                                 32; Indels
                                                                            3;
            6 VVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANVKHLKILNT-PNCA-LQIVARL 63
Qу
                          1: | ||:
                                    11 1
                                            : 1
                                                  1:: ||:
Db
           13 LLLLLLLATSRLATGAPVANELRCQCLQTMTGVHLKNIQSLKVTPPGPHCTQTEVIATL 72
           64 KNNNRQVCIDPKLKWIQEYLEKAL 87
Qу
              | | :: |::|: :|: :| |
Db
           73 K-NGQEACLNPEAPMVQKIVQKML 95
```

Search completed: April 26, 2006, 02:38:13 Job time: 39 secs